Heparan sulfate in glomerular inflammation. by Rops, L.W.M.M.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/53415
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Heparan sulfate in 
glomerular inflammation
Angelique Rops     
ISBN: 978-90-9021586-0
©2007 by Angelique L.W.M.M. Rops 
Heparan sulfate in glomerular inflammation
Rops, Angelique Lucia Wilhelmina Mathea Maria
Thesis Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Cover illustration: Schematic overview of the adhesion of granulocytes to glomerular 
endothelial cells and a mouse kidney section stained for heparan sulfate (red) and the 
endothelial marker CD31 (green).
Printed by: PrintPartners Ipskamp, Enschede, The Netherlands, 2007  
Heparan sulfate in 
glomerular inflammation
Een wetenschappelijke proeve op het gebied van de Medische Wetenschappen
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de Rector Magnificus prof. mr. S.C.J.J. Kortmann,
volgens besluit van het College van Decanen
in het openbaar te verdedigen op dinsdag 19 juni 2007
om 13.30 uur precies
door
Lucia Wilhelmina Mathea Maria Rops
Geboren op 8 september 1979 te Breda
   
Promotor:   
Prof. dr. J.H.M. Berden
Copromotores:  
Dr. J. van der Vlag
Dr. T.H. van Kuppevelt
Dr. L.P.W.J. van den Heuvel
Manuscriptcommissie:  
Prof. dr. P.A.B.M. Smits (voorzitter)
Prof. dr. W.B. van den Berg
Prof. dr. A.J. Rabelink (Leids Universitair Medisch Centrum)
   
The research presented in this thesis was performed at the Nephrology Research Laboratory, 
Nijmegen Centre for Molecular Life Sciences, Division of Nephrology, Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands.
The study described in this thesis was supported by a program grant (902-27-292) from The 
Dutch Organization for Scientific Research and by a grant from the Dutch Kidney Foundation 
(C05.2152).
Contents
List of abbreviations            6
Chapter 1 General introduction             9
Chapter 2 Heparan sulfate proteoglycans in glomerular inflammation   21 
Chapter 3 Isolation and characterization of conditionally immortalized    55
  mouse glomerular endothelial cell lines
                
Chapter 4 Heparan sulfate domains on activated glomerular endothelial   75  
                   cells mediate the adhesion of leukocytes
        
Chapter 5 Heparan sulfate on activated glomerular endothelial cells and   99
  exogenous heparinoids influence the rolling and adhesion of   
                          leukocytes
   
Chapter 6 Syndecan-1 deficiency aggravates anti-GBM nephritis              115
 
Chapter 7 Expression of glomerular heparan sulfate domains in murine  135
  and human lupus nephritis
Chapter 8 Summary and future directions of research   155 
 
Chapter 9 Nederlandse samenvatting en toekomstige richting van het  161
  onderzoek 
Appendix: colour figures       167
Curriculum Vitae        171
List of publications        172 
      
Dankwoord         174
              Contents
List of abbreviations
AU   arbitrary units
BSA   bovine serum albumin
C3c   complement 3c
CS   chondroitin sulfate
DMEM   Dulbecco´s Modified Eagle´s Medium
DS   dermatan sulfate
ECM   extracellular matrix
EDTA   ethylenediaminetetraacetic acid
ELISA   enzyme-linked immunosorbent assay
FACS   fluorescence activated cell sorter
FCS   fetal calf serum
GAG   glycosaminoglycan
GalNAc   N-acetyl-galactosamine
GBM   glomerular basement membrane
GlcA   glucuronate
GlcNAc   N-acetyl-glucosamine
GlcNH3+   N-unsubstituted glucosamine
GlcNSO3  N-sulfo-glucosamine
HA   hyaluronic acid
HBP   heparin-binding protein
HPSE   heparanase
HS   heparan sulfate
HSPG   heparan sulfate proteoglycan
HUVEC   human umbilical vein endothelial cell
ICAM-1   intercellular adhesion molecule-1
IdoA   iduronate
IFN-γ   interferon-γ
Ig   immunoglobulin
IL   interleukin
LMW   low molecular weight
Mac-1   macrophage antigen-1
MCP-1   monocyte chemoattractant protein-1
MDC   macrophage derived chemokine
MFI   mean fluorescence intensity
mGEnC   mouse glomerular endothelial cells
List of abbreviations
6
MPC-5   mouse podocyte cell line-5
NDST   N-deacetylase/N-sulfotransferase
PAS   Periodic acid-Schiff
PBS   phosphate-buffered saline
PCR   polymerase chain reaction
PECAM-1  platelet endothelial cell adhesion molecule-1
PMN   polymorphonuclear granulocyte
ROS   reactive oxygen species
Sdc-1   syndecan-1
SLE   systemic lupus erythematosus
SV40   simian virus 40
TEM   transmission electron microscopy
TGF-β   transforming growth factor-β
TMB   tetramethylbenzidine
TNF-α   tumor necrosis factor-α
VE-cadherin  vascular endothelial-cadherin
VCAM-1  vascular cell adhesion molecule-1
vWF   von Willebrand factor
WT   wild type
                        List of abbreviations
            7

Chapter 1
General introduction
       
Chapter 1
     Proliferative forms of glomerulonephritis are characterized by the influx of inflammatory 
cells (leukocytes), proteinuria, hematuria and decline in renal function. Heparan sulfate 
proteoglycans (HSPGs) play a prominent role in inflammatory processes. HSPGs consist 
of a core protein to which linear heparan sulfate (HS) side chains are attached. HS chains 
consist of up to 150 disaccharide units of α(1-4)-uronic acid-β(1-4)-glucosamine, which 
can be modified at different positions by numerous enzymes, which include N-deacetylases, 
N- and O-sulfotransferases, C5-epimerase, sulfatases and hydrolases. The possible HS 
modifications give rise to an enormous dynamic and structural complexity of the HS chain, 
which corresponds to the variety of biologic functions mediated by HS, including its role 
in inflammation. During inflammation, HS in the extracellular matrix (ECM) and at the 
surfaces of leukocytes and endothelial cells binds chemokines, which directs the movement 
and activation of leukocytes. Endothelial and leukocyte cell surface HS also interacts 
directly with adhesion molecules like selectins and integrins. In particular HS on activated 
endothelium is crucial for the interaction with leukocytes. The common practice for treatment 
of glomerulonephritis is administration of immunosuppressive drugs like corticosteroids 
and cytotoxic immunosuppressives. However, these drugs have unwanted adverse effects 
and it takes several days before they become effective. During this window phase, extensive 
structural damage of the glomerulus can occur. It remains elusive which structures within 
HS on activated glomerular endothelium are important for the interaction with leukocytes. 
Identification of these structures could lead to the rational development of defined 
glycomimetics (HS-based therapeutics) for the supplementary treatment of glomerulonephritis. 
In this thesis, the expression of specific HS domains by glomerular endothelial cells and their 
function in the interaction with leukocytes are evaluated in vitro in leukocyte-endothelium 
adhesion assays, in vivo in experimental forms of glomerulonephritis and in patients with 
systemic lupus erythematosus (SLE) with glomerulonephritis.
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The glomerulus
     The glomerulus consists of a complex network of capillaries within Bowman’s capsule, 
which enables the ultrafiltration process. The main barrier in the ultrafiltration process is 
the glomerular capillary wall, which consists of a layer of fenestrated endothelial cells that 
are attached to the glomerular basement membrane (GBM), which is covered at the outer, 
urinary space with visceral epithelial cells, also called podocytes. The mesangial cell is the 
third glomerular cell type and located between the capillaries and regulates dynamic forces1,2 
(Figure 1).
The GBM is organized as a dense network of interacting ECM molecules, such as collagens, 
laminins and HSPGs. The glomerular capillary wall dictates the charge- and size-properties 
by allowing the passage of small and positively charged molecules into the urinary space, but 
by restricting the passage of large and negatively charged molecules into the urinary space3. 
In recent years, it has been shown that proteins like nephrin, podocin and CD2AP in the slit 
diaphragm between the podocyte foot processes are of prime importance for the shape and
Figure 1. Schematic representation of the structure of the glomerular capillary wall. The glomerular capillary 
wall consists of fenestrated endothelium, which lines the lumen of the microcapillaries and covers the glomerular 
basement membrane (GBM) that is covered at the urinary site with podocytes. Mesangium is situated between 
capillary loops. Reproduced with permission from W. Kriz (Institute of Anatomy and Cell Biology, University of 
Heidelberg, Germany).
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function of the podocyte. Patients and mice with mutations in genes encoding components of 
the slit diaphragm protein complex develop proteinuria, which is associated with effacement 
of podocyte foot processes4-6. The charge-dependent permeability of the glomerular 
capillary wall and in particular the GBM may be determined by the negatively charged 
HS polysaccharide side chains of HSPGs in the GBM. Furthermore, negatively charged 
sialoproteins like podocalyxin and α-dystroglycan, and glycosaminoglycans (GAGs) at the 
cell surface of both glomerular endothelial cells and podocytes may contribute to the charge-
selective properties of the capillary filter7-10. Apart from a possible function in filtration, HS 
in the glycocalyx on glomerular endothelium plays an important role in the interaction with 
leukocytes, as will be discussed below. Furthermore, it dictates the availability and function of 
several chemokines, growth factors and coagulation factors. It is also important as a defense 
mechanism for reactive oxygen species generated during inflammation.
Proliferative glomerulonephritis
     Glomerulonephritis can be classified as a primary renal disease, i.e. when only the 
glomerulus is affected, or as a secondary renal disease, i.e. when the glomerulus is damaged 
as a result of a systemic disease like a systemic autoimmune disease11. Proliferative forms of 
glomerulonephritis are characterized by an acute or chronic inflammation of the glomeruli, 
which can involve all three glomerular cell types, i.e. glomerular endothelial cells, podocytes 
and mesangial cells, respectively. Several types of glomerulonephritis are distinguished 
by light microscopy, immunofluorescence and electron microscopy. By light microscopy 
the proliferating cell types are identified, while by immunofluorescence and electron 
microscopy, the localization of immune complexes or immunoglobulin (Ig) deposits is 
identified. Glomerulonephritis characterized by an endothelial pattern of glomerular injury is 
manifested by glomerular influx of leukocytes like polymorphonuclear granulocytes (PMNs), 
endothelial swelling and cellular proliferation associated with proteinuria and hematuria. 
Glomerulonephritis characterized by an epithelial (podocytic) pattern of glomerular injury is 
manifested by podocyte degeneration and dedifferentiation, podocyte detachment from the 
GBM and severe proteinuria without glomerular leukocyte influx or cellular proliferation. 
Glomerulonephritis characterized by a mesangial pattern of glomerular injury is manifested by 
mesangial cell proliferation and matrix expansion associated with proteinuria, hematuria and 
variable glomerular leukocyte infiltration11,12. 
     Glomerulonephritis with a typical glomerular endothelial pattern of injury includes 
anti-GBM nephritis, lupus nephritis, postinfectious glomerulonephritis, mesangiocapillary 
glomerulonephritis, dense deposit disease, systemic vasculitis glomerulonephritis, 
antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis and cryoglobulinemia-
associated glomerulonephritis. Frequently, glomerulonephritis with this typical glomerular 
12
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endothelial pattern of injury is induced by the binding of antibodies to an antigen in the GBM 
or the accumulation of antibodies or antigen-antibody complexes in the subendothelial space 
or in the GBM, which then may lead to complement activation and glomerular PMN influx. 
The PMNs may cause glomerular endothelial injury by secretion of proteases. At a later 
stage, after capillary loop necrosis, extracapillary cell proliferation may be observed in the 
urinary space between Bowman’s capsule and the capillary tuft, which then results in crescent 
formation and finally to loss of renal function13. 
Heparan sulfate proteoglycans
     HSPGs consist of a core protein with covalently attached HS sugar side chains, which 
are located in basement membranes and at cell surfaces. HSPGs are involved in various 
biologic processes such as cell adhesion, migration, proliferation and differentiation, which 
are mediated by binding of chemokines, cytokines, enzymes, growth factors or other bio-
active molecules to the HS side chain. HS belongs to the family of strongly negatively charged 
GAGs that also includes heavily sulfated heparin and unsulfated hyaluran. HS is a linear chain 
that consists of up to 150 repeating disaccharide units of glucosamine α(1-4)-uronic acid-β(1-
4). The HS chain can be modified extensively, which starts with the N-deacetylation and N-
sulfation of N-acetyl-glucosamine by different isoforms of N-deacetylase/N-sulfotransferases 
(NDSTs) followed by C5-epimerization of glucuronate to iduronate by C5-epimerase and 
O-sulfation at various positions (C-2, C-3, and C-6) by different sulfotransferases14-16. The 
modifications of the HS chain result in a block-like structure of alternating N-acetylated, 
mixed N-acetylated/N- and O-sulfated and N- and O-sulfated (heparin-like) domains. 
The HS chains may also be modified by (extracellular) heparanase (HPSE), a β(1-4)-
endoglucuronidase that cleaves at specific sites within HS, while 6-O-sulfate groups may be 
removed by two extracellular HS 6-O-endosulfatases (Sulf-1 and Sulf-2). Finally, several 
lysosomal enzymes (hydrolases, N- and O-sulfatases) are responsible for the intracellular 
degradation of HS. The modification process gives rise to an enormous structural diversity 
within one HS chain, which is associated with the binding of a myriad of different factors and 
corresponding functions14,16-18.
The role of heparan sulfate in (glomerular) inflammation
     A central theme in inflammatory events is the attraction and transmigration of leukocytes 
from the circulation through the endothelium and the ECM into the injured tissue. The 
leukocyte-endothelium interaction occurs in a sequential four-step process19: (i) tethering of 
leukocytes to the activated endothelium; (ii) rolling of leukocytes over the endothelium; 
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(iii) firm adhesion of leukocytes to the endothelium; and (iv) transmigration (diapedesis) 
of leukocytes through the endothelium into the injured tissue. In all these steps, HS plays a 
prominent role20 (Figure 2). 
Figure 2. Multiple roles of heparan sulfate in leukocyte entry into sites of inflammation. HS on activated 
endothelium binds L-selectin on leukocytes (granulocytes, monocytes and lymphocytes) during the rolling phase of 
leukocytes over the endothelium. Endothelial HS binds and presents chemokines to chemokine receptors on 
leukocytes, which leads to activation of leukocytes and movement of leukocytes towards the site of inflammation, 
while HS is also involved in the transport of chemokines across the endothelial cell barrier. Endothelial HS binds 
integrins on leukocytes like Mac-1 (not shown in this figure), which results in the firm adhesion of leukocytes to the 
activated endothelium. Finally, endothelial HS may play a role in the transmigration of leukocytes through the 
endothelial layer into the tissue that may involve heparin-binding protein (not shown in this figure). 
ICAM, intercellular adhesion molecule; PSGL-1, P-selectin glycoprotein ligand-1; TNF, tumor necrosis factor. 
Reproduced with permission from Macmillan Publishers Ltd: Nature Immunology21.
Tethering of leukocytes involves binding of chemokines to HS on activated endothelial cells 
and in the ECM. For some chemokines it has been established that O-sulfation of HS promotes 
chemokine binding22,23. It has been reported that activation of microvascular endothelial cells 
by proinflammatory cytokines leads to an increased expression of sulfated HS domains and 
binding of RANTES (regulated upon activation, normal T cell expressed and secreted), which 
was mediated by an increased NDST-1 expression24. Rolling of leukocytes is mediated by 
L-selectin expressed by leukocytes and E- and P-selectin expressed by endothelial cells and/or 
platelets. HS can serve as a ligand for both L- and P-selectin, which has also been shown in 
the kidney25-29. Selectins bind 6-O-sulfated HS domains, whereas N-sulfation seems to be less 
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important30-32. In a recent study it has been shown that a mouse conditionally deficient 
in NDST-1 and/or NDST-2 in both endothelial cells and leukocytes showed an impaired 
inflammatory response, which was associated with a 2-3-fold reduction of N-, 2-O- and 
6-O-sulfated HS domains on the endothelium and a higher velocity of rolling leukocytes33. 
Firm adhesion of leukocytes involves interactions between integrins and integrin ligands like 
intercellular adhesion molecule (ICAM)-1. Endothelial HS is a ligand for the integrin 
Mac-1 that is expressed by leukocytes and both N- and O-sulfation seem to be important for 
this process32-35. Transmigration of leukocytes also involves HS-binding factors like HS-
bound chemokines that attract/direct leukocytes through the endothelium into the injured 
tissue, while HS/heparin can influence this process, in which N-sulfation seems not to be 
essential22,33,34,36. In addition to the role of HS in the process of leukocyte trafficking, HPSE 
that is expressed by activated endothelial cells and leukocytes degrades HS in the inflamed 
area, thus facilitating transmigration of leukocytes37,38. The cleavage of HS chains may also 
affect the binding of chemokines or other HS ligands important for tethering/chemotaxis, 
rolling, firm adhesion or transmigration of leukocytes. Interestingly, a HS cleavage product 
produced by HPSE is able to neutralize the inflammatory cytokine tumor necrosis factor 
(TNF)-α39. Elastase, a protease that is expressed by activated leukocytes, thereby facilitating 
their migration, can also be inhibited by HS/heparin40. 
     There are few data on (structural) changes in the expression of glomerular HS during 
glomerulonephritis. In various proliferative forms of glomerulonephritis a reduction of HS 
in the GBM has been observed41, but the expression of HS on glomerular endothelium was 
not evaluated. In (experimental) lupus nephritis it appeared that the decreased staining of 
HS in the GBM was negatively correlated with proteinuria and the presence of Ig deposits42. 
Also in Heymann nephritis, which is a model for membranous glomerulopathy, a decreased 
expression of HS in the GBM was demonstrated43. Finally, in vitro studies with bovine 
glomerular endothelial and activated human microvascular cells showed that activation with 
proinflammatory cytokines led to an increased expression and secretion of sulfated HS24,44. 
In summary, it has been shown that N-sulfated and 6-O-sulfated HS residues on activated 
(microvascular) endothelial cells from different vascular beds play a role in the interaction 
with leukocytes20,31,33,45. However, it remains elusive which HS structures on activated 
glomerular endothelium are important for the interaction with leukocytes. 
Experimental models used in this study
In vitro adhesion of leukocytes to cultured glomerular endothelial cells
     The functional role of endothelial HS structures in the interaction with leukocytes can be 
studied by performing adhesion experiments under either static or dynamic flow conditions. 
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Under static conditions only the firm adhesion of leukocytes to endothelium can be 
determined. Adhesion under conditions of dynamic blood flow can be mimicked by using 
a flow chamber, which enables the separation of the rolling and firmly adhering phase 
of leukocytes on endothelium, while also the rolling velocity of the leukocytes can be 
determined46. The shear forces in a flow chamber, originated by the fluid flow, are indicated 
by the wall shear rate, while the friction between individual blood elements or between blood 
elements and the vessel wall can be calculated by multiplying the shear rate with the fluid 
viscosity, which is called the wall shear stress (τ). In a flow chamber the wall shear stress τ (in 
dynes/cm2) can be calculated according to the Navier Stokes equation: 
τ = (6 x Q x µ)/(w x h2), in which Q is the volumetric flow rate, µ is the viscosity of the fluid, 
w is the slid width and h is the height of the flow chamber.
Experimental anti-GBM nephritis
     Experimental anti-GBM nephritis is a well-characterized model of glomerulonephritis, 
which is induced by the administration of heterologous anti-GBM antibodies47. Two phases 
can be distinguished in experimental anti-GBM nephritis. The first, acute or heterologous 
phase is the result of a rapid fixation of the injected heterologous anti-GBM antibodies to the 
glomerular capillary wall and is associated with glomerular leukocyte influx. The second, 
autologous phase is characterized by the immune response of the host against the heterologous 
antibodies, which leads to an amplification of the disease.  
Systemic lupus erythematosus (SLE)
     SLE is a systemic autoimmune disease that is characterized by the development of 
autoantibodies against nuclear antigens. SLE is associated with a broad spectrum of clinical 
manifestations that frequently involves glomerulonephritis. SLE glomerulonephritis is 
characterized by granular deposits of Ig and complement factors along the glomerular 
capillary wall and in the mesangium. The extent of Ig deposits in the capillary loops and the 
albuminuria is correlated with a decreased expression of HS in the GBM42. Several mouse 
strains, including the MRL/lpr mouse, spontaneously develop an autoimmune disease similar 
to human SLE48.  
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Scope and outline of the thesis
     The major aim of this thesis was to evaluate the role of HS(PGs) in glomerular 
inflammation. The research focused on the identification of structural changes in HS on 
glomerular endothelium under inflammatory conditions. In addition, the role of HS on 
activated glomerular endothelium in the interaction with leukocytes was evaluated. 
     The literature on the role of HS(PGs) in glomerular inflammation with a specific focus on 
the interaction of leukocytes with endothelium is reviewed in chapter 2. 
     To study the role of glomerular endothelial HS(PGs) in the adhesion of leukocytes in an 
in vitro system, a glomerular endothelial cell line was required. However, a well-defined 
glomerular endothelial cell line was not available and the culture of primary glomerular 
endothelial cells is difficult and limited due to the loss of characteristic features and/or 
differentiation markers during propagation. Therefore, the H-2Kb-tsA58 transgenic mouse 
(“immortomouse”) was used as a possible source for the isolation of a glomerular endothelial 
cell line. The transgenic expression of a temperature sensitive variant of simian virus 40 
(SV40) large T antigen by cells derived from the immortomouse allows proliferation of 
cells when cultured at the permissive temperature (33°C) in the presence of interferon-γ and 
differentiation of cells when cultured at the nonpermissive temperature (37°C). The isolation 
and characterization of a mouse glomerular endothelial cell line is described in chapter 3.
     The role of HS and specific structures within HS on activated mouse glomerular endothelial 
cells (mGEnC-1) in the firm adhesion of leukocytes is evaluated in chapter 4. The expression 
of different HSPGs, specific HS structures and HS-modifying enzymes was determined in 
unstimulated mGEnC-1 and mGEnC-1 activated with proinflammatory cytokines. The role of 
HS on glomerular endothelial cells in the firm interaction with leukocytes, i.e. granulocytes, 
was assessed in a static in vitro adhesion assay. The effects of removal of HS on mGEnC-1 
and the addition of heparinoids or anti-HS antibodies that recognize specific domains within 
HS, on the firm adhesion of leukocytes were evaluated. In addition, the involvement of the 
downstream NF-κB signaling pathway in cytokine-induced changes in HS on mGEnC-1 was 
assessed. Finally, the glomerular leukocyte influx was determined in MRL/lpr mice with lupus 
nephritis treated with either buffered saline or heparinoids. 
     A dynamic in vitro flow system was developed and used to study the interaction of 
leukocytes with mGEnC-1 to approximate the in vivo situation. This is described in chapter 
5. The role of HS in the rolling and firm adhesion of leukocytes to mGEnC-1 was evaluated 
under dynamic flow conditions by the removal of HS on activated mGEnC-1 and the addition 
of heparinoids. 
     The role of the cell surface HSPG syndecan-1 (sdc-1) in experimental anti-GBM nephritis 
is evaluated by inducing anti-GBM nephritis with heterologous, i.e. rabbit, anti-mouse GBM 
antibodies in wild type and sdc-1-deficient mice (chapter 6). The glomerular leukocyte influx,
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albuminuria and serum creatinine levels were determined. Furthermore, the expression of 
HS on glomerular endothelium was evaluated during the acute heterologous phase, while the 
immune response against the heterologous anti-GBM antibodies during the autologous phase 
was assessed by measuring mouse Ig anti-rabbit IgG levels in the serum and in glomerular 
deposits.
     The expression of specific HS domains in the GBM and on the glomerular endothelium in 
lupus mice and SLE patients with nephritis is evaluated in chapter 7. MRL/lpr lupus nephritis 
mice were divided into three groups, i.e. no albuminuria, short albuminuria and long, more 
pronounced albuminuria. The glomerular expression of specific HS domains was determined 
before and after elution of Ig from renal sections of mice with lupus nephritis and in renal 
sections of mice with lupus nephritis that had been treated with buffered saline or heparinoids.
     Finally, in chapter 8 and chapter 9 the findings are summarized and possible future 
directions are discussed.
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Abstract
     Heparan sulfate proteoglycans (HSPGs) are glycoproteins consisting of a core protein 
to which linear heparan sulfate side chains are covalently attached. These heparan sulfate 
side chains can be modified at different positions by several enzymes, which include 
N-deacetylases, N- and O-sulfotransferases, and an epimerase. These heparan sulfate 
modifications give rise to an enormous structural diversity, which corresponds to the variety of 
biologic functions mediated by heparan sulfate, including its role in inflammation. The HSPGs 
in the glomerular basement membrane (GBM), perlecan, agrin, and collagen XVIII, play an 
important role in the charge-selective permeability of the glomerular filter. In addition to these 
HSPGs, various cell types express HSPGs at their cell surface, which include syndecans, 
glypicans, CD44, and betaglycan. During inflammation, HSPGs, especially heparan sulfate, in 
the extracellular matrix (ECM) and at the surface of endothelial cells bind chemokines, which 
establishes a local concentration gradient recruiting leukocytes. Endothelial and leukocyte 
cell surface HSPGs also play a role in their direct adhesive interactions via other cell surface 
adhesion molecules, such as selectins and β2 integrin. Activated leukocytes and endothelial 
cells exert heparanase activity, resulting in degradation of heparan sulfate moieties in the 
ECM, which facilitates leukocyte passage into tissues and the release of heparan sulfate-bound 
factors. In various renal inflammatory diseases the expression of agrin and GBM-associated 
heparan sulfate is decreased, while the expression of CD44 is increased. Heparan sulfate or 
heparin preparations affect inflammatory cell behavior and have promising therapeutic, anti-
inflammatory properties by preventing leukocyte adhesion/influx and tissue damage.
Chapter 2
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Introduction
     Heparan sulfate proteoglycans (HSPGs) are a class of biomolecules with structural and 
regulatory functions that consist of a core protein with covalently attached heparan sulfate 
sugar side chains. HSPGs are located in basement membranes and at cell surfaces of various 
cell types, and are involved in biologic processes such as glomerular filtration, cell adhesion, 
migration, proliferation, and differentiation1-4, which are mediated by binding of chemokines, 
cytokines, enzymes, growth factors, or other bioactive molecules5. The common denominator 
of all HSPGs is the heparan sulfate side chain, which belongs to the family of strongly 
negatively charged glycosaminoglycans (GAGs)6,7. The heparan sulfate side chain consists of 
up to 300 alternating N-acetyl-glucosamine α1→ 4 glucuronate β1→ 4 residues, which both 
can be modified extensively. Modification of heparan sulfate starts with the N-deacetylation 
and N-sulfation of N-acetyl-glucosamine by different isoforms of glucosaminyl N-deacetylase/
N-sulfotransferases (NDSTs). The subsequent steps are C5-epimerization of glucuronate to 
iduronate by the enzyme D-glucuronyl C5-epimerase and O-sulfation at various positions 
(C-2, C-3, and C-6) by different sulfotransferases (Figure 1). Due to the sequential order of the 
modification reactions and the different enzymes involved, the initial distribution of N-sulfate 
groups will greatly determine the location of iduronate residues and O-sulfate groups within 
the heparan sulfate side chains. This results in a block-like structure in which alternating N-
acetylated, mixed N-acetylated/N-sulfated and N-sulfated (heparin-like) domains are 
found6-8. Since a heparan sulfate chain can contain up to 150 disaccharide units, the 
modification process gives rise to an enormous potential of different heparan sulfate
domains4-6. Such specific heparan sulfate domains are involved in the binding and modulation 
of specific proteins (Table 1)1,5,8-12. The specific binding of ligands to heparan sulfate depends 
on the degree of modification and is most likely determined by the spatial presentation of 
specific carboxyl and sulfate groups5,12. The functional consequences of ligand binding 
to HSPGs are: (1) immobilization of the ligand and increase of its local concentration; 
(2) induction of conformational changes, both within the heparan sulfate chain and/or its 
ligand, allowing presentation to a signaling receptor; (3) induction of oligomerization of 
bound growth factors or chemokines leading to receptor dimerization and signaling; and (4) 
protection of growth factors or chemokines from denaturation or proteolysis1,5,7-9,13. The best-
characterized heparan sulfate-ligand interaction, important for coagulation and inflammation, 
is the binding of antithrombin III to heparan sulfate5,8,12. This high-affinity binding is mediated 
through a specific pentasaccharide sequence (N-acetylglucosamine 6-O-sulfate→glucuronic 
acid→glucosamine N-sulfate 3-O-sulfate ± 6-O-sulfate→iduronic acid 2-O-sulfate→
glucosamine N-sulfate 6-O-sulfate). Within this sequence, the 3-O-sulfate group is essential 
for high-affinity antithrombin III binding and enhancement of antithrombin III activity. 
However, a mouse deficient in the enzyme 3-O-sulfotransferase that catalyses the sulfation at 
the 3-O position does not show changes in normal homeostasis8,14.
Heparan sulfate proteoglycans in glomerular inflammation
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Figure 1. The modification reactions in the biosynthesis of heparan sulfate. The first modification step, 
N-deacetylation and N-sulfation of N-acetyl-glucosamine, has an important function because the remaining 
N-acetylated regions will largely escape subsequent modifications. The N-deacetylase/N-sulfotransferase (NDST) 
enzymes (four isozymes) are responsible for this modification. N-sulfated regions are subject to the next modification 
steps, which include C5-epimerization of glucuronate to iduronate (by D-glucuronyl C5-epimerase) and O-sulfation
at various positions. The various sulfotransferases include 2-O-sulfotransferase (2-O-sulfation of iduronate), three or
more isozymes of 6-O-sulfotransferase (6-O-sulfation of N-acetyl/-sulfo-glucosamine), and six isozymes of 
3-O-sulfotransferase (3-O-sulfation of N-unsubstituted/sulfo-glucosamine). Abbreviations are: GlcA, glucuronate; 
GlcNAc, N-acetyl-glucosamine; GlcNSO3, N-sulfo-glucosamine; IdoA, iduronate; IdoA,2S, 2-O-sulfated iduronate; 
GlcNSO3,6S, 6-O-sulfated N-sulfo-glucosamine; GlcNSO3,3S, 3-O-sulfated N-sulfo-glucosamine.
24
Heparan sulfate proteoglycans in glomerular inflammation
The antithrombin III-cell surface heparan sulfate complex inhibits neutrophil rolling, adhesion, 
and migration in inflammatory reactions, most likely by interfering with inflammatory 
signaling pathways. Other factors involved in inflammation, especially chemokines, like 
platelet factor-4 (PF-4), stromal cell-derived factor-1α (SDF-1α), interleukin-8 (IL-8), growth 
regulated oncogene-α (GRO-α), RANTES (regulated on activation, normal T cell expressed 
and secreted), macrophage inflammatory protein-1α (MIP-1α), monocyte chemoattractant 
protein-1 (MCP-1), interferon-γ-inducible protein-10 (IP-10), fractalkine, eotaxin, secondary
Abbreviations are: IL-8, interleukin-8; RANTES, regulated on activation, normal T cell expressed and secreted; 
MIP-1, macrophage inflammatory protein-1; MCP-1, monocyte chemoattractant protein-1; SDF-1α, stromal cell-
derived factor-1α; PF-4, platelet factor-4; IP-10, interferon-γ-inducible protein-10; SLC, secondary lymphoid-tissue 
chemokine; TARC, thymus and activation-regulated chemokine; Mac-1, macrophage antigen-1; NCAM, neural cell 
adhesion molecule; PECAM-1, platelet endothelial cell adhesion molecule-1; HBP, heparin-binding protein; CAP37, 
cationic antimicrobial protein of 37 kD; HSV, herpes simplex virus; HIV, human immunodeficiency virus1,5,8-12.
Table 1. Groups of heparan sulfate-binding proteins   
       
                                                   Heparan sulfate-binding proteins 
                                                       
 Chemokines     Enzyme inhibitors  
    IL-8, RANTES, MIP-1, MCP-1, SDF-1α,     Serine protease inhibitors  
    PF-4, eotaxin, IP-10, fractalkine, SLC, TARC
      Extracellular matrix proteins
 Selectins        Fibronectin, collagens, vitronectin,
    L-selectin (CD62L), P-selectin (CD62P)     laminin, fibrillin, thrombospondin 
      
 Integrins     Lipoproteins
    Mac-1 (CD11b/CD18)       Low and very low density
         lipoproteins, apolipoproteins                    
 Cell adhesion molecules 
    NCAM, PECAM-1 (CD31)   Receptor proteins
         Steroid receptor, channel protein,
 Growth factors        growth factor receptors 
    Fibroblast growth factors, hepatocyte growth  
    factor, epidermal growth factor, vascular  Protease inhibitors               
    endothelial growth factors, transforming     Antithrombin III, heparin cofactor II, 
    growth factor, platelet-derived growth     protease nexin I, protease C inhibitor, 
    factor, insulin-like growth factor      mucus proteinase inhibitor  
   
 Enzymes     Viral coat proteins       
    Proteases, HBP/Cap37, esterases, lipolytic    HSV, HIV, Dengue                         
    enzymes, phosphatases, kinases, carbohydrate                                             
    hydrolases, eliminases, transferases, nucleases, Nuclear proteins           
    polymerases, topoisomerases, oxidases,     Transcription factors, histones
    synthetases, dismutases
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lymphoid-tissue chemokine (SLC), and thymus and activation-regulated chemokine (TARC), 
but also selectins, integrins, heparin-binding protein (HBP)/cationic antimicrobial protein 
of 37 kD (CAP37), and the heparan sulfate-degrading enzyme heparanase are able to bind 
heparan sulfate and/or heparin. However, the specific sequences within heparan sulfate and/or 
heparin, to which these inflammatory factors bind to, are less well characterized than for 
antithrombin III10-12,15-27. 
     Quantitative changes in HSPGs have been observed in various glomerulonephritides, in a 
number of proteinuric nephropathies, including diabetic nephropathy, and in renal sclerosis/
fibrosis3,28-32. Mice lacking the heparan sulfate-modifying enzyme 2-sulfotransferase do not 
develop kidneys, which demonstrates that the regulated synthesis of heparan sulfate can affect 
kidney morphogenesis during vertebrate development33. 
     Heparin, a highly sulfated heparan sulfate with a higher iduronate/glucuronate ratio 
and a higher percentage of sulfated domains than heparan sulfate12, and specific heparan 
sulfate/heparin preparations (heparinoids) are known to have strong anticoagulant and anti-
inflammatory activities11,24,34-39. This review aims to summarize the current knowledge of the 
role of HSPGs in glomerular inflammation.
Chapter 2
Inflammation
     Tissue injury caused by infection or physical damage evokes inflammatory reactions and 
events that are necessary for regaining normal homeostasis. Central to these events is the 
translocation of leukocytes, including monocytes, neutrophils, and T lymphocytes, from the 
vascular system through the endothelium and the extracellular matrix (ECM) to the injured 
tissue40. This transendothelial migration occurs in a sequential four-step process and involves 
the concerted action of chemoattractants and adhesion promoting molecules, like selectins and 
integrins (Figure 2) (Table 2)13,40-42. In the first step, chemoattractants, cytokines, and 
complement components, generated in the local inflammatory area, lead to activation of 
endothelium and leukocytes. Upregulation of local and systemic cytokines, like tumor necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β), induces expression of intercellular and 
vascular adhesion molecules (ICAM and VCAM), and selectins on the endothelium, by which 
the leukocytes roll over the endothelial monolayer. Tethering interactions, which involve the 
interaction of the L- and P-selectins with cell surface-associated heparan sulfate20,25,43, between 
leukocytes and endothelial cells cause circulating cells to slow down and roll along the vessel 
wall. In the second step, triggering factors, principally cytokines, which may be bound to 
endothelial cell surface heparan sulfate22,40,42, activate leukocyte adhesion molecules, the 
integrins, thereby promoting strong adhesion that can stop the rolling leukocyte. The third step 
in leukocyte recruitment depends on tighter adhesion, via ICAM and VCAM on the 
endothelium. 
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Figure 2. Sequential steps in adhesion of leukocytes to endothelium. Upon tissue injury, for example podocyte 
injury, rolling and subsequent de-acceleration of leukocytes is facilitated by reversible binding of L- and P-selectins 
expressed on respectively leukocytes and endothelium. Presented chemokines are permitted easier access to the 
leukocyte, leading to activation of integrins and subsequent binding to their adhesion molecules on the endothelium.
Under the influence of additional chemokines, strongly adhering and flattened leukocytes will undergo diapedesis. 
Abbreviations are: RBC, red blood cell; RANTES, regulated on activation, normal T cell expressed and secreted; 
MCP-1, monocyte chemoattractant protein-1; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; iNOS, inducible 
nitric-oxide synthase; TGF-β, transforming growth factor-β; NO, nitric oxide; O2-, superoxide; ONOO-, peroxynitrite 
anion; OH-, hydroxyl radicals; OCl-, hypochlorite anion [adapted with permission from Adams and Shaw, 199440 and 
from De Greef KE: Role of inflammatory cells in the early phase after acute renal injury (Ph.D. Thesis), University of 
Antwerp, Belgium 2001].
These adhesion molecules bind to heterodimeric proteins of the integrin family on the 
leukocytes, which are activated by heparan sulfate-bound chemokines19,40,42. In the fourth step, 
the leukocyte transmigrates or crosses the endothelial monolayer (diapedesis). This step also 
involves VCAM, ICAMs, and integrins, as well as a further adhesive interaction involving an 
immunoglobulin-related molecule called platelet endothelial cell adhesion molecule-1 
(PECAM-1/CD31), which is expressed both on the leukocyte and at the intercellular junctions 
of endothelial cells. These interactions enable the phagocyte to squeeze between the 
endothelial cells and to penetrate the basement membrane by the release of proteolytic 
enzymes. The leukocytes then migrate through the tissues under the influence of 
chemokines19,40-42,44. Diapedesis and leukocyte migration in the injured tissue are directly 
influenced by heparan sulfate-bound chemokine gradients. Finally, leukocyte migration and 
the combined action of heparan sulfate and heparan sulfate-bound chemokines are influenced 
by the heparan sulfate-degrading enzyme heparanase, which can be produced both by 
endothelial cells and leukocytes26,45-47. As will be discussed below in more detail, HSPGs are 
involved in several steps of this inflammatory reaction leading to transendothelial migration of 
leukocytes. In the next paragraphs, we first will introduce the HSPGs present in the ECM and 
at the cell surface of various cell types.  
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Abbreviations are: PSGL-1, P-selectin glycoprotein ligand-1; sLex, sialyl-Lewisx; ESL-1, E-selectin ligand-1; CLA, 
cutaneous lymphocyte antigen; GlyCAM-1, glycosylation-dependent cell adhesion molecule-1; MAdCAM-1, mucosal 
adressin cell adhesion molecule-1; LFA-1, lymphocyte associated antigen-1; Mac-1, macrophage antigen-1; VLA, 
very late antigen; ICAM, intercellular adhesion molecule; VCAM-1, vascular cell adhesion molecule-1; PECAM-1, 
platelet endothelial cell adhesion molecule-113,40-42.  
Table 2. Adhesion molecules in leukocyte-endothelial interactions
Major families Individual members       Cellular distribution Ligands on target cells
        
Selectins P-selectin  Endothelial cells,               PSGL-1, sLex, HSPGs/
     platelets   heparin, other
        glycoconjugates
 
  E-selectin  Endothelial cells  ESL-1, CLA, sLex,  
        PSGL-1, L-selectin,
        other glycoconjugates 
  L-selectin  Leukocytes  CD34, GlyCAM-1,  
        MAdCAM-1, HSPGs/ 
        heparin, CLA, sLex,  
        E-selectin, various  
        fucosylated and 
        sulfated carbohydrates
Integrins αLβ2 (LFA-1;  Leukocytes  ICAM-1, ICAM-2,
  CD11a/CD18)     ICAM-3
   αMβ2 (Mac-1; CR3; Granulocytes,  ICAM-1, fibrinogen,
  CD11b/CD18)  monocytes  HSPGs/heparin, iC3b
  αXβ2 (CR4; p150,95; Granulocytes,  iC3b
  CD11c/CD18  monocytes
  
  α5β1 (VLA-5;  Monocytes,  VCAM-1, fibronectin
  CD49/CD29)  lymphocytes,
     eosinophils
Immunoglobulin ICAM-1 (CD54)  Endothelial,  LFA-1, Mac-1
superfamily    epithelial, mesangial,
     smooth muscle cells
  ICAM-2 (CD102) Endothelial cells,  LFA-1
     lymphocytes, platelets
  VCAM-1 (CD106) Endothelial,  VLA-4
     epithelial, mesangial,
     smooth muscle cells,
     monocytes
  PECAM-1 (CD31) Endothelial cells,  CD31
     platelets, monocytes,
     granulocytes
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Glomerular proteoglycans
     The kidney contains a large number of functional units, the so-called nephrons. Each 
nephron is composed of a glomerulus, proximal tubule, loop of Henle, and distal tubule. A 
layer of parietal epithelial cells on a basement membrane (called Bowman’s capsule) 
encapsulates the glomerulus, which is a specialized tuft of capillaries with the afferent and 
efferent arteriole at either end. The wall of the glomerular capillary consists of a single layer 
of fenestrated endothelial cells, attached to the glomerular basement membrane (GBM), which 
is covered at the other side with visceral epithelial cells, also called podocytes. The GBM 
is a dense network of interacting ECM molecules, such as collagens, laminins, and HSPGs. 
Formation of the meshwork of molecules is also facilitated by multiple binding interactions of 
heparan sulfate. The GBM plays a key role in glomerular filtration by providing mechanical 
support to the glomerular capillary wall and by regulating the access of plasma molecules to 
the tubular system of the nephron. The permeability through the glomerular capillary wall for 
a given molecule is highly dependent on its size, shape, and charge. The charge-selective 
permeability of the GBM is largely determined by the electrostatic properties of heparan 
sulfate within the GBM3,48. The HSPGs perlecan, agrin, and collagen XVIII are ECM 
components localized in the GBM49-52. In addition to the ECM, HSPGs are also present at the 
cell surface of various cell types, including endothelial cells and leukocytes. These cell surface 
HSPGs include glypicans, syndecans, CD44, and betaglycan1,13,53,54. In contrast to the HSPGs 
in the GBM, they are probably not so important for the charge-dependent permeability of the 
GBM, but they have other functions, also in the process of inflammation. Syndecan and 
glypican expression is often associated with morphologic transitions or major changes in 
tissue organization1,55. Syndecan-1, -3 and -4 and glypican-1 are differently expressed by 
different endothelial cell types13. Betaglycan is a type III transforming growth factor-β 
(TGF-β) receptor and is present in the cortical renal interstitium53,56 and on microvascular 
endothelial cells57. CD44, a cell surface receptor for the GAG hyaluronic acid (HA), is 
expressed by mesangial cells58,59, and different endothelial cell types13. 
GBM-associated HSPGs
     The perlecan core protein contains five domains based on amino acid homology with other 
known proteins (Figure 3)60. There are three GAG attachment sequences located in close 
proximity to each other in domain I (unique for perlecan) at the N-terminal end of the 
molecule. One additional substitution site for a heparan sulfate chain has been localized to 
domain V61 and there is one alternate splice site in domain IV. Chondroitin sulfate or dermatan 
sulfate chains occasionally replace heparan sulfate chains in perlecan4. 
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Figure 3. Molecular anatomy of the glomerular basement membrane (GBM)-associated heparan sulfate 
proteoglycans (HSPGs). Perlecan is a HSPG of which domain I is the only unique region. This module contains an 
acidic region followed by three repeated Ser-Gly-Asp sequences, which are the primary heparan sulfate attachment 
sites for perlecan. Domain II of perlecan is homologous to the class A, low-density lipoprotein (LDL) receptor. 
Domain III contains modules with homology to the laminin epidermal growth factor (EGF)-like domain (LE) and 
the laminin B domain (LamB). Domain IV contains a repeat of immunoglobulin (Ig) G modules, similar to neural 
cell adhesion molecule (NCAM), and domain V is the C-terminus of perlecan, containing three laminin G domain 
like modules (LamG) spaced by two EGF-like modules. It also contains an additional substitution site for a heparan 
sulfate chain. Agrin is a multimodular composition of a globular laminin-binding domain, nine follistatin-like protease 
inhibitor domains, two laminin EGF-like repeats, two serine/threonine (ST)-rich domains, one SEA (sperm protein-
enterokinase-agrin) module, four EGF repeats and three domains sharing homology with globular domains of laminin 
G. There are three glycosaminoglycan (GAG) attachment sites located N-terminally to the SEA domain. Collagen 
XVIII is a nonfibrillar collagen. Its domains are characterized by the spacing of collagenous and noncollagenous 
regions. The endostatin domain is present at the C-terminus. The bottom panel provides the key to the protein modules 
and GAG attachment sites.
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Chondroitin sulfate consists of N-acetyl-galactosamine and glucuronate disaccharides and it 
can be sulfated at positions 4 and 6 of the N-acetyl-galactosamine unit and at position 2 of the 
uronic acid residue5. Dermatan sulfate, a form of chondroitin sulfate in which the 
glucuronate has been epimerized to iduronate during transport to the cell surface, contains 
10% to 15% of iduronate62. Perlecan expression correlates universally with tissue maturation 
and is always prominent in the endothelial basement membranes of all vascularized organs4. 
In the kidney, perlecan is present in the GBM, Bowman’s capsule, and the tubular basement 
membrane (TBM)49,63. Perlecan is also localized in the mesangial matrix, predominantly on 
the endothelial side with a nonhomogenous distribution49. Immunofluorescence analysis shows 
that the expression of perlecan is higher in the mesangium than in the GBM3. Perlecan binds to 
the basement membrane components, laminin, collagen IV, entactin/nidogen, and fibulin64,65. 
Perlecan has also been found to bind the ECM component fibronectin via its heparan sulfate 
chains64,66, but also via its core protein66. It also binds to the podocyte cell surface-associated 
protein α-dystroglycan by its conserved laminin G domains67. Recently, it has been shown that 
the C-terminal domain of perlecan (endorepellin) interacts with the C-terminal domain of 
collagen XVIII (endostatin), another GBM-associated HSPG, thereby counteracting its 
angiogenic effects68. Until recently, it was thought that perlecan was important for the 
permeability of the GBM. However, a mouse with a targeted disruption of domain I 
(containing the heparan sulfate attachment sites) of perlecan did not show renal abnormalities, 
nor proteinuria but developed lens degeneration69.
     The protein sequence of agrin also shows homologies with other known proteins (Figure 
3)70,71. Three GAG attachment sites are located N-terminally to the sperm protein-
enterokinase-agrin (SEA) domain. There are three alternative splice sites, x, y, and z, one 
near the N-terminus and two at the C-terminus72,73, but there are also short NH2-terminal (SN) 
and long NH2-terminal (LN) isoforms
74. Agrin is the most abundantly expressed HSPG in the 
GBM50, while expression is less in the TBM, Bowman’s capsule, and vascular walls70. There 
are differences in the distribution of SN and LN isoforms and N-terminal and C-terminal 
agrin50. SN-agrin is selectively expressed in the nervous system, while LN-agrin is expressed 
in both neural and nonneural tissues, including the GBM74. N-terminal agrin is present in all 
renal basement membranes, including the TBM, while C-terminal agrin is almost exclusively 
expressed in the GBM, which indicates the existence of several isoforms of agrin in the kidney 
(i.e. a “large” agrin containing both the C- and N-terminus and a “shorter” variant missing C-
terminal regions). The existence of these isoforms might be due to alternative splicing and/or 
posttranslational processing. HSPGs influence the glomerular permeability by their negatively 
charged heparan sulfate side chains3,48. Injection of a monoclonal antibody against GBM-
associated heparan sulfate induces instantly a massive albuminuria31. Agrin acts as a major 
structural component of the GBM that interacts with components of the matrix as well as with 
components at the surfaces of podocytes. The heparan sulfate side chains on the N-terminal 
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half of agrin bind to the heparin-binding site on the neural cell adhesion molecule (NCAM) 
and to heparin-binding proteins in the basement membrane75, like laminin, fibronectin, and the 
membrane-associated glycoprotein α-dystroglycan exposed by podocytes76,77, which facilitates 
the formation of the GBM.
     In addition to agrin and perlecan, collagen XVIII is also an ECM-associated HSPG 
expressed in the kidney52. It is more prominent in the mesangium than in the GBM3. 
Collagen XVIII has three GAG attachment sequences for heparan sulfate (Figure 3)78. 
Alternative splicing at the N-terminus produces long and short forms of the molecule. The 
alternate spliced variants are differently expressed in different tissues. The short variant is 
predominantly present in the fetal and adult kidney79. Endostatin is a carboxy-terminal 
proteolytic cleavage product of collagen XVIII that significantly inhibits endothelial cell 
proliferation and migration and also inhibits angiogenesis80,81. Recently, it has been shown 
that endostatin colocalizes with perlecan in basement membranes82. It has been shown that 
the inhibitory effect of endostatin on vascular growth factor-induced endothelial migration is 
blocked by a 10/12 mer endostatin-binding sequence of heparan sulfate83. 
Cell surface HSPGs
     Syndecans are type I transmembrane HSPGs, with an extracellular domain that contains 
several consensus sequences for GAG attachment, a single hydrophobic transmembrane 
domain, and a short C-terminal cytoplasmic domain (Figure 4)1. This class of transmembrane 
molecules is a family of four members: syndecan-1 (syndecan), syndecan-2 (fibroglycan), 
syndecan-3 (N-syndecan), and syndecan-4 (ryudocan, amphiglycan)1,9,84. Whereas the majority 
of GAG chains attached to syndecan core proteins are of the heparan sulfate type (Figure 4), 
syndecan-185 and syndecan-486 may also contain chondroitin sulfate. Syndecan-1 and -3, and 
syndecan-2 and -4 can be considered to form subfamilies based on sequence similarities, GAG 
attachment sites, and core protein size. The cytoplasmic domains are short, highly conserved, 
and may interact with cytoskeletal elements and kinases, which has implications for signal 
transduction events87,88. The length of the extracellular domain varies markedly among the 
different family members1,84. Syndecan-1, -2, and -4 are expressed by vascular endothelial 
cells, predominantly at the basolateral surfaces84,89. Only syndecan-1 and -4 are expressed in 
the kidney. Syndecan-1 is present at the basolateral surface of renal epithelial cells90,91 and 
syndecan-4 is predominantly present on endothelial cells92. Syndecan-4 is the only syndecan 
consistently found in focal adhesions, which are specialized regions of the plasma membrane 
that mediate tight adhesion between the cell and the underlying ECM87,88,93. It is a regulator of 
focal adhesion and stress fiber formation, and influences both cell morphology and 
migration94. Syndecan expression is often associated with morphologic transitions or major 
changes in tissue organization, such as in development1,84,92. Both cell surface expression and
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Figure 4. The four families of cell surface heparan sulfate proteoglycan (HSPG) core proteins, which contain 
heparan sulfate (HS) and/or chondroitin sulfate (CS) side chains. Six isoforms of  glypican (in this figure only two 
isoforms of glypican are represented), four isoforms of syndecan, and numerous isoforms of CD44, (with the standard 
form CD44H) exist.
shedding of syndecan-1 and -4 are increased in response to injury and play a role in 
inflammation1,10. 
     The glypicans are a family of HSPGs that are linked to the outer surface of the plasma 
membrane through a covalent glycosyl-phosphatidylinositol (GPI) anchor (Figure 4)9. There 
are six known members of the glypican family: glypican-1 (glypican), glypican-2 
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(cerebroglycan), glypican-3 (OCI-5), glypican-4 (K-glypican), glypican-5, and glypican-6. All 
share a modular structure with a large extracellular domain, including a cysteine-rich globular
region, and carry exclusively heparan sulfate chains. The core protein of all glypicans is 
roughly of similar size and contains Ser-Gly repeats in their C-terminal parts, which are the 
attachment sites for heparan sulfate chains55,84,95. All glypicans are highly expressed during 
embryonic development. Expression levels have been shown to change in a stage- and tissue-
specific manner, suggesting that glypicans are involved in morphogenesis55,96. Glypican-155, 
-397, -498, and -596 are expressed in the (developing) kidney. Glypican-5 mRNA is expressed 
by pretubular aggregates and early tubular structures, but is downregulated before complete 
glomerular structures are formed96. Glypican-1 is expressed by early epithelial aggregates, 
but persists in their glomerular derivatives. It is also shown that this glypican is present on 
vascular endothelial cells99. Glypican-3 directly controls collecting duct cell responses97 and 
glypican-4 is associated with mature tubular, but not glomerular, derivatives98. Glypican-3 also 
plays an important role during renal development, since this HSPG is mutated in a mouse 
model of Simpson-Golabi-Behmel (overgrowth) syndrome that includes renal abnormalities100. 
In addition to their role in development, another function of glypicans is to serve as low-
affinity receptors for endostatin in renal tubular and arterial endothelial cells95. Although 
endothelial cells express glypican-1, a role of glypicans in inflammation is not as clear as for 
the syndecans2,54.
     Betaglycan has been shown to contain both heparan sulfate and chondroitin sulfate chains 
(Figure 4) and is present in the cortical renal interstitium53,56 and on microvascular endothelial 
cells57. Betaglycan is a type III TGF-β receptor that binds various forms of TGF-β with high 
affinity and specificity53,56. The core protein binds TGF-β and associates with type II receptor 
in a ligand-dependent manner, thereby modulating the effects of TGF-β101. The GAG chains of 
betaglycan are not necessary for the expression of betaglycan at the cell surface, the binding of 
TGF-β to the betaglycan core protein, and the inhibitory effect of TGF-β102. A naturally 
occurring soluble form of betaglycan is found in serum and in the ECM101. Betaglycan is 
involved in glomerular inflammation, since its mRNA expression is increased in various types 
of glomerulonephritis56. The expression of TGF-β is also upregulated in decorin-deficient mice 
with unilateral ureteral kidney obstruction. Decorin is a small dematan sulfate proteoglycan 
and a member of the family of small leucine-rich proteoglycans (SLRPs). Decorin appears to 
form complexes with TGF-β and exerts beneficial effects on tubulointerstitial fibrosis103.
     CD44 is a so-called “part-time” proteoglycan, which means that it can exist in a 
proteoglycan and nonproteoglycan form. The GAG chains can be either chondroitin sulfate 
or heparan sulfate. Like syndecans it has a short highly conserved intracellular domain and a 
large extracellular domain (Figure 4)104. CD44 is a cell surface glycoprotein that is encoded by 
one single gene, but expressed in numerous isoforms. The highly tissue-specific 
expression is due to differential splicing of up to twelve alternative exons into a single site 
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within the extracellular domain. The standard form of CD44 (CD44H) contains the products of 
exons 1-5 and 16-17. Splicing events may result in isoforms that lack transmembrane and 
cytoplasmic domains, thus yielding secreted, soluble CD44105. However, soluble CD44 can 
also arise via shedding from the cell surface, apparently as a result of proteolytic cleavage106. 
CD44 is a cell surface receptor for HA and is involved in the homing of lymphocytes107. It 
is synthesized by synovial epithelial cells, synovial fibroblasts, glial cells, Kupffer cells107, 
mesangial cells58,59 and different endothelial cells13. In endothelial cells108 and macrophages109, 
interaction of low molecular weight HA with CD44 leads to the activation of the immediate 
early-response genes involved in proliferation and inflammation. HA, a constituent of the
ECM, is a nonsulfated, linear GAG consisting of repeating units of N-acetyl-glucosamine and 
glucuronate molecules. HA is synthesized by specific HA synthases in all mammalian cells 
and it is extruded into the extracellular space by these plasma membrane enzymes110. HA also 
plays an important role in inflammation, since the expression of HA on endothelial cells is 
induced by proinflammatory cytokines111. HA fragments can induce chemokine expression in 
alveolar macrophages, which can be inhibited by CD44109. 
      In addition to the expression at the surface of endothelial cells (syndecan-1, syndecan-2, 
syndecan-4, glypican-1, CD44, and betaglycan), mesangial cells (CD44), and visceral/tubular 
epithelial cells (betaglycan, syndecan-1, and glypican-1), cell surface HSPGs are also 
expressed on leukocytes112-117. HSPGs, such as CD44, on leukocytes help to regulate 
leukocyte trafficking in tissues, participating in the rolling interactions with HA on endothelial 
cells. CD44 and syndecan-2 are specifically upregulated on macrophages, following in vitro 
differentiation and activation with IL-1 and lipopolysaccharide112,113. Syndecan-1 and -4 are 
expressed on leukocytes, including B cells114 and macrophage-like cells115, while syndecan-4 is 
also expressed on neutrophils116, and peripheral blood monocytes117. 
Role of HSPGs in glomerular inflammation
Chemotaxis and HSPGs
     Chemokines that are produced by endothelial cells or platelets, which are often the initial 
cells responding to injury, become often localized on the vascular endothelium via 
interaction with GAGs. Chemokines are basic proteins, which bind to negatively charged 
heparin and heparan sulfate22. The capture of chemokines by HSPGs in the ECM and on the 
surface of endothelial cells creates a local concentration gradient at the point of chemokine 
production. HSPGs on leukocytes also sequester chemokines and trigger integrin-mediated T 
cell adhesion. The chemokines are a family of small chemoattractant proteins that are capable 
of activating and promoting vectorial migration of a variety of leukocytes118. Chemokines can 
be grouped into four subfamilies dependent on the position of conserved cysteine residues, 
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designated C, CC, CXC, and CX3C. Lymphotactin and fractalkine are the prototypes of 
respectively the C and CX3C subclass
119,120. Lymphotactin has chemotactic activity for 
lymphocytes, but not for monocytes or neutrophils120. Soluble fractalkine is chemoattractive 
for T cells and monocytes, while cell surface-bound fractalkine, which is induced on activated 
endothelial cells, promotes strong adhesion of those leukocytes119. The CXC subclass 
mediates acute inflammatory reactions mainly via neutrophil attraction and activation, and 
includes IL-8, SDF-1α, PF-4, IP-10, and GRO-α, -β, and -γ, which all bind to 
heparin/heparan sulfate. The CC subclass is implicated in chronic inflammation through the 
attraction of lymphocytes, eosinophils, basophils, dendritic cells, and macrophages, and 
includes RANTES, eotaxin, SLC, TARC, macrophage derived chemokine (MDC), MIP-1 
through -3α, -β, -γ, and MCP-1 through -4, which also bind to heparin/heparan sulfate. These 
chemokines are expressed by many cell types, including leukocytes and endothelial cells, and 
they interact with a family of seven transmembrane receptors, the CC- and CXC-chemokine 
receptors (CCRs and CXCRs), that are predominantly expressed on leukocytes22,40,118, but also 
by podocytes121. The GAGs that are present on the cells help to increase locally the 
concentration of chemokines on the cell surface by inducing chemokine oligomerization and 
facilitating presentation to their respective receptors122. However, it was shown that GAG 
expression is not necessary for the biologic activity of the chemokines MIP-1α, RANTES, or 
MIP-1β, but cell surface-associated GAGs do enhance the activity of low concentrations of 
these chemokines by sequestration at the cell surface15,16. Conversely, chemokines can also 
bind soluble GAGs and the complexes formed are unable to bind to the receptor, resulting in 
a block of the biologic activity. The chemokines IL-8, MCP-1, MIP-1α, and RANTES bind to 
endothelial GAGs, with a higher preference for O-sulfation than N-sulfation123. SDF-1α 
interacts selectively and with high affinity with heparan sulfate in vitro. SDF-1α binds to 
highly sulfated, heparin-like, sequences within heparan sulfate through direct interaction via 
clusters of basic, positively charged residues on SDF-1α17,124. It can be concluded therefore 
that the interaction between chemokines and GAGs can have different, sometimes opposite, 
functions. 
     In many proliferative forms of glomerulonephritis, there is a massive influx of monocytes, 
neutrophils, and T cells into the glomerulus125 recruited by both mesangial and endothelial 
cells126. The chemokines MCP-1, MIP-1α, MIP-1β, RANTES, and IL-8 are thought to be 
involved in this leukocyte infiltration127. Mesangial cells secrete the CC chemokines 
MCP-1 and RANTES128,129, the CXC chemokines IL-8 (CXCL8), and GRO (CXCL1)130,131, 
while glomerular endothelial cells exhibit inducible expression of the chemokines RANTES 
and MCP-1132,133. Moreover, immunofluorescence staining in nephritic, but not normal, kidneys 
has demonstrated that the CX3C chemokine fractalkine is expressed in a nonlinear pattern 
typical of glomerular endothelium18,134. In a study about the role of chemokines and their 
receptors produced by mesangial or glomerular endothelial cells in the recruitment of 
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monocytes135, it has been shown that after TNF-α stimulation of mesangial cells, GRO-α, and 
IL-8 are immobilized on the mesangial cell surface via binding to HSPGs, whereas MCP-1 is 
secreted. Endothelial cell activation with TNF-α results in surface immobilization of GRO-α, 
secretion of MCP-1, and upregulation of fractalkine at the cell surface135,136. Soluble MCP-1 is 
required for the intraglomerular influx of monocytes135, while the chemokines GRO-α and 
IL-8, via their receptor CXCR2, are crucial for firm arrest of monocytes and neutrophils136. 
These results indicate that an ordered sequence of events, enacted by chemokines and their 
receptors, drives glomerular monocyte infiltration. Recently, it has been shown that in the rat 
the heparan sulfate chains of collagen XVIII interact with MCP-1 and after presentation to 
a monocytic cell line induce α4β1 integrin activation in vitro. This may indicate that collagen 
XVIII binds locally produced MCP-1 and presents it to infiltrating monocytes in the inflamed 
glomerulus137.
Leukocyte rolling and HSPGs 
     Heparan sulfate interacts with L- and P-selectins and modulates leukocyte rolling20,43. 
Moreover, heparinase treatment, which leads to heparan sulfate degradation, inhibits 
significantly the monocyte attachment to TNF-α-stimulated aortic endothelium under flow 
conditions by inhibiting L-selectin binding to these cells43. The selectins of the adhesion 
cascade, L-, E-, and P-selectin, are a family of adhesion molecules, which mediate the initial 
step, “rolling”, leading to the recruitment of leukocytes to sites of inflammation (Figure 2) 
(Table 1). L-selectin is expressed at the surface of leukocytes, E-selectin on endothelial cells, 
and P-selectin on platelets and endothelial cells42. All selectins interact with the tetrasaccharide 
sialyl-Lewisx, consisting of sialylated, fucosylated galactosamine structures, and with heparin-
like structures24. An in vitro study showed that HSPGs from cultured human umbilical vein 
endothelial cells (HUVECs) and aortic endothelial cells that bind to L-selectin are enriched in 
free amino groups in the glucosamine residues on their heparan sulfate chains25. Subsequently, 
it was shown that these heparan sulfate chains could also bind to P-selectin, but not to E-
selectin20. E-selectin expressed at the surface of endothelial cells did not bind to heparin24, 
while the binding of soluble E-selectin to capillary endothelial cells was blocked by heparin, 
chondroitin sulfate, and the HSPG syndecan-1, but not by sialyl-Lewisx-containing 
oligosaccharides138, indicating that heparan sulfate and/or chondroitin sulfate proteoglycans on 
the endothelial cell surface may be ligands for soluble E-selectin. The properties of heparin to 
inhibit the binding of L-selectin to capillary endothelial cells are critically dependent on 6-O-
sulfated glucosamine residues, while N-sulfation seems not important139. The anti-
inflammatory activity of heparin in vivo is largely determined by its interactions with P- and 
L-selectin. Thus endothelium-derived heparan sulfate, but also leukocyte-derived heparan 
sulfate, may have a role in modulating the biologic function of selectins. Moreover, it has been 
shown that syndecan-1 affects the slow rolling of leukocytes on the surface of activated 
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endothelium, since in the absence of syndecan-1 the number of rolling leukocytes and their 
average velocity were reduced140. Thus, syndecan-1 acts as a negative modulator of leukocyte-
endothelial interactions. The lack of syndecan-1 could lead to a dysregulation of chemokine 
action, or to an exposure of heparin-binding sites on molecules involved in the leukocyte-
endothelium adhesion process10. 
     Ligands for L-selectin are expressed not only on high endothelial venules (HEV) in the 
lymph nodes, but also in the distal tubuli and capillary blood vessels of the kidney141. The L-
selectin-reactive molecules on HEV are sialyl-Lewisx-like carbohydrates, while the L-
selectin-reactive molecules in the kidney are chondroitin sulfate proteoglycans (CSPGs) and 
HSPGs. L-selectin binds to the HSPG via its lectin domain in a Ca2+-dependent manner and 
requires heparan sulfate side chains, while sialic acid is not involved142. The reactive HSPGs 
are neither agrin nor perlecan, the major basement membrane HSPGs in the kidney. A recent 
study137 showed that these L-selectin-binding HSPGs in the kidney, with core proteins sizes of 
160 and 180 kD, were both collagen XVIII. Collagen XVIII in the basement membranes of the 
renal tubules of the outer medulla binds L-selectin, whereas collagen XVIII in the glomeruli 
and tubules in the renal cortex does not bind L-selectin137. This implies that only a subset of 
collagen XVIII species present in the kidney is reactive with L-selectin. It has been suggested 
that besides free amino groups also N- and O-sulfation of heparan sulfate chains are required 
for the interaction with L-selectin25,137.
Leukocyte adhesion and HSPGs
     In the previous paragraph, we discussed the involvement of HSPGs in the selectin-
dependent rolling and weak adhesion of leukocytes to endothelial cells. For strong adhesion 
and emigration of leukocytes integrins are important. Integrins mainly act as matrix receptors, 
and tie the ECM to the cytoskeleton. In blood cells they, however, act as cell-cell adhesion 
molecules. These integrins are heterodimers consisting of an α and a β chain. Integrins have 
been arranged in subfamilies according to the β subunits and each β subunit can be associated 
with eight different α subunits. However, individual α subunits may also be associated with 
several different β subunits143. Integrin activation depends on chemokine action, which is 
modulated by heparan sulfate. Also the expression of integrin ligands, like ICAM-1, on target 
cells is induced by heparan sulfate144. Heparan sulfate is an adhesive ligand for Mac-1 (CD11b/
CD18), a β2 integrin expressed on leukocytes (Figure 2) (Table 1). It has been shown that 
complete desulfation of heparin significantly reduced its binding to Mac-1, whereas 
N-sulfation of N-acetyl-glucosamine restored adhesion. Since forms of heparin that lack N-
sulfation are still capable of binding to Mac-1, secondary O-sulfated moieties are also 
sufficient for heparin to bind efficiently to Mac-1. Continuous flow experiments with heparins 
and E-selectin as co-substrates showed that neutrophils tether to E-selectin and form strong 
adhesions through a Mac-1-heparin interaction19. It has been shown that syndecan-1 acts as 
38
Heparan sulfate proteoglycans in glomerular inflammation
a negative modulator in the adhesion process, since absence of syndecan-1 increases the β2 
integrin-dependent adhesion process of neutrophils, monocytes, and lymphocytes to the vessel 
wall140. Recently, it has been shown that the enzyme heparanase that cleaves heparan sulfate, 
mediates cell adhesion to ECM independent of its enzyme activity46.
     The accumulation of the GAG matrix molecule HA in the cortical renal interstitium is 
linked to classic proinflammatory events in the kidney145. Accumulation of HA, its breakdown 
into low molecular weight products by specific hyaluronidases or oxygen-free radicals, and the 
subsequent stimulation of chemokines, cytokines, and adhesion molecules leads to a 
coordinated inflammatory response that could occur in many renal injury processes. The 
expression of CD44, the HA receptor, is markedly enhanced in inflammatory renal diseases 
(lupus nephritis and anti-GBM glomerulonephritis), particularly at the cell surface of tubular 
epithelial cells and in glomerular crescents145,146. HA fragments of a defined size upregulate the 
adhesion molecules ICAM-1 and VCAM-1, which suggests a possible link between matrix 
degradation and leukocyte adhesion147. 
Leukocyte transmigration and HSPGs
     Heparan sulfate not only affects leukocyte adhesion to a stimulated endothelium, it also 
influences leukocyte chemotaxis and transmigration118. Once the leukocytes are firmly attached 
to the endothelium they are able to crawl out of the blood vessel between adjacent endothelial 
cells. Activated and adherent leukocytes, including polymorphonuclear cells (PMNs), release 
reactive oxygen species (ROS), proteases, elastases, and additional enzymes that damage the 
injured tissue directly, thereby enhancing inflammatory cell infiltration and increasing 
vasoconstriction. These substances, together with the inflammatory mediators leukotriene-B4 
and platelet-activating factor (PAF), increase vascular permeability and upregulate adhesion 
molecule expression on endothelial cells, thereby promoting further inflammation. It has been 
reported that PMNs as well as cell-free neutrophil supernatants lead to a rapid and dramatic 
loss of proteoglycans from endothelial cells, which is mediated by neutrophil-derived serine 
proteases148. Elastase and heparanase can be released during inflammation by activated 
leukocytes and endothelial cells26,45,47,148. Elastase enhances additional inflammatory cell 
infiltration and can also enhance the effect of heparanase. Heparanase action on intact ECM 
or derivatives of heparin generates a trisulfated disaccharide that inhibits secretion of active 
TNF-α by activated T cells and macrophages, respectively. The inhibitory effects of the 
trisulfated disaccharide are lost if the sulfate groups are removed149. Inhibitors of neutrophil 
elastase appear to be the most effective inhibitors of proteoglycan release from endothelial 
cells. In addition, GBM-associated HSPG is susceptible to proteolytic cleavage by elastase. 
Intrarenal perfusion of elastase leads to a dose-dependent loss of heparan sulfate in the GBM, 
while HSPG core expression was only slightly reduced. The heparan sulfate loss is due to 
cleavage at the serine residue, at the attachment site of the heparan sulfate side chain150. 
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Heparanase (HPA1 or HPSE1) is a heparan sulfate-degrading enzyme that plays an 
important role in inflammation. Heparanase is a β-endoglucuronidase that degrades heparan 
sulfate chains at specific sites and specifically hydrolyzes the β1→ 4 bond between uronic acid 
and glucosamine residues151. Heparanases can remove ligand-binding sites from HSPGs either 
by cleavage of the heparan sulfate chain from the core protein, or by cleavage of ligand 
binding motifs in heparan sulfate45. Several blood-borne cells, including macrophages, 
neutrophils, activated CD4+ T cells, mast cells, monocytes, and platelets, but also endothelial 
cells, exhibit heparanase activity47,152. The degradation of heparan sulfate moieties during 
inflammation by heparanase may facilitate passage of leukocytes into tissues by altering the 
permeability of the ECM. In addition to disrupting the ECM for immune cell passage, the 
resultant products of heparanase-degraded substrates (heparan sulfate-derived 
oligosaccharides) or the release of heparan sulfate-bound inflammatory mediators may 
actually potentiate other pro- or anti-inflammatory processes47. 
     Heparin-binding protein is an inactive protease homologue that is produced by activated 
neutrophils and endothelial cells upon their interaction. Heparin-binding protein is able to bind 
to a wide range of cell surface HSPGs and may be endocytosed. Heparin-binding protein has 
an anti-apoptotic effect on endothelial cells and facilitates leukocyte influx in the injured 
tissue21,153,154.
     In certain proliferative forms of glomerulonephritis, ROS can be released locally by 
infiltrating leukocytes, which results in damage of the GBM and concomitant proteinuria. 
Overproduction of ROS has also been found in glomerular diseases in which the podocyte is 
the primary target of injury. The release of ROS leads to proteinuria by affecting glomerular 
endothelial and epithelial cells and disturbing normal glomerular permselectivity155,156, most 
likely by degradation of GBM-associated heparan sulfate3,28,157. The susceptibility of different 
GAGs to depolymerization by ROS depends on the degree of sulfation; low- or nonsulfated 
GAGs are more sensitive to depolymerization than high-sulfated GAGs157-159. Although 
changes in heparan sulfate during inflammation (and other pathological processes in the 
kidney) may be very dynamically, pinpointing to specific changes of heparan sulfate may give 
clues for the development of therapeutic heparin or heparan sulfate preparations, which we 
will address in the next two paragraphs. 
HSPG-related alterations in glomerular inflammation
     As we have outlined previously, there are several mechanisms that can induce heparan 
sulfate alterations in proteinuric diseases3. These mechanisms include: (1) masking of heparan 
sulfate by nucleosome containing immune complexes; (2) depolymerization of heparan sulfate 
by ROS; (3) proteolytic cleavage by elastase; (4) hyperglycemia-induced heparan sulfate 
undersulfation and reduction of heparan sulfate production; and (5) proteolytic cleavage by
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complement factors. Some of these mechanisms are related to inflammation. The evidence for 
this will be discussed briefly. 
     Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a broad 
spectrum of clinical manifestations, very often including renal involvement. SLE-associated 
glomerulonephritis is associated with granular deposits of immunoglobulins (Ig) and 
complement factors along the glomerular capillary wall and in the mesangium. One study160 
showed that both the extent of Ig deposits in the capillary loops and the albuminuria were 
correlated with a decreased staining of GBM-heparan sulfate, while the staining for the HSPG 
core protein was not altered. The negative correlation between GBM-heparan sulfate and Ig 
deposits and between GBM-heparan sulfate and albuminuria suggests that the neutralization 
of heparan sulfate-related anionic sites in lupus nephritis is caused by deposition of immune 
complexes in the capillary loops thereby blocking the negative charge of heparan sulfate. 
Instrumental for this complex formation is the binding of nucleosomes to heparan sulfate. This 
binding is due to the binding of the positively charged histones within the nucleosome to 
heparan sulfate. Heparin and noncoagulant heparin derivatives are able to bind to these 
nephritogenic complexes by covering these positive charges in histones36. This binding of 
heparin and heparin derivatives to the nucleosome-autoantibody complexes prevents the 
subsequent deposition of these nephritogenic immune complexes in the GBM and reduces the 
glomerular inflammation and albuminuria. 
     As outlined before, elastase and heparanase can be produced by different inflammatory 
cells. In various proliferative forms of glomerulonephritis a segmental reduction was 
observed for heparan sulfate staining in the glomerulus32. It remains to be determined whether 
this reduction in heparan sulfate staining is due to enzymatic cleavage and/or ROS production 
exerted by the infiltrating glomerular cells. 
     An in vitro study with bovine glomerular endothelial cells161 showed that IL-1β, a 
proinflammatory cytokine that activates endothelial cells and upregulates ICAM, MCP-1162,163, 
and the GAG HA in microvascular endothelium111, induces an increased synthesis of sulfated 
GAGs by glomerular endothelial cells. This effect may be a part of the cell defense to maintain 
the permselective properties of the glomerular barrier. Glomerular endothelial cells are capable 
of producing heparan sulfate, chondroitin sulfate, and dermatan sulfate164.      
     The differential expression of syndecans in response to inflammatory stimuli was a first 
sign of their direct involvement in these processes. The expression of syndecan-1 can be 
induced on the surface of endothelial cells in the context of inflammation165, suggesting a role 
for syndecan-1 in the interaction of leukocytes with endothelial cells. Lack of syndecan-1 
promotes the increase in vascular permeability and leukocyte extravasation under 
inflamma-tory conditions10,140. Also the expression of syndecan-4 can be induced on 
endothelial cells (and other inflammatory cells) in response to inflammatory stimuli10,166. 
     Since it can be envisaged that structural alterations in HSPGs are associated with renal
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inflammatory processes, further study is warranted to unravel structural and topologic 
alterations of HSPGs in glomerular inflammation and to evaluate heparan sulfate domains 
as markers for progressive loss of renal function. These analyses could provide clues for the 
therapeutic use of heparan sulfate and/or heparin.  
     Overall, at this moment there is not much literature on specific changes in heparan sulfate 
structure(s) in relation to inflammation, especially glomerulonephritis. Currently, we are 
analyzing (experimental) glomerulonephritis models with single chain antibodies that are 
specific for structural epitopes within heparan sulfate14,167-172.      
Heparan sulfate intervention therapies in inflammation
     It is plausible that heparan sulfate or heparin derivatives affect inflammatory cell behavior 
and may have promising therapeutic, anti-inflammatory properties11. As outlined, HSPGs are 
involved in several ways in the activation of leukocytes and endothelial cells, the rolling, the 
firm adhesion, and diapedesis of leukocytes through the endothelium and subsequent 
migration into the tissue, one can think of many potential targets for therapeutic heparin/
heparinoid fractions (glycomimetics). In several (inflammatory) diseases, like rheumatoid 
arthritis and diabetic nephropathy, heparin/heparinoids are already clinically applied173-175. 
Indeed, it has been shown that therapeutic intervention with heparinoids prevents leukocyte 
adhesion/influx and disease manifestation in inflamed tissue43,176. However, the main
application of heparin/heparinoids still is its use as anticoagulant. It can be more safely used 
as an anti-inflammatory drug, if the anticoagulant properties are abrogated, leaving the anti-
inflammatory properties unchanged. Partial chemical desulfation of heparin showed that the 
anti-inflammatory effects of heparin are independent of anticoagulant activity11,37,177. Heparin 
blocks P- and L-selectin-initiated cell adhesion wherein the sulfate groups at C6 on the 
glucosamine residues play a critical role. Some nonanticoagulant forms of heparin have the 
same effect and such analogues may be useful as therapeutically effective inhibitors of 
inflammation139. In SLE, heparin and noncoagulant heparin derivatives are equally effective 
in inhibiting the binding of nucleosome complexed antibodies to heparan sulfate in the GBM. 
These drugs prevented the development of glomerular lesions in MRL/lpr mice36. In an 
intravital microscopy study, administration of low molecular weight heparin markedly 
reduced TNF-α-induced leukocyte rolling, adhesion, and tissue infiltration38. When heparin 
was given after TNF-α, only leukocyte rolling was reduced and not the firm adhesion of 
leukocytes. However, heparin inhibits binding of soluble ligands, like fibrinogen, factor X, and 
iC3b to Mac-119. Heparin also inhibits heparanase activity of neutrophils, lymphocytes, 
endothelial cells and platelets as well as ECM degradation26. Enoxaparin, a low molecular 
weight heparin, protects cultured valvular endothelial cells from activation and monocyte
42
Heparan sulfate proteoglycans in glomerular inflammation
adhesion by inhibiting the expression of the cell adhesion molecules ICAM-1 and E-selectin39. 
Another study with low molecular weight heparin35 showed that N-desulfated heparin inhibits 
leukocyte adhesion and transmigration and has the lowest anticoagulant activity among low 
molecular weight heparins and chemically modified heparin derivatives. 
     Flow perfusion adhesion experiments with bone marrow endothelium and hematopoietic 
progenitor cells showed that heparins inhibit both rolling and firm adhesion, whereas 
heparan sulfate-GAGs inhibit firm adhesion178. The same authors179 showed that soluble 
heparan sulfate but not heparin enhanced SDF-1α-induced migration. In vivo experiments with 
infused sulfated saccharides showed inhibition of the rolling of leukocytes34. A rat model 
similar to human chronic progressive glomerulonephritis has been used to study the 
therapeutic effect of a sulfated GAG, sulfated hyaluronic acid (SHA)180. Proteinuria and 
leukocyte infiltration into the glomeruli were inhibited by the administration of SHA in both 
the acute and the chronic phase. SHA ameliorated rat proliferative glomerulonephritis by 
inhibiting P-selectin-dependent leukocyte infiltration in glomeruli. 
     As mentioned, the evaluation of heparan sulfate domains as markers for progressive loss of 
renal function and as potential therapeutics is important in glomerulonephritides. If it becomes 
possible to define groups and monosaccharide sequences of heparan sulfate that are relevant 
in the inflammation process, specific heparan sulfate-analogues may be developed to stop or 
influence this inflammatory process.
Conclusion
     There is convincing evidence that HSPGs not only play an important role in the 
permeability of the GBM, but also are important in glomerular inflammation. HSPGs capture 
chemokines in the ECM and on the surface of glomerular endothelial cells to establish a local 
concentration gradient by inducing chemokine oligomerization and facilitating their 
presentation to receptors. Chemokines can also bind soluble GAGs, which results in a 
blockade of their biologic activity. HSPGs are not only involved in the mobilization and 
attraction of inflammatory cells, they also promote adhesion, diapedesis, and migration. 
Heparan sulfate chains bind both L-selectin and the β2 integrin Mac-1. Several leukocytes, like 
macrophages, neutrophils, activated CD4+ T cells, mast cells, and endothelial cells, exhibit 
heparanase activity, which degrades heparan sulfate, thereby facilitating passage of 
lymphocytes into tissues and potentiating other pro- or anti-inflammatory processes. Several 
important studies described in this review showed that heparan sulfate or heparin derivatives 
affect the behavior of inflammatory cells and have promising therapeutic and anti-
inflammatory properties by preventing leukocyte adhesion/influx and glomerular damage.
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Abstract
     The culture and establishment of glomerular cell lines has proven to be an important tool 
for the understanding of glomerular cell functions in glomerular physiology and pathology. 
Especially, the recent establishment of a conditionally immortalized visceral epithelial cell line 
has greatly boosted the research on podocyte biology.   
     Glomeruli were isolated from H-2Kb-tsA58 transgenic mice that contain a gene encoding 
a temperature sensitive variant of the SV40 large tumor antigen, facilitating proliferative 
growth at 33°C and differentiation at 37°C. Glomerular endothelial cells were isolated from 
glomerular outgrowth by magnetic beads loaded with CD31, CD105, GSL I-B4, and ULEX. 
Clonal cell lines were characterized by immunofluorescence staining with antibodies/lectins 
specific for markers of endothelial cells, podocytes, and mesangial cells. Putative glomerular 
endothelial cell lines were analyzed for: (1) cytokine-induced expression of adhesion 
molecules; (2) tube formation on Matrigel coating; and (3) the presence of fenestrae. 
     As judged by immunostaining for Wilms tumor-1, smooth muscle actin (SMA), 
podocalyxin, and von Willebrand factor (vWF), we obtained putative endothelial, podocyte 
and mesangial cell lines. The mouse glomerular endothelial cell clone #1 (mGEnC-1) 
was positive for vWF, podocalyxin, CD31, CD105, VE-cadherin, GSL I-B4 and ULEX, 
internalized acetylated-low-density lipoprotein (LDL), and showed increased expression of 
adhesion molecules after activation with proinflammatory cytokines. Furthermore, mGEnC-1 
formed tubes and contained nondiaphragmed fenestrae. 
     The mGEnC-1 represents a conditionally immortalized cell line with various characteristics 
of differentiated glomerular endothelial cells when cultured at 37°C. Most important, 
mGEnC-1 contains nondiaphragmed fenestrae, which is a unique feature of glomerular 
endothelial cells.  
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Introduction
     Endothelial cells play a role in many biologic and pathologic processes like coagulation, 
angiogenesis, and inflammatory responses. The morphology and biologic responses of 
endothelial cells vary depending on the vascular system they originate from, either within one 
organism or between different species. Endothelial cells play a key role during inflammation 
and their activation leads to the recruitment of leukocytes to the local area of inflammation, 
which involves various factors like chemokines, selectins, integrins, and heparan
sulfates1-4. The glomerular endothelial cell layer is attached to the glomerular basement 
membrane (GBM), which is covered at the urinary side by visceral epithelial cells, also 
called podocytes. This triple sandwich of fenestrated endothelial cells, GBM, and podocytes 
constitutes the glomerular capillary filter, which is responsible for the charge- and size- 
dependent filtration of plasma molecules2,5-7. A characteristic feature of glomerular endothelial 
cells is the presence of numerous nondiaphragmed fenestrae8, which in humans are about 100 
nm in diameter9. 
     The in vitro culture of the different types of glomerular cells (i.e., fenestrated endothelial 
cells, mesangial cells, podocytes and parietal epithelial cells) is an important tool to obtain 
a better understanding of their respective roles in renal physiology and pathology (including 
proteinuria, inflammation, sclerosis/fibrosis, and hyperglycemia). Techniques for the isolation 
and culture of glomerular cells, including endothelial cells, have been developed and 
successfully applied. A major draw back of the in vitro culture of isolated primary glomerular 
endothelial cells is their limited life span and the loss of characteristic features and/or 
differentiation markers after propagation5,10-12. 
     The development of genetically modified mice has allowed for the establishment of 
glomerular (endothelial) cell lines with a more constant phenotype and a longer life span. 
Initially, glomerular cell lines transgenic for the simian virus 40 (SV40) large T antigen 
have been established, which usually resulted in a cellular transformation of cells to a more 
proliferative and less differentiated phenotype (“immortalized”) compared to normal primary 
cells. Later on, the H-2Kb-tsA58 transgenic mouse (“immortomouse”) was established13, 
which expresses, depending on the temperature, SV40 large T antigen protein encoded by the 
temperature sensitive (ts) A58 allele controlled by the interferon-γ (IFN-γ)-inducible H-2Kb 
promoter. In cells derived from this mouse, the SV40 large T antigen protein is functionally 
expressed at the permissive temperature of 33°C, which results in cell proliferation. Exposure 
of the cells to the nonpermissive temperature of 37°C, leads to the degradation of the SV40 
large T protein, which then results in a less proliferative and more differentiated phenotype 
that is comparable to that of primary cells. Therefore, these cell lines are designated as 
conditionally immortalized cells13.
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     The H-2Kb-tsA58 transgenic mouse has been used to establish various cell lines including 
mesangial cells14, but also podocytes that are normally difficult to isolate and culture without 
loss of their differentiated phenotype. These conditionally immortalized podocyte cell 
lines have greatly boosted the research on podocyte biology and pathology15,16. In addition, 
endothelial cell lines have been derived from the brain and the heart of these mice17,18. 
However, thus far no glomerular endothelial cell lines have been described. 
     In this paper, we describe the isolation and characterization of the first conditionally 
immortalized glomerular endothelial cell line. We show that this cell line has all characteristics 
of a functional glomerular endothelial cell, including the presence of nondiaphragmed 
fenestrae. This cell line enables future studies on the role of glomerular endothelial cells in 
glomerular physiology and pathology.
Methods
Mice and genotyping
     The H-2Kb-tsA58 transgenic mice13 were obtained from Charles River Laboratories (CRL, 
Wilmington, DE, USA), and housed and handled according to the guidelines of the University 
Medical Centre Nijmegen, The Netherlands. 
     Toe biopsies were lysed in lysis buffer [100 mmol/L Tris, pH 7.5, 5 mmol/L ethylene-
diaminetetraacetic acid (EDTA), 200 mmol/L NaCl, 0.2% sodium dodecyl sulfate (SDS), 5 
μg protein K (Invitrogen Life Technologies, Breda, The Netherlands)] for 16 hours at 60°C. 
Subsequently, DNA was precipitated by isopropanol and centrifugation and finally dissolved 
in 100 μl TE buffer (10 mmol/L Tris, pH 8.0, and 1 mmol/L EDTA).  
     Polymerase chain reaction (PCR) was performed with the use of Platinum PCR SuperMix 
(Invitrogen Life Technologies) and a specific primer pair; forward primer (nucleotide 
position 1159-1179) 5’-GAGCGAATTCTGGATGGCTGGAGTTGCTTG-3’, reverse primer 
(nucleotide position 1441-1460) 5’-GATCGGATCCGAAGGCAAATCTCTGGACTC-3’ 
(Biolegio BV, Malden, The Netherlands). PCR cycling parameters were: (1) denaturation of 
94°C/5 minutes; (2) 35 cycles with 94°C/1 minute (denaturation), 55°C/1 minute (annealing), 
and 72°C/1 minute (elongation); and (3) elongation of 72°C/5 minutes using the Mastercycler 
5330 (Eppendorf, Hamburg, Germany). PCR-products were analyzed by agarose gel 
electrophoresis.
Isolating and cloning of mouse glomerular cells
     Glomeruli were isolated from kidneys of 14 mice aged between 6 to 8 weeks under sterile 
conditions by gradually sieving with stainless steel sieves (150, 90, 75, 53, and 32 μm) 
(Endecotts, London, UK), which resulted in 95% pure glomeruli as judged by light
58
Mouse glomerular endothelial cell lines
microscopy inspection. These glomeruli were washed with 50 mL Dulbecco´s modified 
Eagle´s medium (DMEM) (Invitrogen Life Technologies) and subsequently treated with 2.5 
mL 0.1% collagenase type II (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) in 
DMEM at 37°C for 1.5 hours. The cell suspension was washed in 5 mL Hanks’ balanced salt 
solution (HBSS) containing 10% fetal calf serum (FCS) (Invitrogen Life Technologies), and 
subsequently resuspended in 25 mL cloning medium, consisting of microvascular endothelial 
cell growth medium (EGM)-2MV (Cambrex Bioscience, Verviers, Belgium), supplemented 
with 100 μg/mL endothelial cell growth supplement (ECGS) (PeproTech, London, UK), 5 
U/mL heparin (Sigma-Aldrich), 5% FCS, 10% newborn calf serum (NCS), 1% penicillin/
streptomycin (Invitrogen Life Technologies), and 20 U/mL recombinant mouse IFN-γ 
(PeproTech). The cells were cultured in tissue culture flasks (Corning Life Sciences B.V., 
Schiphol-Rijk, The Netherlands) precoated with a mixture of 1% gelatin (Sigma-Aldrich) and 
human fibronectin (1 μg/cm2) (Sigma-Aldrich) at the permissive temperature of 33°C in a 
humidified 5% CO2 atmosphere. On days 7 to 14 after initial seeding, outgrowths of individual 
glomeruli were detached by trypsin-EDTA (Invitrogen Life Technologies) and glomerular 
endothelial cells were isolated using magnetic beads loaded with antibodies directed against 
endothelial markers and lectins using a MPC-50 magnet (Dynal, Hamburg, Germany). Details 
on these magnetic beads loaded with antibodies/lectins are given in Table 1. After culture for 1 
week at 33°C, this procedure was repeated once. 
Table 1. Magnetic beads loaded with anti-endothelial antibodies/lectins used to isolate 
glomerular endothelial cells
Magnetic beads   Catching antibodies/lectins         Ratio beads:cells
Dynabeads with sheep  Rat anti-mouse PECAM-1 (CD31)b,        3:1     
anti-rat IgGa, 25 μL  1.5 μg/2.5 x 105 beads
(1 x 107 beads/mL)     Rat anti-mouse endoglin (CD105)b,         3:1 
    1.5 μg/2.5 x 105 beads 
  
Biomag streptavidin ultraload Biotinylated Griffonia simplicifolia         50:1
particlesc, 25 μL (12.5 x 107 isolectin B4 (GSL I-B4)d,
beads/mL)   7.5 μg/3 x 106 beads  
     Biotinylated Ulex europaeus         50:1
    agglutinin I (ULEX)d,
    7.5 μg/3 x 106 beads
a Dynal, Hamburg, Germany.  
b BD Biosciences, Alphen aan den Rijn, The Netherlands.
c Westburg, Leusden, The Netherlands.  
d Vector Laboratories Inc., Burlingame, CA, USA.
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Characterization of glomerular cells by immunofluorescence 
     The cells were grown in slide flasks (Nunc, Roskilde, Denmark), precoated with 1% 
gelatin, for 1 week at 33°C (permissive temperature) or for 1 week at 37°C (nonpermissive 
temperature) in normal growth medium with or without IFN-γ, respectively, until they 
were 80% to 100% confluent. Cells were fixed for 10 minutes with 2% paraformaldehyde-
phosphate-buffered saline (PBS) with 0.3% Triton X-100 (TX-100) (Sigma-Aldrich) for 
the evaluation of the SV40 expression or with 90% acetone for all other markers, and then 
blocked with 2% bovine serum albumin (BSA) (Sigma-Aldrich) in PBS for 30 minutes. 
Cells were incubated with antibodies (2 to 4 μg/mL) specific for SV40 large T antigen 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), platelet endothelial cell adhesion 
molecule (PECAM)-1 (CD31), endoglin (CD105) (BD Biosciences, Alphen aan den Rijn, The 
Netherlands), vascular endothelial (VE)-cadherin (Santa Cruz Biotechnology), the biotinylated 
lectins Griffonia simplicifolia isolectin B4 (GSL I-B4) and Ulex europaeus agglutinin I 
(ULEX) (Vector Laboratories Inc., Burlingame, CA, USA), von Willebrand factor (vWF) 
(Dako, Glostrup, Denmark), and podocalyxin (0601) in 2% BSA-PBS for 45 minutes, rinsed 
with PBS and incubated with the appropriate Alexa 488-conjugated secondary antibody 
(Molecular Probes, Leiden, The Netherlands) in 2% BSA-PBS for 45 minutes at room 
temperature. Finally, the cells were rinsed in PBS, postfixed with 1% paraformaldehyde-PBS, 
rinsed in PBS, and embedded in VectaShield mounting medium H-1000 (Vector Laboratories).
The slides were investigated by fluorescence microscopy (Zeiss Axioskop microscope 
equipped with an epi-illuminator) and photographed with a digital camera (Nikon Coolpix 
DXM 1200, Bunnik, The Netherlands). To distinguish glomerular endothelial cells from 
other glomerular cells (mesangial cells and podocytes), we also stained for smooth muscle 
actin (SMA) (A-2547, Sigma-Aldrich) and Wilms tumor-1 (Santa Cruz Biotechnology), 
respectively. As a positive control for mesangial cells and podocytes we used mouse mesangial 
cells (SV40 MES 13) (CRL-1927, ATCC, Manassas, VA, USA) and the conditionally 
immortalized mouse podocyte cell line (MPC-5), which was cultured as described 
previously15.
The retrieved cells were then subcloned by limiting dilution and by electronic sorting 
(Epics Elite Flowcytometer) (Beckman Coulter, Miami, FL, USA) and cultured in normal 
growth medium, consisting of DMEM:HAM-F12 medium (Invitrogen Life Technologies) 
supplemented with 10% FCS, 1% penicillin/streptomycin, and 20 U/mL recombinant 
mouse IFN-γ at 33°C. Unless stated otherwise, this normal growth medium was used for all 
subsequent experiments.
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Uptake of acetylated-low-density lipoprotein (LDL) by glomerular endothelial cells
     For evaluation of uptake of acetylated-LDL by the glomerular endothelial cells, the cells 
were grown in slide flasks, precoated with 1% gelatin, for 1 week at 37°C in normal growth 
medium without IFN-γ, until they were 80% to 100% confluent. The cells were incubated in 
normal growth medium without IFN-γ supplemented with 10 μg/mL Dil-labeled acetylated-
LDL (Biomedical Technologies Inc., Stoughton, MA, USA) at 37°C. After 4 hours the cells 
were rinsed with PBS, fixed with 3% formaldehyde-PBS, rinsed with PBS, mounted in 
VectaShield, and evaluated by fluorescence microscopy. As controls we used mouse mesangial 
cells (SV40 MES 13) (ATCC, CRL-1927) and the conditionally immortalized mouse podocyte 
cell line (MPC-5) cultured for 1 to 2 weeks at 37°C.
Activation of glomerular endothelial cells by tumor necrosis factor (TNF)-α and 
interleukin (IL)-1β as determined in enzyme-linked immunosorbent assay (ELISA) 
     The glomerular endothelial cells were grown in 96-well plates (Corning Life Sciences) 
precoated with 1% gelatin, for 1 week in normal growth medium without IFN-γ at 37°C, 
until they were 100% confluent. The cells were then incubated with normal growth medium 
supplemented with murine TNF-α (10 ng/mL) and/or IL-1β (10 ng/mL) (PeproTech) for 
18 hours at 37°C. After washing with PBS, the cells were fixed with 2% formaldehyde-
PBS, washed with PBS, incubated with 2% BSA-PBS for 2 hours at room temperature, and 
washed with PBS containing 0.05% Tween 20 (PBS/Tween). Cells were incubated with rat 
antibodies against mouse intercellular adhesion molecule (ICAM)-1 or vascular adhesion 
molecule (VCAM)-1 in 2% BSA-PBS for 1 hour at room temperature, washed with PBS/
Tween and incubated with mouse anti-rat IgG (H+L) conjugated with horseradish peroxidase 
(Jackson ImmunoReseach Laboratories, Inc., West Grove, PA, USA) in 2% BSA-PBS for 
1 hour at room temperature. Finally, the cells were washed with PBS/Tween and incubated 
with tetramethylbenzidine (TMB) substrate solution (SFRI Laboratories, Berganton, France). 
After exactly 15 minutes, the reaction was stopped with 2 mol/L H2SO4 and absorption was 
measured at 450 nm using a Bio-Rad Multiplate Reader (Biorad Laboratories Inc., Hercules, 
CA, USA).  
Demonstration of fenestrae by scanning and transmission electron microscopy 
(TEM)
     The glomerular endothelial cells were grown in normal growth medium without IFN-γ 
on glass coverslips precoated with 1% gelatin, for 1 week at 37°C, until they were 100% 
confluent. Cells were rinsed with basic DMEM medium and fixed in 2.5% glutaraldehyde 
dissolved in 0.1 mol/L sodium cacodylate buffer, pH 7.4, for 3 hours at 4˚C. Subsequently,
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cells were washed in the same buffer, rinsed in palade buffer, pH 7.3, and postfixed in palade 
buffered 2% osmium (OsO4) for 2 hours. Cells were dehydrated by subsequent incubations 
with 70%-90%-100% alcohol and acetone, critical point dried using a Polaron EMS 850 
critical point drier (Balzers, Eindhoven, The Netherlands) and coated with gold by the use 
of an Edwards EMS 550 sputter coater (Aurion, Wageningen, The Netherlands). Cells were 
visualized with a Jeol 6310 scanning electron microscope (JEOL, Tokyo, Japan). As a control 
we used a microvascular endothelial cell line (EOMA) (CRL-2586, ATCC).
     For TEM, cells were cultured to confluency in normal growth medium on a 30 mm, 2 μm 
thick, foil bottom Willco-dish (WillCo Wells BV, Amsterdam, The Netherlands) precoated 
with 1% gelatin, for 1 week at 37˚C. After the filter was rinsed with culture medium, the cells 
were fixed with 2.5 % glutaraldehyde in 0.1 mol/L sodium cacodylate buffer, pH 7.2, for 2 
hours at 4°C. Subsequently, cells were rinsed several times in PBS, postfixed in cacodylate-
buffered 1% OsO4 for 30 minutes, rinsed in 50% alcohol, and incubated with 50% alcohol 
and 2% uranyl acetate for 20 minutes at 4˚C. After the cells were rinsed in 50% alcohol, the 
cells were dehydrated via subsequent alcohol steps to alcohol 100%, alcohol 100%/epon 1:1 
overnight, and finally embedded in Epon 812. Ultrathin sections were cut on an ultratome, 
Reichert Ultracut S (Leica Microsystems, Heidelberg, Germany). The specimens were 
examined by electron microscopy (JEOL 1200 EX2, JEOL).
Determination of the proliferation rate
     Glomerular endothelial cells from one confluent 75 cm2 flask, precoated with 1% gelatin, 
cultured at 33°C, were split into four and cultured in normal growth medium with or without 
IFN-γ at 33°C or 37°C, respectively, for 48 hours. Subsequently, cells were passaged into 
96-well plates, precoated with 1% gelatin and/or fibronectin (1 μg/cm2), at 10,000 cells/well. 
Cells were cultured for up to 96 hours before cell proliferation reagent WST-1, 10 μL/well, 
(Roche Diagnostics GmbH, Germany) was added. For the background control the same 
volume per well of growth medium and WST-1 was used. After 2 hours the absorbance was 
determined at 450 nm with a reference of 605 nm for the cleavage of the tetrazolium salt 
WST-1 to formazan.
Microtube formation assay
     Glomerular endothelial cells (3 x 105) in 1 mL of normal growth medium with or without 
IFN-γ were plated on polymerized Matrigel (BD Biosciences), 600 μL/well, in 6-wells and 
cultured at 33°C or 37°C, respectively. After 20 hours tube formation was analyzed by phase-
contrast microscopy and photographed (Nikon Coolpix 990).
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Results
Isolation and cloning of mouse glomerular endothelial cells (mGEnC) 
     Following the isolation with magnetic beads and subcloning, we finally obtained numerous 
clonal cell lines. The cell lines had different morphology and growth characteristics, especially 
when cultured at 37°C. Immunofluorescence staining with Wilms tumor-1 (podocyte marker), 
SMA (mesangial cell marker), vWF (endothelial cell marker), and podocalyxin (podocyte and 
endothelial cell marker) revealed potential podocyte, mesangial, and glomerular endothelial 
cell lines (not shown). We focused further on the characterization of seven potential 
glomerular endothelial cell lines (mGEnC-1 to -7), which positively stained for vWF and 
podocalyxin and negatively stained for SMA and Wilms tumor-1.
Morphology of mGEnC
     The mGEnC had typical cobblestone morphology when grown on gelatin-coated tissue 
culture flasks at 33°C (Figure 1A). The morphology of most mGEnC clones was different 
at permissive (33°C) or nonpermissive (37°C) culture conditions. The mGEnC cultured at 
permissive conditions had more active nuclei with an increased number of mitotic figures, 
were smaller in size, and grew faster than cells cultured at nonpermissive conditions. Similar 
to other mGEnC clones, clone mGEnC-1 cultured at 37°C appeared to be more flattened with 
a transparent appearance (Figure 1B). Furthermore, mGEnC clones cultured on Matrigel 
rapidly formed the characteristic microtubes, especially apparent at 37°C (Figure 2).
Figure 1. Morphology of mouse glomerular endothelial cells (mGEnC-1). (A) mGEnC-1 [passage (P) 12] imaged 
under phase-contrast microscopy and cultured at 33°C in normal growth medium supplemented with 20 U/mL 
interferon-γ (IFN-γ), formed cobblestone monolayers on gelatin-coated plastic. (B) mGEnC-1 (P12) cultured at 
37°C on gelatin in medium without IFN-γ demonstrated flattened cobblestone morphology with a transparent 
appearance (phase contrast x 200).
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     Since glomerular endothelial cells are one of the few types of endothelial cells that contain 
fenestrae, scanning electron microscopy was used to visualize these fenestrae in the mGEnC. 
As seen in Figure 3A and B, the mGEnC-1 cell line contains fenestrae, some of which are 
indicated by arrows, with a diameter between 50 and 100 nm. In contrast, the microvascular 
cell line EOMA did not contain these fenestrae (Figure 3C). In addition, TEM was performed 
to show that the fenestrae in the mGEnC lacked a diaphragm as for example observed in 
peritubular capillary endothelial cells. We checked hundreds of cells by TEM for the presence 
of diaphragmed fenestrae. However, we never observed any diaphragm (Figure 3D, E, and F).
Figure 2. Tube formation of mouse glomerular endothelial cells (mGEnC-1). mGEnC-1 (3 x 105) [passage (P) 
14] cultured for 20 hours on Matrigel in a 6-well plate in normal growth medium under permissive conditions [with 
interferon-γ (IFN-γ) at 33°C] (A) formed less developed microtubes than under nonpermissive conditions [without 
IFN-γ at 37°C] (B) (phase contrast x 100).
Identification and characterization of mGEnC-1
     As seen in Figure 4A, mGEnC-1 cultured at 33°C with IFN-γ demonstrated abundant 
nuclear staining for the mouse anti-SV40 large T antigen. However, after 1 week at 37°C 
in the absence of IFN-γ, the expression of the SV40 large T antigen was hardly detectable 
(Figure 4B). 
     Indirect immunofluorescence microscopy was used to demonstrate the expression of 
endothelial markers by mGEnC-1. The vWF staining of the mGEnC-1 cell line cultured at 
33°C (Figure 4C) or at 37°C (Figure 4D) nicely revealed the Weibel-Pallade bodies that are 
characteristic for endothelial cells. mGEnC-1 cultured at 33°C and 37°C stained also positive 
for podocalyxin (Figure 4E and F) and for the markers used for the initial selection [i.e. 
PECAM-1 (CD31), endoglin (CD105), and the lectins GSL I-B4 and ULEX (not shown)]. The 
endothelial specific antigen VE-cadherin was present at the regions of intercellular contacts.
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Figure 3. Presence of fenestrae in mouse glomerular endothelial cells (mGEnC-1). mGEnC-1 [passage (P) 15]               
cultured at 37°C on glass coverslips and foil bottom Willco-dishes were analyzed by scanning (A, B, and C) and 
transmission electron microscopy (D, E, and F), respectively. Some fenestrae (A) and one fenestra (B) are indicated by 
arrows. The microvascular endothelial cell line EOMA was used as negative control (C). Nondiaphragmed fenestrae 
are indicated by arrows (D, E, and F). The bars represent 1 μm (A, B, C, and D) and 0.25 μm (E and F). 
Importantly, the VE-cadherin expression was not observed in mGEnC-1 grown at 33°C 
(Figure 4G), but exclusively in mGEnC-1 grown at 37°C (Figure 4H). In addition, the 
mGEnC-1 cell line was able to phagocytose acetylated-LDL (Figure 5A), a function mediated 
by specific receptors typically found on endothelial cells and macrophages19. In contrast, 
mouse mesangial cells and the podocyte cell line MPC-5 were not able to internalize 
acetylated-LDL (Figure 5B and C). When the mGEnC-1 cell line was subcultured for more 
then 30 passages, the cells remained positive for all these markers. The results shown for 
mGEnC-1 are representative for several other mGEnC cell clones that we have isolated.
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Figure 4. Expression of the SV40 large T antigen and endothelial markers by mouse glomerular endothelial 
cells (mGEnC-1). mGEnC-1 [passage (P) 14] cultured in slide flasks at 33°C in medium supplemented with 20 U/mL 
interferon-γ (IFN-γ) (A) or at 37°C in normal growth medium (B) for 1 week were fixed, stained with the antibody 
against mouse SV40 large T antigen followed by an Alexa 488-conjugated secondary antibody, and visualized by 
fluorescence microscopy. mGEnC-1 (P14) cultured in slide flasks for 1 week in normal growth medium with or 
without IFN-γ under permissive or nonpermissive conditions, respectively, were fixed and stained with the antibodies 
against vWF (C and D), podocalyxin (E and F), and VE-cadherin (G and H) followed by an Alexa 488-conjugated 
secondary antibody, and visualized by fluorescence microscopy (250x).
Proliferation of mGEnC-1
     Comparison of endothelial cell proliferation using the cell proliferation reagent WST-1 
demonstrated a clear difference between several cell lines cultured at 33°C with IFN-γ and 
those cultured at 37°C without IFN-γ. A minimum of 24 hours was required for the mGEnC 
clones to adapt to the change in temperature, and therefore the mGEnC clones derived from 
a single flask grown at 33°C were cultured for 48 hours in tissue culture flasks that were 
precoated with 1% gelatin and/or fibronectin in normal growth medium with or without IFN-γ 
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Figure 5. Uptake of acetylated-low-density lipoprotein (LDL) by mouse glomerular endothelial cells
(mGEnC-1), mesangial cells and podocytes. (A) mGEnC-1 [passage (P) 14] cultured in slide flasks for 1 week at 
37°C in normal medium were incubated with Dil-labeled acetylated-LDL for 4 hours, fixed and visualized by 
fluorescence microscopy at 570 nm. As negative controls we used mouse mesangial cells (B) and the mouse podocyte 
cell line MPC-5 cultured for 2 weeks at 37°C (C) (250x).
at 33°C and 37°C, respectively, before the proliferation experiments started. As shown in 
Figure 6, mGEnC-1 maintained under permissive conditions, entered the log phase of growth 
and proliferated rapidly. In contrast, the same cells cultured at 37°C in the absence of 
IFN-γ showed a markedly reduced proliferation rate. mGEnC-1 grown in wells precoated with 
both 1% gelatin and fibronectin grew faster than mGEnC-1 grown in wells precoated with 
gelatin alone (Figure 6). Fibronectin also resulted in a distinct change in cellular morphology, 
inducing cellular extensions when subconfluent. 
Figure 6. Proliferation rates of mouse glomerular endothelial cells (mGEnC-1) cultured on different coatings 
and at different temperatures. The cleavage of tetrazolium salts WST-1 to formazan in mGEnC-1 [passage (P) 15] 
cultured at 33°C in growth medium supplemented with 20 U/mL interferon-γ (IFN-γ) or at 37°C in growth medium 
alone on 1% gelatin or 1% gelatin and 1 μg/mL fibronectin for 1 to 4 days. Data are expressed as the optical density 
(OD) in nm (means ± SD) (N = 3) and are representative of three experiments.
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The mGEnC-1 cell line shows increased adhesion molecule expression in response 
to TNF-α and/or IL-1β 
     In mGEnC-1 the expression of ICAM-1 and VCAM-1 was detectable on resting cells and 
was upregulated at least threefold after activation by TNF-α and/or IL-1β (Figure 7). Further 
analysis of mGEnC-1 at later passages (up to 30 tested) showed that the cells retain their 
sensitivity for cytokine-induced upregulation of adhesion molecules. The results shown for 
mGEnC-1 are representative for other mGEnC clones.
Figure 7. Surface antigen expression on resting and cytokine-stimulated mouse glomerular endothelial cells
(mGEnC-1). Monolayers of mGEnC clones [passage (P) 14 to 16], cultured for 1 week at 37°C in 96-well plates, 
were stimulated for 18 hours with normal growth medium alone or supplemented with 10 ng/mL tumor necrosis factor 
(TNF)-α and/or interleukin (IL)-1β and analyzed by enzyme-linked immunosorbent assay (ELISA) for the expression 
of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). The results are 
expressed as mean ± SD optical density (OD) for triplicate wells. The figure is representative of four experiments.
Discussion
     In this study, we describe the isolation and characterization of conditionally immortalized 
mouse glomerular endothelial cell lines. The establishment of glomerular cell lines (podocytes, 
parietal epithelial cells, mesangial cells, endothelial cells) will improve our understanding of 
their roles in glomerular function both in health and disease. Until now, several (conditionally) 
immortalized podocyte, parietal epithelial, mesangial, and endothelial cell lines derived from 
different species have been described (Table 2). Especially, the conditionally immortalized 
mouse podocyte cell line has greatly boosted research on podocyte physiology and pathology 
in recent years15,20-22. As far as we know no conditionally immortalized glomerular parietal 
epithelial and endothelial cell lines have been described. For glomerular endothelial cells, 
several cell lines have been described containing the intact SV40 large T antigen23-26 or another 
immortalizing gene24. Primary glomerular endothelial cells have also been isolated from cow
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and human2,6,9,10,27-29. However, the isolation of normal mouse glomerular endothelial cells 
from BALB/c mice is almost impossible, since the primary mouse glomerular endothelial 
cells hardly proliferate or differentiate and die after a few days (own experience). This 
problem can be overcome through the use of the immortomouse, which allows the generation 
of continuously proliferating cell lines capable of differentiation after degradation of the 
immortalizing protein. The H-2Kb-tsA58 transgenic mice have the oncogene in all cells at the 
same locus30-33. The presence of the inducible tsA58 SV40 large T antigen allows mGEnC-1 
to expand rapidly under permissive conditions (33°C + IFN-γ), to obtain sufficient glomerular 
endothelial cells for analysis, before switching to the untransformed state for experimentation 
by culture at 37°C in the absence of IFN-γ. Thus, these cells proliferate much slower and 
differentiate when cultured at 37°C in the absence of IFN-γ. This was confirmed by the lack 
of detectable SV40 tsA58 large T antigen and by the reduction in proliferation of mGEnC-1 
cultured under nonpermissive conditions compared to mGEnC-1 cultured under permissive
Table 2. Several podocyte, mesangial, endothelial and parietal epithelial cell lines derived 
from different species
Glomerular cell line Immortalizing gene  Species       Reference
Podocytes  Intact SV40 large T antigen Rat       Coers et al.40
       Human       Delarue et al.41 
              Ardaillou et al.42 
       Mouse       MacKay et al.23
   Temperature sensitive SV40  Mouse       Mundel et al.15
   large T antigen   Human       Saleem et al.16
Mesangial cells  Intact SV40 large T antigen Human       Sraer et al.43  
              Banas et al.44
       Rat       Huwiler et al.45
              Nitta et al.46
   Temperature sensitive variant  Mouse       Barber et al.14
   SV40 large T antigen
  
Endothelial cells  Intact SV40 large T antigen Mouse       MacKay et al.23
       Cow       Kester et al.25
              Nitta et al.26
   Oncogenic type 31 adenovirus Rat       Laulajainen et al.24   
              Kester et al.25
Parietal epithelial cells Intact SV40 large T antigen Rat       Huwiler et al.45 
              Yaoita et al.47
              Kanemoto et al.48
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conditions. Our mGEnC cells expressed SV40 large T antigen mRNA at 33°C and 37°C, but 
the SV40 large T antigen protein could be observed only at 33°C by Western blot analysis 
(data not shown). The mGEnC-1 cell line has been cultured under permissive conditions 
for more than 30 passages with no signs of senescence and has retained the temperature and 
IFN-γ responsiveness for large T antigen expression. However, after 2 weeks of culture under 
nonpermissive conditions, they showed signs of senescence. This phenomenon has also been 
described in another study17. 
     The morphologic appearance of the glomerular capillary endothelial cell clones we have 
isolated is similar to that described by others for capillary endothelial cells derived from 
a variety of sources2,6,9,10,17,27-29,34-36. The appearance of tubular capillary-like structures has 
also been observed37, although this morphologic characteristic is not specific for capillary 
endothelial cells, since endothelial cells from human umbilical vein also form tube-like 
structures38. Most importantly, the only difference between glomerular (and hepatic) 
endothelial cells and endothelial cells from other sources is the presence of nondiaphragmed 
fenestrae8,9, which indeed are present in our mGEnC clones based on scanning electron 
microscopy and TEM (Figure 3).
     The endothelial nature of mGEnC-1 was further confirmed by the expression of PECAM-1 
(CD31), endoglin (CD105), vWF in the Weibel-Pallade bodies, podocalyxin, binding of GSL 
I-B4 and ULEX, and uptake of acetylated-LDL2,18,39. VE-cadherin did stain the intercellular 
junctions of mGEnC-1 cultured at 37°C and seems to be a differentiation marker for our 
endothelial cells since mGEnC-1 cultured at 33°C with IFN-γ did not express VE-cadherin.
     Fibronectin coating results in a significant higher proliferation rate of mGEnC-1 cultured 
at 33°C and induced cellular extensions when the cells were subconfluent. The difference in 
growth and morphology of glomerular endothelial cells cultured on different coatings has also 
been observed in other studies6,24. 
     We isolated mGEnC-1 for the study of interaction between leukocytes and glomerular 
endothelial cells. Therefore, the expression of cellular adhesion molecules on resting and 
cytokine-stimulated mGEnC-1 was studied. ELISA analysis of resting mGEnC-1 confirmed 
basal expression of ICAM-1 and VCAM-1 and this expression was at least threefold up-
regulated by cytokines.
Chapter 3
Conclusion
     We have described the isolation of conditionally immortalized mouse glomerular 
endothelial cells that can be expanded rapidly under permissive conditions before switching 
to the differentiated state for experimentation. The mGEnC-1 cell line retains the phenotypic 
characteristics of glomerular endothelial cells and can be used in further adhesion studies to 
study the role of heparan sulfate proteoglycans in glomerular inflammation. In addition, 
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coculture experiments with podocytes can be done to study the functional roles of these cells 
in inflammation, proteinuria, and sclerosis/fibrosis.
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Abstract
     Proliferative glomerulonephritis is characterized by the influx of inflammatory cells. 
Heparan sulfate (HS) plays a key role in the leukocyte-endothelium interaction. However, the 
nature and function of glomerular endothelial HS in leukocyte adhesion remain elusive. Here, 
we evaluated the specific features within glomerular endothelial HS that promote leukocyte 
adhesion. Mouse glomerular endothelial cells (mGEnC-1) activated with TNF-α or IL-1β 
showed an increased expression of N- and 6-O-sulfated HS domains concomitant with an 
altered expression of HS-modifying enzymes. Inhibition of the canonical NF-κB pathway 
completely prevented the cytokine-induced alterations in HS and gene expression. HS 
enriched in N- and 6-O-sulfated domains was present in the culture supernatant of activated 
mGEnC-1, and accompanied with an increased heparanase expression. Leukocyte adhesion 
to mGEnC-1 increased 4-fold after activation with cytokines, while removal of HS reduced 
leukocyte adhesion 2-3-fold. Leukocyte adhesion was reduced after adding N- and 6-O-
sulfated heparinoids, or blocking N- and 6-O-sulfated HS domains on activated mGEnC-1  
with specific antibodies. Finally, treatment of murine lupus nephritis with heparinoids 
prevented glomerular leukocyte influx. In conclusion, N- and 6-O-sulfated domains in HS on 
activated glomerular endothelium are crucial for leukocyte adhesion. This knowledge may 
lead to the development of defined HS-based therapeutics for treatment of glomerulonephritis.
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Introduction
     Proliferative glomerulonephritis is manifested in a range of diseases and characterized 
by the influx of inflammatory cells (leukocytes). Leukocyte-endothelium interactions are a 
central event in inflammation in general and leukocyte trafficking to/on/through activated 
endothelium can be divided into four sequential steps, i.e. leukocyte tethering, rolling, firm 
adhesion and transmigration, respectively1,2. Heparan sulfate proteoglycans (HSPGs) play an 
important role in all these steps3-5.
     HSPGs are expressed in a tissue- and stage-specific manner at the surface of virtual all cells 
and in the extracellular matrix. HSPGs consist of a core protein with linear covalently attached 
heparan sulfate (HS) sugar side chains, which belong to the family of strongly negatively 
charged glycosaminoglycans (GAGs) that also includes heparin and nonsulfated hyaluronan. 
HSPGs are involved in many biologic processes such as cell adhesion, migration, proliferation 
and differentiation, which is mediated by the binding of chemokines, cytokines, enzymes and 
growth factors to HS3,6,7. The HS chain consists of up to 150 α(1-4)-glucuronate-β(1-4)-
N-acetyl-glucosamine disaccharide units that can be modified extensively. Modification of HS 
starts with N-deacetylation and N-sulfation of N-acetyl-glucosamine catalyzed by 4 different 
N-deacetylase/N-sulfotransferase isoenzymes. Subsequently, C5-epimerization of glucuronate 
to iduronate catalyzed by C5-epimerase, and O-sulfation at various positions (C-2, C-3, and 
C-6) catalyzed by al large family of sulfotransferases may occur6. The structure of HS chains 
may be further edited by HS-modifying enzymes such as heparanase, a β(1-4)- 
endoglucuronidase that cleaves HS at specific sites8,9, and HS 6-O-endosulfatases (Sulf-1 and 
Sulf-2) that specifically remove 6-O-sulfate10,11. Due to the combination of possible 
modifications, HS is characterized by an enormous structural diversity, in particular in 
sulfation patterns, which is important for the specific binding and modulation of a wide range 
of factors corresponding to the different biologic activities of HS6,12. 
     The role of HS in the different steps of leukocyte trafficking is recently reviewed3-5. 
In brief, tethering of leukocytes involves binding of chemokines to HS at the surface of 
endothelial cells and in the extracellular matrix13,14. Rolling of leukocytes is mediated by L-
selectin expressed by leukocytes and P-selectin expressed by endothelial cells. HS can serve 
as a ligand for both L- and P-selectin15-22. Firm adhesion of leukocytes involves interactions 
between integrins, like Mac-1, and integrin ligands, like endothelial HS22,23. Transmigration of 
leukocytes also involves HS-binding factors, like heparin-binding protein, while GAGs can 
influence this process22,24. Notably, heparanase expressed by activated endothelial cells and 
leukocytes degrades HS in the inflamed area, thus facilitating transmigration of leukocytes25,26. 
     HS isolated from different (microvascular) endothelial cells shows distinct sulfation 
patterns, which implies differences in HS structure-function relationships, including its role in 
the leukocyte-endothelium interaction3,4,27-29. The HS domains on glomerular endothelial cells 
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that promote the firm adhesion of leukocytes remain elusive. This knowledge could lead to the 
development of well-defined supplementary HS-based therapeutics with anti-inflammatory 
effects. Therefore, we evaluated the features within glomerular endothelial HS that are 
important for the firm adhesion of leukocytes using a static adhesion assay. Furthermore, we 
evaluated the effect of heparinoid treatment on glomerular granulocyte influx in murine lupus 
nephritis.
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Cell culture and treatment with GAG-degrading enzymes
     Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) with all 
features of primary glomerular endothelial cells were cultured as described30. Primary human 
glomerular endothelial cells and HUVEC were isolated and propagated as described31. Cells 
were activated with TNF-α (10 ng/ml; Peprotech, Rocky Hill, USA) or IL-1β (10 ng/ml; 
Peprotech) for 18 hours. Where indicated, BAY-110782 (7.5 μM; Tebu-Bio, Heerhugowaard, 
The Netherlands) or calcitriol (10 nM; Tebu-Bio), inhibitors of the canonical and the non-
canonical NF-κB pathway, respectively, were added. The murine granulocyte cell line 32Dcl3 
was cultured as described32,33. Primary mouse granulocytes were isolated using a gelatin 
sponge34. HS was removed by treatment with 0.25 U/ml heparinase III (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) for 1 hour at 37°C. The terminal 4,5-unsaturated uronate 
residues that arise after heparinase III treatment are recognized by antibody 3G1035, which 
was used to evaluate enzyme activity. Chondroitin sulfate (CS)/dermatan sulfate (DS) was 
removed by treating with 1U/ml chondroitinase ABC (Sigma-Aldrich) for 1 hour at 37°C. The 
activity of chondroitinase ABC was checked with the anti-CS antibody IO3H1036.
Flow cytometry
     Cells were detached with 10 mM EDTA and washed with PBS. Cells were incubated 
with primary antibody (Table 1) in PBA (PBS containing 0.5% BSA (Sigma-Aldrich)) for 
30 minutes and subsequently washed in PBA. Appropriate Alexa-/FITC-labeled antibodies 
(Table 1) were used for detection, while anti-HS scFv antibodies (Table 2) were detected by 
an anti-VSV antibody (clone P5D4; Sigma-Aldrich) followed by an Alexa-labeled antibody. 
All detecting antibodies were incubated in PBA for 30 minutes. Subsequently, cells were 
washed and resuspended in PBA. Heparanase expression was measured using Fix and Perm 
reagents (Sanbio, Uden, The Netherlands). Fluorescence was measured using a FACScan 
(BectonDickinson, San Jose, USA). 
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Table 2. Structural features of the epitopes of anti-GAG antibodiesa
Antibody     HS/CS moieties required for antibody binding
10E4   GlcA-GlcNS-GlcA-GlcNAc
AO4B08     GlcNS6S-IdoA2S-GlcNS6S 
EV3B2      GlcNS±6S-GlcA/IdoA-GlcNS±6S 
EW3D10  GlcNS6S
EW4G2      GlcNS6S-GlcA-GlcNS6S 
HS3A8      GlcNS6S-IdoA2S
HS4C3      GlcNS3S6S-IdoA2S
HS4E4      GlcNS 
LKIV69     GlcNS-IdoA2S
RB4Ea12    IdoA-GlcNS6S
IO3H10   GlcA2S-GalNac4S6S
aGAG: glycosaminoglycan; HS: heparan sulfate; CS: chondroitin sulfate; GlcA: glucuronate; GlcNS: N-sulfated-
glucosamine; GlcNAc: N-acetylated-glucosamine; IdoA: iduronate; S: sulfate; GalNAc: N-acetylated-
galactosamine36,43,44.
RNA isolation and real-time reversed transcription-PCR
     RNA was isolated using the RNeasy Mini protocol, including a DNase I step (Qiagen, 
Venlo, The Netherlands). Reversed transcription of 1 µg RNA was performed with Oligo dT 
primers and the Superscript First-Strand Synthesis System (Invitrogen Life Technologies, 
Breda, The Netherlands). One tenth of cDNA was used as template in real-time PCR using 
SYBR Green Supermix (Bio-Rad, Veenendaal, The Netherlands) with gene-specific primers 
(10 μM; Biolegio, Malden, The Netherlands; Table 3) on the MyiQ PCR system (Bio-Rad). 
PCR conditions: denaturation at 95°C (5 minutes); 40 cycles of 95°C (30 seconds), 55°C 
(45 seconds), and 72°C (30 seconds); elongation at 72°C (10 minutes). Expression of the 
housekeeping gene GAPDH was used to quantify gene expression.
Determination of the structural features of HS released in cell culture supernatants 
of mGEnC-1 by an inhibition ELISA
     Flat bottom 96-well plates (Nunc A/S, Roskilde, Denmark) were coated with 5 μg/well HS 
from bovine kidney (Seikagaku, Tokyo, Japan) in PBS overnight at 4°C. Wells were blocked 
with PBS/gelatin (BD Biosciences, Alphen a/d Rijn, The Netherlands) for 2 hours. Cell culture 
supernatants were incubated with anti-HS antibodies for 1 hour in a separate plate precoated 
with PBS/gelatin. In addition, different amounts of HS from bovine kidney were incubated 
with the same anti-HS antibodies to prepare individual standard curves. The HS-coated plate 
was washed with PBS/Tween and the anti-HS antibodies preincubated with cell culture
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Table 3. Primers used in real-time PCR
Target gene       Primer sequence (5’-3’)
N-deacetylase/N-sulfotransferase-1  (F) GAGCGATGCATCCTCAAAGCTGCGTG
     (R) GATCGTAATCCTTTAGGAAG
N-deacetylase/N-sulfotransferase-2  (F) GAGCCCCTCTGCTACTTCGCT
     (R) GATCTGGCTGGCCAAGCCGAC
N-deacetylase/N-sulfotransferase-3  (F) TGTGTTTCCTGTGAGTCCAGATGTGTG
     (R) ATTGTCCTCCTCACTTCCATCAGCCTG
N-deacetylase/N-sulfotransferase-4  (F) GGACTTTTTCCCCAC
     (R) TTTAAATCAGGAGGGGCCC
6-O-sulfotransferase-1   (F) CGCCCAGAAAGTTCTACTACATC
     (R) GGTTGTTAGCCAGGTTATAGGG
6-O-sulfotransferase-2   (F) TCCTTCAGACCCATTTCC
     (R) CCCACACACAGCATAACAC
6-O-sulfotransferase-3   (F) TGAATGAGAGCGAGCGGAAC
     (R) CCAAAGTAATCCAAGAGAAG
6-O-sulfatase-1    (F) CCACCTCTCCCTTCTTGGTA
     (R) TGCACAGCAGACACTCATGT
6-O-sulfatase-2    (F) GGGGCAGGAACACTGTAAGA
     (R) TAAACGCTGTGGCTAGGATCA
Heparanase    (F) GAGCGGAGCAAACTCCGAGTGTATC
     (R) GATCCAGAATTTGACCGTTCAGTTGG
ICAM-1     (F) GTCGAAGGTGGTTCTTCTGAGC
     (R) TCCGTCTGCAGGTCATCTTAGG
GAPDH     (F) AGAAACCTGCCAAGTATGATGAC
     (R) TCATTGTCATACCAGGAAATGAG
supernatants or HS from bovine kidney were added and incubated for 1 hour. Subsequently, 
wells were washed with PBS/Tween and anti-HS antibody binding was detected by incubating 
with the appropriate horseradish peroxidase-conjugated antibody for 1 hour. Finally, the plates 
were washed with PBS/Tween and incubated with tetramethylbenzidine (TMB) solution (SFRI 
Laboratories, Berganton, France). After 15 minutes, the reaction was stopped with 2 M H2SO4 
and absorption was measured at 450 nm. 
GAG preparations and determination of GAG content
     GAG preparations included HS from bovine kidney (Seikagaku), heparosan (K5), O-
sulfated heparosan, CS and hyaluronic acid (all from Sigma-Aldrich). Modified heparinoids
          81
Chapter 4
were kindly provided by Drs. Van Dedem (Diosynth, Oss, The Netherlands) and Casu (G. 
Ronzoni Institute, Milan, Italy) and included 2-O-desulfated heparin, 6-O-desulfated heparin, 
N-desulfated heparin and O-desulfated heparin (Figure 1). Low molecular weight (LMW) 
heparins used are listed in Table 4. The amount of sulfated HS in cell culture supernatants was 
determined by the Farndale assay37. 
Static adhesion assay
     mGEnC-1 was cultured in 96-well plates until confluence. 32Dcl3 cells or primary 
granulocytes (6 x 105 cells/ml) were labeled with Calcein-AM (25 μg/ml; Invitrogen) in PBS 
for 30 minutes, washed in PBS and resuspended in medium. Standard curves of adhesion of 
different numbers of labeled granulocytes to mGEnC-1 were always included. In general, 
Figure 1. Structural features of disaccharide units of GAGs and heparin(oids). Each disaccharide unit illustrates 
a characteristic unit in the indicated preparation and does not present the overall structure of the preparation. X = H or 
SO3
-.
82
Ta
bl
e 
4.
 C
ha
ra
ct
er
is
tic
s o
f L
M
W
 h
ep
ar
in
s5
2a
G
en
er
ic
 d
ru
g 
na
m
e 
   
   
 C
om
po
si
tio
n 
   
   
   
   
   
M
ol
ec
ul
ar
   
   
   
   
Tr
is
ul
fa
te
d 
   
   
   
D
is
ul
fa
te
d 
   
   
   
   
   
   
 M
on
os
ul
fa
te
d
(B
ra
nd
 n
am
e;
 
 
 
 
   
   
   
   
   
w
ei
gh
t (
kD
a)
   
   
 d
is
ac
ch
ar
id
es
 (A
U
)  
   
  d
is
ac
ch
ar
id
es
 (A
U
)  
   
di
sa
cc
ha
rid
e 
(A
U
)
m
an
uf
ac
tu
re
r)
 
 
 
 
 
 
   
   
   
   
   
2S
N
S6
S 
   
 N
S3
S6
S 
   
 N
S6
S 
   
 2
SN
S 
   
6S
H
ep
ar
in
  
 
   
   
 H
ep
ar
in
 
   
   
   
   
   
 5
-3
0 
   
   
   
   
   
34
.7
   
   
   
   
1.
2 
   
   
   
4.
0 
   
   
   
1.
6 
   
0.
9
(S
ig
m
a-
A
ld
ric
h)
D
al
te
pa
rin
 
 
   
   
 L
M
W
 h
ep
ar
in
 
  4
-6
 
   
   
   
   
   
49
.3
   
   
   
   
2.
6 
   
   
   
3.
2 
   
   
   
3.
1 
   
2.
0
(F
ra
gm
in
; P
ha
rm
ac
ia
)
En
ox
ap
ar
in
 (C
le
xa
ne
; 
   
   
 L
M
W
 h
ep
ar
in
 
  3
.5
-5
.5
   
   
   
   
   
 7
1.
3 
   
   
   
  1
.9
 
   
   
 1
1.
4 
   
   
   
2.
5 
   
1.
4 
S
an
ofi
-A
ve
nt
is
)
Ti
nz
ap
ar
in
 
 
   
   
 L
M
W
 h
ep
ar
in
 
  3
.4
-5
.6
   
   
   
   
   
 8
8.
9 
   
   
   
  1
.9
 
   
   
   
7.
5 
   
   
   
5.
4 
   
1.
4
(I
nn
oh
ep
; B
ro
ca
ce
f H
ol
di
ng
)
D
an
ap
ar
oi
d 
(O
rg
ar
an
; 
   
   
 H
S/
D
S/
C
S 
 
   
   
   
   
   
 4
-1
0 
   
   
   
   
   
- 
   
  -
 
   
   
   
-  
   
   
   
   
- 
   
   
  
   
-
O
rg
an
on
) 
 
   
   
 (8
4/
12
/4
%
)
S
ul
od
ex
id
e 
(V
es
se
l D
ue
 
   
   
 8
0%
 f
as
t-
m
ov
in
g 
   
   
   
<
 8
 
   
   
   
   
   
- 
   
  -
 
   
   
   
- 
   
   
   
   
 -
 
   
   
  
   
-
F
; A
lf
a-
W
as
se
rm
an
n)
 
   
   
 h
ep
ar
in
, 2
0%
 D
S
  
N
ad
ro
pa
ri
n 
(F
ra
xi
pa
ri
n;
 
   
   
 L
M
W
 h
ep
ar
in
 
  2
.4
-7
.2
   
   
   
   
   
 1
7.
2 
   
   
   
  0
.8
 
   
   
   
1.
2 
   
   
   
1.
8 
   
0.
7
S
an
ofi
-A
ve
nt
is
)
F
on
da
pa
ri
nu
x 
(A
ri
xt
ra
; 
   
   
 P
en
ta
sa
cc
ha
ri
de
   
   
   
   
1.
72
8 
   
   
   
   
   
- 
   
   
   
   
   
 -
 
   
   
   
- 
   
   
   
   
 -
 
   
   
  
   
-
S
an
ofi
-A
ve
nt
is
) 
 
   
   
 (
C
31
H
43
N
3N
a1
0S
8)
a 2
S:
 2
-O
-s
ul
fa
te
; N
S:
 N
-s
ul
fa
te
; 6
S:
 6
-O
-s
ul
fa
te
; 3
S:
 3
-O
-s
ul
fa
te
; L
M
W
: l
ow
 m
ol
ec
ul
ar
 w
ei
gh
t; 
H
S:
 h
ep
ar
an
 su
lfa
te
; D
S:
 d
er
m
at
an
 su
lfa
te
; C
S:
 c
ho
nd
ro
iti
n 
su
lfa
te
; A
U
: a
rb
itr
ar
y 
un
it;
 -:
 n
ot
 a
na
ly
ze
d.
 
          83
Results
Expression of HS(PGs) by unstimulated and activated mGEnC-1 and the 
involvement of NF-κB signaling      
     The expression of different HSPG core proteins and specific HS domains (Tables 1 and 2) 
by unstimulated or mGEnC-1 activated with TNF-α or IL-1β was evaluated. Expression of the 
core proteins syndecan-1, syndecan-4, glypican-1, CD44 and endostatin/collagen XVIII was 
significantly upregulated after activation, while glypican-3, agrin and perlecan were hardly 
expressed (Figure 2A). The amount of HS expressed by mGEnC-1, as estimated by heparinase
Chapter 4
Treatment of mice with lupus nephritis with heparinoids and determination of 
glomerular granulocyte influx, albuminuria and glomerulonephritis
     MRL/lpr mice were treated daily with a subcutaneous injection of 50 μg heparin (n=15) 
or N-desulfated heparin (n=15) in PBS, or only PBS (n=15), from week 8 until week 21 as 
described38. Albuminuria was analyzed with radial immunodiffusion. Mice were sacrificed 
at week 21 and kidneys were paraffin embedded. The severity of glomerulonephritis was 
determined on deparaffinized and dehydrated sections by staining with Periodic acid-Schiff 
and silver methenamine38. Glomerular granulocyte influx was determined by incubating 
sections with a rat antibody specific for granulocytes (NIMP-R14)39 for 1 hour, followed by 
a peroxidase-labeled anti-rat secondary antibody (Dako, Glostrup, Denmark) for 30 minutes, 
followed by incubation with diaminobenzidine (Sigma-Aldrich) for 10 minutes. Sections 
were counterstained with hematoxylin for 2 minutes. Two independent observers evaluated on 
blinded sections at least 50 glomeruli per animal. The local animal ethics committee approved 
all experiments.
Statistical Analysis
     Values are expressed as means ± SEM and significance was evaluated by Mann-Whitney 
U testing using GraphPad Prism, version 4.0 software (GraphPad Software, Inc., San Diego, 
CA).
60,000 labeled 32Dcl3 cells/granulocytes were added in one well and incubated for 30 minutes 
at 37°C. Where indicated, mGEnC-1 or 32Dcl3 cells/granulocytes were treated by GAG-
degrading enzymes or preincubated with GAGs/heparinoids or anti-HS antibodies. After 
incubation, plates were filled with medium and centrifuged upside down for 5 minutes at 300 x 
g, this was repeated once, subsequently cells were lysed in 50 mM Tris pH 8.3 with 0.1% SDS 
and fluorescence was measured. 
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III treatment followed by 3G10 staining, increased 2-fold after activation with TNF-α (Figure 
2B) or IL-1β (Figure 2C). Anti-HS antibodies recognizing distinct structural features within 
HS, which include sulfation of various residues and epimerization of glucuronate (Table 2), 
were used to characterize the structural features of HS on mGEnC-1. The reactivity of the 
anti-HS antibody 10E4, which recognizes a N-sulfated/N-acetylated domain35, increased 
about 1.5-fold after activation with TNF-α (Figure 2B) or IL-1β (Figure 2C). In addition, 
the reactivities of AO4B08, EW3D10 and EW4G2, which all recognize N- and 6-O-sulfated 
domains (Table 2), increased about 1.5- to 2.5-fold after activation. The reactivities of EV3B2, 
HS3A8, HS4C3 and LKIV69, which recognize N- and/or 2-O-sulfated domains (Table 2), 
decreased about 1.5-fold after activation. Finally, the reactivities of HS4E4 and RB4Ea12, 
which recognize N-sulfated domains, did not change upon activation. Similar results were 
obtained with primary human glomerular endothelial cells after activation with TNF-α (data 
not shown). The NF-κB pathway may mediate the cytokine-induced activation of endothelial 
cells40,41. To get a clue about the mechanisms underlying cytokine-induced changes in 
glomerular endothelial HS structure and function, the canonical or the noncanonical 
NF-κB pathway was inhibited with BAY-110782 and calcitriol, respectively. BAY-110782 
completely prevented alterations in HS on mGEnC-1 activated with TNF-α (Figure 2B) or 
IL-1β (Figure 2C), whereas BAY-110782 had no effect on the expression of HS by unactivated 
mGEnC-1 (data not shown). Inhibition of the noncanonical NF-κB pathway had no effect 
on cytokine-induced HS alterations on mGEnC-1 (data not shown). An altered expression 
profile of HS-modifying enzymes could explain the increased expression of N- and 6-O-
sulfated HS domains by activated mGEnC-1. Indeed, mRNA expression of N-deacetylase/
N-sulfotransferase-1, and -2, and 6-O-sulfotransferase-1 and -2 increased about 2-fold after 
activation with TNF-α, while the mRNA expression of 6-O-sulfatase-2 decreased about 4-fold 
(Table 5). The expression of the other evaluated HS-modifying enzymes was not detectable. 
Inhibition of the canonical NF-κB pathway prevented the TNF-α-induced alterations in 
mRNA expression of HS-modifying enzymes (Table 5). Cells activated with IL-1β yielded 
essentially the same results (data not shown). The cytokine-induced mRNA expression of 
ICAM-1, included as a control, was also inhibited by BAY-110782. Taken together, activation 
of glomerular endothelial cells with TNF-α or IL-1β leads to an increased HS(PG) expression 
and structural HS alterations that include N- and 6-O-sulfated HS domains, which are 
accompanied with changes in expression of the relevant HS-modifying enzymes. Furthermore, 
the canonical NF-κB pathway mediates cytokine-induced changes in glomerular endothelial 
HS.
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Table 5. Gene expression profile of HS-modifying enzymes in unactivated and activated 
mGEnC-1 and the effect of inhibiting the canonical NF-κB pathwaya 
Relative expression (Ct)
Target gene         Unactivated         Activated
        -BAY         +BAY
N-deacetylase/N-sulfotransferase-1   1   2.7      0.97 
N-deacetylase/N-sulfotransferase-2   1   1.5      0.94
N-deacetylase/N-sulfotransferase-3   -   -      -
N-deacetylase/N-sulfotransferase-4   -   -      - 
6-O-sulfotransferase-1    1    1.7       0.95
6-O-sulfotransferase-2    1    2.0      1.05 
6-O-sulfotransferase-3    -   -      -
6-O-sulfatase-1     -   -      -
6-O-sulfatase-2     1    0.29      0.96
Heparanase     1       2.17      0.93
ICAM-1      1              51      1.3
aThe expression is relative to the expression in unactivated cells that is set at 1 and is calculated by the delta-delta Ct 
method using GAPDH as a reference gene. -: not detectable (Ct > 40); BAY: BAY-110782; ICAM-1: intercellular 
adhesion molecule-1.
Figure 2. Expression of HSPG core proteins and different HS domains by unstimulated and activated 
mGEnC-1 and the involvement of the NF-κB signaling pathway. The expression of HSPG core proteins and 
different HS structures by unstimulated and TNF-α- or IL-1β-activated mGEnC-1 was measured by flow cytometry. 
(A) Relative mean fluorescence intensity (MFI) (upper panel) and percentage positive cells (lower panel) are shown. 
The MFI of unstimulated mGEnC-1 cells is set at 100. Sdc-1: Syndecan-1; Sdc-4: Syndecan-4; Glp-1: Glypican-1; 
Glp-3: Glypican-3; Endst: Endostatin/CollagenXVIII. (B) The expression of several HS domains recognized by anti-
HS antibodies (Table 2) was measured by flow cytometry in unactivated mGEnC-1, mGEnC-1 activated with TNF-α 
and mGEnC-1 activated with TNF-α in the presence of BAY-110782, an inhibitor of the canonical NF-κB pathway. 
The MFI of unstimulated mGEnC-1 cells is set at 100. (C) The expression of several HS domains recognized by anti-
HS antibodies (Table 2) was measured by flow cytometry in unactivated mGEnC-1, mGEnC-1 activated with IL-1β 
and mGEnC-1 activated with IL-1β in the presence of BAY-110782. The MFI of unstimulated mGEnC-1 cells is set at 
100. (A, B, C) * p < 0.05 versus unstimulated mGEnC-1. ^ p < 0.05 versus activated mGEnC-1 (n=5).
Enhanced release of HS enriched in N- and 6-O-sulfated domains in the cell 
culture supernatant of activated mGEnC-1 is associated with an increased 
heparanase expression 
     A 2-fold increase of sulfated HS in the culture supernatant of mGEnC-1 activated with 
TNF-α or IL-1β was measured biochemically. Expression of the HS-hydrolyzing enzyme
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HS on activated mGEnC-1 is crucial for the firm adhesion of granulocytes 
     The role of GAGs on mGEnC-1 in the firm adhesion of leukocytes was evaluated in an in 
vitro static adhesion system with the granulocyte cell line 32Dcl3, which expresses L-selectin, 
Mac-1, LFA-1 and NIMP-R1432,33. In contrast to primary leukocytes/granulocytes, 32Dcl3 
cells lack HS, which makes them suitable to delineate the role of endothelial HS in leukocyte/
granulocyte adhesion. The adhesion of 32Dcl3 cells increased about 4-fold after activation 
of mGEnC-1 with TNF-α (Figure 4A) or IL-1β (Figure 4B). The removal of endothelial HS 
reduced adhesion 2-fold, while removal of CS/DS had no effect (Figure 4A and 4B). Primary 
mouse granulocytes revealed results similar to 32Dcl3 cells (Figure 4A and 4B). Additional 
heparinase III treatment of primary granulocytes led to a reduced binding of only 10% (data 
not shown). Inhibition of the canonical NF-κB pathway completely prevented the enhanced 
binding of granulocytes to mGEnC-1 activated with TNF-α (Figure 4A) or IL-1β (Figure 4B), 
which indicates that the expression of non-HS inflammatory adhesion molecules is regulated 
by NF-κB signaling. In summary, HS expressed by activated mGEnC-1 is crucial for the firm 
adhesion of granulocytes, whereas HS on granulocytes is less important. Furthermore, the 
enhanced binding of granulocytes to activated mGEnC-1 depends on the canonical NF-κB 
pathway.
heparanase by mGEnC-1 increased more than 2-fold after activation with TNF-α or IL-1β 
(Figure 3A) and could serve as a possible explanation for the presence of HS in the culture 
supernatant25,26,42. Primary human glomerular endothelial cells and HUVEC also showed 
an increased expression of heparanase after activation with TNF-α (data not shown). The 
features of the released HS were evaluated by using anti-HS antibodies. The reactivity of the 
majority of the anti-HS antibodies with released HS was hardly affected by activation, while 
the reactivity of 10E4, AO4B08, EW3D10 and EW4G2 increased 2-6-fold after activation 
with TNF-α (Figure 3B) or IL-1β (Figure 3C). Furthermore, inhibition of the canonical NF-κB 
pathway prevented the release of HS enriched in N- and 6-O-sulfated domains by mGEnC-1 
activated with TNF-α or IL-1β, and the upregulation of heparanase (Table 5). These data show 
that HS released by activated glomerular endothelial cells is enriched in specific N- and 6-O-
sulfated domains, which is mediated by the canonical NF-κB pathway.
GAGs, heparinoids, anti-HS antibodies and HS from cell culture supernatant 
of activated mGEnC-1 can inhibit the firm adhesion of 32Dcl3 cells to activated 
mGEnC-1
     The effect of different GAGs, heparinoids (Figure 1; Table 4) and anti-HS antibodies 
(Table 2) on the firm adhesion of 32Dcl3 cells to activated mGEnC-1 was tested. Adhesion of 
32Dcl3 cells was about 40% reduced by the addition of HS, while CS and the unsulfated HS 
hyaluronic acid and heparosan (K5) had no effect (Figure 5A). However, chemically 
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Figure 3. Heparanase expression and release of HS in cell culture supernatant by unstimulated and activated 
mGEnC-1. (A) The mRNA and protein expression of heparanase by unstimulated, TNF-α-activated or IL-1β-
activated mGEnC-1. About 100% of both unstimulated and activated mGEnC-1 expressed heparanase (not shown).
The mRNA expression and mean fluorescence intensity (MFI) of unstimulated mGEnC-1 is set at 1. * p < 0.01 versus 
unstimulated mGEnC-1. (B) HS in culture supernatant of unactivated mGEnC-1, TNF-α-activated mGEnC-1 and 
TNF-α-activated mGEnC-1 in the presence of BAY-110782. (C) HS in culture supernatant of unactivated mGEnC-1, 
IL-1β-activated mGEnC-1 and IL-1β-activated mGEnC-1 in the presence of BAY-110782. HS was measured by an
inhibition ELISA. Plates coated with HS from bovine kidney were incubated with the depicted antibodies (Table 2) 
that had been preincubated with culture supernatant from either unstimulated, TNF-α- or IL-1β-activated mGEnC-1, 
either in the presence or absence of BAY-110782. The results are expressed as mean ± SEM. * p < 0.01 versus 
unstimulated mGEnC-1. (B, C) * p < 0.01 versus unstimulated mGEnC-1. ^ p < 0.01 versus activated mGEnC-1 
(n=5). AU: arbitrary units (“μg/ml”).
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Figure 4. HS plays an important role during adhesion of 32Dcl3 cells to activated mGEnC-1. (A) Monolayers 
of mGEnC-1 either unstimulated or activated with TNF-α were treated with heparinase III, chondroitinase ABC or 
BAY-110782 as indicated. (B) Monolayers of mGEnC-1 either unstimulated or activated with IL-1β were treated 
with heparinase III, chondroitinase ABC or BAY-110782 as indicated. Subsequently, labeled 32Dcl3 cells or primary 
granulocytes were added. Percentage adhesion of 32Dcl3 cells or granulocytes to activated mGEnC-1 is set at 100%. 
* p < 0.001 versus activated mGEnC-1 (n=5).
O-sulfated heparosan significantly reduced adhesion. Heparin reduced adhesion about 2-fold 
(Figure 5B), whereas the inhibitory effects of modified heparinoids increased in this order: 
O-desulfated heparin < 6-O-desulfated heparin or N-desulfated heparin < 2-O-desulfated 
heparin (Figure 5B). Testing of clinically applied LMW heparins revealed that tinzaparin 
and enoxaparin inhibited adhesion most efficiently (Figure 5B). Notably, tinzaparin and 
enoxaparin have the highest degree of N-sulfated and 6-O-sulfated residues of the analyzed 
(LMW) heparins (Table 4). Blocking of endothelial HS structures on activated mGEnC-1 with 
specific anti-HS antibodies (Table 2) revealed that EW4G2, EW3D10 and AO4B08 were the 
most potent inhibitory antibodies (Figure 5C). 
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Figure 5. Inhibitory capacity of sulfated GAGs, heparinoids and anti-HS antibodies on adhesion of 32Dcl3 cells 
to activated mGEnC-1. Monolayers of mGEnC-1 activated with TNF-α were co-incubated with labeled 32Dcl3 cells 
and various GAGs (A) and heparinoids (B). Monolayers of mGEnC-1 activated with TNF-α or IL-1β were 
co-incubated with labeled 32Dcl3 cells and anti-HS antibodies (C). The percentage inhibition of adhesion is calculated 
by the formula [(100-X)/100 x 100%], in which X is the relative adhesion compared to the control without addition 
(adhesion of 32Dcl3 cells without addition to activated mGEnC-1 is set at 100%). The concentrations giving 25% 
inhibition (IC25) in µg/ml are indicated. All anti-HS antibodies were used at 25 µg/ml. (A) * p < 0.01 versus control 
without GAGs. (B) &a p < 0.01 versus O-desulfated H; ‡b p < 0.01 versus 6-O-desulfated H, N-desulfated H, and O-
desulfated H; #c p < 0.01 versus heparin. (C) ^ p < 0.05 versus control without antibody (n=5). H: heparin.
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Figure 6. Inhibitory effect of released HS on adhesion of 32Dcl3 cells to activated mGEnC-1. A monolayer of 
activated mGEnC-1 was co-incubated with 32Dcl3 cells and conditioned medium from TNF-α- (“culture sup HS 
(TNF-α)”) or IL-1β-activated mGEnC-1 (“culture sup HS (IL-1β)”), either in the absence or presence of BAY-110782 
(“culture sup HS (TNF-α + BAY)” and “culture sup HS (IL-1β + BAY)”). Where indicated the conditioned medium 
was treated with heparinase III. Adhesion of 32Dcl3 cells without addition to activated mGEnC-1 is set at 100% (n = 
4). * p < 0.01 versus activated mGEnC-1 without addition.        
Treatment with heparinoids reduces glomerular granulocyte influx, albuminuria 
and glomerulonephritis in murine lupus nephritis
      To extend the in vitro observations, the effect of administrating heparinoids on glomerular 
granulocyte influx in murine lupus nephritis was evaluated. MRL/lpr lupus mice were treated 
with PBS, heparin or N-desulfated heparin38. The glomerular granulocyte influx decreased
These antibodies preferentially bind to specific N- and 6-O-sulfated HS domains (Table 
2), which were also upregulated at the cell surface and enriched in the culture supernatant 
of activated mGEnC-1 (Figures 2B-C and 3B-C). Therefore, the effect of cell culture 
supernatants of mGEnC-1 on adhesion was determined. Adhesion was reduced 2-fold by cell 
culture supernatant from mGEnC-1 activated with TNF-α or IL-1β (Figure 6). Heparinase III 
treatment of the culture supernatant abolished this inhibitory effect indicating that HS was 
responsible for the inhibition. Culture supernatant of unactivated mGEnC-1 was not able to 
inhibit the adhesion (data not shown). Furthermore, cell culture supernatants of mGEnC-1 
activated with cytokines and treated with BAY-110782 completely failed to inhibit granulocyte 
adhesion (Figure 6). Taken together, specific N- and 6-O-sulfated HS domains on activated 
glomerular endothelial cells are crucial for the firm adhesion of leukocytes, while the released 
HS enriched in the same HS domains is able to modulate leukocyte adhesion. The canonical 
NF-κB pathway is an important mediator in these processes.
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3-fold after either heparin or N-desulfated heparin treatment compared to PBS 
treatment (Figure 7A). Heparin treatment also prevented albuminuria (Figure 7B) and 
glomerulonephritis (Figure 7C), essentially as described38. Since N-desulfated heparin was as 
effective as heparin, O-sulfated HS residues are more important than N-sulfated residues for 
glomerular granulocyte influx.
Figure 7. Inhibitory effect of (N-desulfated) heparin treatment on leukocyte influx, albuminuria and 
glomerulonephritis in MRL/lpr lupus mice. (A) The average number of polymorphonuclear granulocytes (PMNs) in 
50 glomeruli from 6 21 weeks-old mice is shown. * p < 0.05 versus PBS control. (B) The percentage of 
albuminuric mice. Each group is comprised of 15 mice. (C) The percentage of mice with glomerulonephritis. Each 
group is comprised of 15 mice.
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Discussion
 
     Previously, an increased expression of the HSPG core proteins syndecan-1, syndecan-4 
and CD44 by activated endothelial cells from other vascular beds has been shown, while 
other HSPG core proteins were not evaluated3,5. An explicit role of the core proteins in 
inflammatory leukocyte trafficking is not established and may only be determined by the 
attached HS side chains18,19. We observed both an increased and structurally altered HS 
expression by mGEnC-1 after activation with cytokines. Several anti-HS antibodies that 
recognize N- and 6-O-sulfated HS domains showed an enhanced reactivity with activated 
mGEnC-1. These antibodies most likely require next to N- and 6-O-sulfation other features 
for binding; i.e. the exact localization of these sulfate groups in a specific HS context, and 
elucidation of the complete epitopes remains a major future challenge43,44. An even larger 
challenge will be the exact structural determination of the inflammatory HS domains, which 
may be achieved by partially digesting HS from activated glomerular endothelium, followed 
by affinity purification with functional ligands like Mac-1 and L-selectin, then followed by 
HS disaccharide analysis and mass spectrometry analysis45. The altered expression profile 
of HS-modifying enzymes upon endothelial activation explains the increased expression of 
specific N- and 6-O-sulfated HS domains. The pronounced decrease in expression of 6-O-
sulfatase-2 is of interest, since both 6-O-sulfatase-1 and -2 also play an important role in 
HS-editing in other biologic processes10,11. Importantly, we could demonstrate that cytokine-
induced alterations of glomerular endothelial HS and HS-modifying enzymes are mediated by 
the canonical NF-κB pathway, which is also involved in the regulation of expression of other 
inflammatory molecules on activated endothelial cells40,41. Our findings are in agreement with 
the increased synthesis of HS by activated primary bovine glomerular endothelial cells and 
the increased expression of N-sulfated HS on activated human microvascular cells, which was 
also associated with an increased N-deacetylase/N-sulfotransferase-1 expression14,46.
     The release of HS in the culture supernatant from activated mGEnC-1 has also been 
described for activated bovine glomerular endothelial cells46. Our analysis of the features 
of the released HS revealed enrichment in N- and 6-O-sulfated HS domains. The release of 
HS can be explained by the increased expression of the HS-degrading enzyme heparanase, 
which cleaves off cell surface HS42,47. Heparanase cleaves the β(1-4) bond within HS and the 
proposed cleavage site for heparanase requires N- and 6-O-sulfated moieties in a specific 
context8,9. Therefore, the enrichment of N- and O-sulfated domains in cell surface endothelial 
HS after activation could make the HS chains more susceptible to cleavage by heparanase.
     The importance of endothelial HS for the adhesion of leukocytes is well established, 
whereas leukocyte HS also plays a role in this process3-5. We showed that in particular 
glomerular endothelial HS was important for adhesion of leukocytes. Recently, a conditional 
endothelial/leukocyte-specific mouse knockout for N-deacetylase/N-sulfotransferase-1 has
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been established, which showed a reduced leukocyte influx in experimental peritonitis22. 
Transfer of wild type bone marrow into this mouse did not lead to a restoration of leukocyte 
influx, which underscores that especially endothelial HS is important for leukocyte adhesion. 
We showed that removal of HS from activated mGEnC-1 did not reduce the adhesion of 
32Dcl3 cells/granulocytes completely, which indicates that in addition to HS-dependent 
interactions also HS-independent interactions play a role. 
     Apparently, receptors on leukocytes require specific N- and 6-O-sulfated HS domains on 
activated mGEnC-1 for firm adhesion as revealed by the inhibitory effect of defined GAGs, 
heparinoids, LMW heparins and anti-HS antibodies, which in part has been described for other 
endothelial cells21,48. The HS released in the cell culture supernatant of activated 
mGEnC-1 contained the same N- and 6-O-sulfated domains as HS on the cell surface of 
activated mGEnC-1, which explains the inhibitory capacity of cell culture supernatant in 
leukocyte adhesion. The released HS may have an anti-inflammatory role under normal 
physiological conditions or in the early phases of inflammation by preventing premature 
leukocyte adhesion. Also in vivo, we found that the glomerular leukocyte influx in MRL/lpr 
lupus mice38 was 3-fold reduced after heparin or N-desulfated heparin treatment, underscoring 
the importance of O-sulfated HS residues in glomerular inflammation. Furthermore, we have 
recently shown an increased glomerular endothelial expression of the inflammatory N- and 6-
O-sulfated HS domains in lupus mice and SLE patients (chapter 7), and in experimental anti-
GBM nephritis (chapter 6). Ligands on 32Dcl3 cells/granulocytes, such as the integrin Mac-1 
and L-selectin, may serve as receptors for the N- and 6-O-sulfated HS domains on activated 
mGEnC-1. Other reports also describe the importance of both N- and 6-O-sulfation for the 
leukocyte-endothelium interaction4,19,21-23. 
     In conclusion, using several approaches, we demonstrated that N- and 6-O-sulfated 
HS domains on activated glomerular endothelial cells are crucial for the firm binding of 
leukocytes, whereas the canonical NF-κB pathway mediates these cytokine-induced changes 
in glomerular endothelial HS. Additional experiments are required to determine which specific 
HS domains play a role in tethering, i.e. chemokine binding, rolling or transmigration of 
leukocytes to the inflamed glomerular endothelium. Since leukocyte infiltration is important 
in the formation of glomerular inflammatory lesions, characterization of the glomerular 
endothelial HS structures that play a role in the leukocyte-endothelium trafficking is of prime 
importance. This may lead to the development of selective well-defined HS-based analogues 
as supplementary therapeutic strategies in treating glomerulonephritis12.
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Abstract
     Proliferative glomerulonephritides are characterized by the influx of leukocytes. Heparan 
sulfate (HS) plays an important role in the recruitment, rolling and firm adhesion of leukocytes 
to activated endothelium. Recently, we have shown the importance of HS on activated mouse 
glomerular endothelial cells (mGEnC-1) for the firm adhesion of leukocytes in a static 
adhesion assay. In the present study, we evaluated the role of HS on glomerular endothelial 
cells and the effect of adding heparinoids on the leukocyte-glomerular endothelium interaction 
under dynamic flow conditions. 
     The number of rolling and firmly adhering leukocytes, and the rolling velocity of 
leukocytes was determined on a monolayer of unactivated or TNF-α-activated 
mGEnC-1 under dynamic flow conditions using physiological relevant shear stress rates in a 
flow chamber system. Furthermore, the effects of removal of HS on TNF-α-activated 
mGEnC-1 by heparinase III treatment and of different concentrations of heparin, tinzaparin 
and HS, on the rolling and adhesion of leukocytes were evaluated. 
     At the calculated physiological shear stress rate of 0.8 dynes/cm2 the number of rolling and 
firmly adhering leukocytes to mGEnC-1 increased 2-fold after activation with TNF-α, whereas 
the rolling velocity of the leukocytes decreased 2-fold. Addition of heparin, tinzaparin or HS, 
and the removal of HS on mGEnC-1 reduced the number of leukocytes rolling and adhering to 
activated mGEnC-1 about 2-3-fold, while the rolling velocity increased more than 2-fold. 
     HS on activated glomerular endothelial cells is important for the interaction with 
leukocytes under flow conditions, while exogenous heparinoids interfere with this interaction. 
These results suggest that supplementary treatment of proliferative glomerulonephritides with 
heparinoids is an interesting option to pursuit.
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Introduction
     Inflammatory lesions are manifested in a range of glomerular diseases and are characterized 
by the influx of leukocytes. The endothelial trafficking of leukocytes occurs in a sequential 
four-step process, i.e. tethering to, rolling over, firm adhesion to, and transmigration through 
the activated endothelium1 (Figure 1). 
Figure 1. The sequential steps of leukocyte trafficking on the activated endothelium. Circulating leukocytes are 
tethered to the activated endothelium. Subsequently, leukocytes are slowing down by rolling over the activated 
endothelium, which is facilitated by interaction of selectins and selectin ligands. During this process locally produced 
chemokines/cytokines bound to endothelial HS further activate integrin on leukocytes leading to stronger leukocyte-
endothelium interactions. Thereafter, firmer adhesion of leukocytes to the activated endothelium takes place, which is 
mediated by integrins and integrin ligands. Finally, leukocytes transmigrate/cross the endothelial monolayer. Notably, 
in all steps in leukocyte trafficking over activated endothelium heparan sulfate is involved2,3.
In all these steps, heparan sulfate (HS) plays an important role by binding chemokines, 
cytokines, selectins, integrins and adhesion molecules4. HS belongs to the family of strong 
negatively charged glycosaminoglycans that also includes heparin, which contains more 
sulfate groups and iduronic acid residues compared to HS (Figure 2).
     The adherence of leukocytes to the vessel wall depends on the strength of the interaction 
between leukocytes and the endothelium, which is determined by receptor-ligand interactions 
and affected by shear forces imposed by the fluid flow in the circulation. Wall shear stress 
plays a role in maintaining vascular hemodynamics and haemostasis, and also affects 
heparan sulfate proteoglycan synthesis and fine structure5. An increased synthesis of 
glycosaminoglycan has been observed for endothelial cells that were subjected to a shear 
stress rate of 15-40 dynes/cm2 for 24 hours6, while an inhibition of glycosaminoglycan 
synthesis has been observed for endothelial cells that were subjected to a shear stress rate of 1 
dyne/cm2 for 2 hours7. Furthermore, endothelial HS participates in mechanosensing that
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mediates nitric oxide production in response to shear stress8, while vascular smooth muscle 
cell HS promotes contractile responses to increases in shear stress9. The concerted action of 
adhesion molecules, chemokines and endothelial HS during inflammation is dependent on 
the shear stress in a specific microvascular bed. The in vivo conditions of dynamic blood flow 
can be mimicked in vitro by flow chambers (Figure 3), which are frequently used to evaluate 
the rolling and firm adhesion of leukocytes to cultured endothelium10. In a flow chamber the 
shear stress rate τ (in dynes/cm2) can be calculated by the Navier Stokes equation and set by 
adjusting the volumetric flow rate (Figure 3).
Figure 2. Structural features of heparin/heparan sulfate. The possible modifications, i.e. N-deacetylation and N-
sulfation of N-acetyl-glucosamine, C5-epimerization of glucuronate to iduronate and O-sulfation at various positions 
(C-2, C-3, and C-6), are indicated in bold. Heparin contains a higher iduronate/glucuronate ratio and a higher 
percentage of sulfated domains than heparan sulfate. n is 50 to 150 disaccharide units of glucosamine and uronic acid.
     Recently, we have shown the importance of HS on activated mouse glomerular endothelial 
cells (mGEnC-1)11 for the firm adhesion of leukocytes by using an in vitro static adhesion 
assay (chapter 4). Heparin and low molecular weight heparin are frequently clinically 
applied as anticoagulants, but could also be considered for supplementary treatment of 
glomerulonephritis by interfering with the interaction between leukocytes and glomerular 
endothelium. Currently, there are no data whether HS on activated glomerular endothelium 
plays a role in the interaction of leukocytes under dynamic flow conditions. Furthermore, it 
is not known whether heparinoids are able to interfere with the interaction of leukocytes with 
the activated glomerular endothelium under dynamic flow conditions. Therefore, we evaluated 
in vitro the number of rolling and firmly adhering leukocytes and the rolling velocity of 
leukocytes on glomerular endothelial cells under dynamic flow conditions after removal of HS 
on glomerular endothelial cells and in the presence or absence of heparin, tinzaparin or HS. 
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Figure 3. In vitro dynamic flow chamber system. The shear stress rate (τ) expressed in dynes/cm2 in the flow 
chamber can be calculated and set according to the Navier Stokes equation, τ = (6 x Q x µ)/(w x h2), in which Q is 
the volumetric flow rate, µ is the viscosity of the fluid (in mPa.sec), w is the slid width and h is the height of the flow 
chamber, respectively. w, width; mm, millimeter; h, height; µ, viscosity; mPa.sec, milliPascal.seconds.
Methods
Cell cultures
     The conditionally immortalized mouse glomerular endothelial cell line (mGEnC-1) with all 
features of primary glomerular endothelial cells was cultured as described11. mGEnC-1 was 
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grown on coverslips (40 mm) (Bioptechs, Inc., Butler, PA, USA) precoated with 1% gelatin 
and fibronectin (1 μg/cm2) (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) in 
normal growth medium at 37°C, until they were 100% confluent. Where indicated, cells 
were activated by incubation with TNF-α (10 ng/ml; Peprotech, Rocky Hill, NJ, USA) for 18 
hours. The murine granulocyte cell line 32Dcl312,13, which lacks cell surface HS14, but highly 
expresses L-selectin, Mac-1 and the granulocyte marker (NIMP-R14)15 was maintained in 
RPMI-1640 (Invitrogen Life Technologies, Breda, The Netherlands), supplemented with 10% 
WEHI-3B-conditioned medium as a source of murine interleukin-3 (DSMZ, Braunschweig, 
Germany), 1% pyruvate, 1% glutamax, 10% fetal calf serum, and 1% penicillin/streptomycin 
(Invitrogen Life Technologies). 
Removal of endothelial heparan sulfate
     HS on TNF-α-activated mGEnC-1 was removed by treatment with 0.25 U/ml heparinase 
III (Sigma-Aldrich, Zwijndrecht, The Netherlands) in cell culture medium (pH 7.5) for 1 hour 
at 37°C. The terminal 4,5-unsaturated uronate residues that arise after heparinase III treatment 
are recognized by antibody 3G1016, which was used to evaluate enzyme activity.
Adhesion experiments under flow conditions
     Adhesion of 32Dcl3 granulocyte cells to mGEnC-1 was measured under flow conditions 
in a parallel plate Focht flow perfusion chamber with well-defined characteristics, essentially 
as depicted in Figure 3. A coverslip with a monolayer of mGEnC-1 was assembled in the flow 
chamber, which was mounted on an inverted phase-contrast microscope stage (Axiovert 35M, 
Zeiss, Germany) that was connected to a camera (VarioCam, PCO computer Optics GmbH, 
Kelheim, Germany) and controlled by a computer. The x, y and z positions of the microscope 
table were regulated by a computer-driven x, y, z stage controller. 32Dcl3 granulocyte cells 
were resuspended in plain DMEM:HAM-F12 medium (Invitrogen Life Technologies) at a 
concentration of 0.5 x 106 cells/ml and pre-warmed to 37°C. The 32Dcl3 granulocyte cells 
were aspirated from a reservoir through the perfusion chamber with a withdrawal syringe 
pump (Harvard apparatus, Holliston, MA, USA; ANTEC, Leiden, The Netherlands). The 
complete system was present in a 37°C incubator. Temperature fine-tuning was performed by 
the Bioptechs FCS2 controller. 
     The experiment started with a continuous flow of plain DMEM:HAM-F12 medium of 37°C 
for 2 minutes over the monolayer of mGEnC-1. Subsequently, 32Dcl3 granulocyte cells were 
perfused for 60 seconds at shear stress rates in the physiological range of 0.4 to 1.6 dynes/cm2,
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i.e. with a volumetric flow rate Q of 1.2 to 4.7 µl/second, respectively. Video recordings of 
one microscopic field (0.14 mm2) were read continuously (1 image/second) and analyzed 
afterwards with an in house developed software program17. Individual 32Dcl3 granulocyte 
cells received a unique ID and could be tracked and analyzed in time, which allowed the 
determination of the average number of rolling (defined at a movement of 4-100 µm/second) 
and firmly adhering (defined at a movement of 0-4 µm/second) cells, as well as the average 
rolling velocity. The effect of 10, 50 or 250 µg/ml heparin (Sigma-Aldrich), tinzaparin 
(Innohep®) (Brocacef Holding NV, Maarssen, The Netherlands) or HS from bovine kidney 
(Seikagaku, Tokyo, Japan)18 on the average number of rolling and firmly adhering 32Dcl3 
granulocyte cells, and on the average velocity of rolling 32Dcl3 granulocyte cells was 
evaluated on TNF-α-activated mGEnC-1 at a shear stress rate of 0.8 dynes/cm2 for 60 seconds 
with a recording of 10 images/second. All perfusions were performed in triplicate on at least 
three separate experiments. 
Statistical Analysis
     All values are expressed as means ± SEM and significance was determined by Mann-
Whitney U testing using GraphPad Prism, version 4.0 software (GraphPad Software, Inc., San 
Diego, CA).
Results
Rolling and adhesion of granulocytes to unstimulated and TNF-α-activated mouse 
glomerular endothelial cells at different shear stress rates 
     We calculated an approximate shear stress rate in mouse glomerular capillaries of about 
0.8 dynes/cm2 using Hagen-Poiseuille’s law. However, the actual value of the shear stress 
rate in glomerular capillaries may be different from 0.8 dynes/cm2, since Hagen-Poiseuille’s 
law is only suitable for Newtonian fluids, while in addition the viscosity and volumetric flow 
rate of the blood in the glomerular capillaries, and the diameter of the glomerular capillaries 
may dynamically change. Therefore, we evaluated the number of rolling and firmly adhering 
32Dcl3 granulocyte cells on both unstimulated and TNF-α-activated mGEnC-1 at shear stress 
rates of 0.4, 0.8 and 1.6 dynes/cm2, respectively. In addition, the average rolling velocity of 
32Dcl3 granulocyte cells at different shear stress rates was determined. It appeared that at a 
shear stress rate of 0.4 dynes/cm2 the results were not discriminating, since the numbers of 
rolling and firmly adhering 32Dcl3 granulocyte cells, and the average rolling velocity of
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Figure 4. Rolling and adhesion of 32Dcl3 granulocyte cells on unstimulated and TNF-α-activated mouse 
glomerular endothelial cells at different shear stress rates. A monolayer of mGEnC-1 was either unstimulated or 
stimulated with TNF-α for 18 hours. 32Dcl3 granulocyte cells were perfused at shear stress rates of 0.8 or 1.6 
dynes/cm2. The average number ± SEM of rolling cells (A), the average number ± SEM of firmly adhering cells (B) 
and the average ± SEM rolling velocity (C) is shown from three independent experiments. * p < 0.05 compared to 
unstimulated mGEnC-1.
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32Dcl3 granulocyte cells were not significantly different between unstimulated mGEnC-1 and 
TNF-α-activated mGEnC-1 (data not shown). In contrast, at a shear stress rate of 0.8 
dynes/cm2 the numbers of rolling and firmly adhering 32Dcl3 granulocyte cells to mGEnC-1
increased about 2-fold after activation with TNF-α (Figures 4A and B), while the average 
rolling velocity decreased about 2-fold (Figure 4C). 
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At a shear stress rate of 1.6 dynes/cm2 the numbers of rolling and firmly adhering 32Dcl3 
granulocyte cells, and the average rolling velocity were already reduced several folds on 
unactivated mGEnC-1 when compared to the shear stress rate of 0.8 dynes/cm2 (Figures 4A 
and B). However, despite these lower numbers, also at a shear stress rate of 1.6 dynes/cm2 the 
numbers of rolling and firmly adhering 32Dcl3 granulocyte cells to mGEnC-1 significantly 
increased after activation with TNF-α (Figures 4A and B). In contrast to the shear stress rate 
of 0.8 dynes/cm2, the average rolling velocity of 32Dcl3 granulocyte cells at a shear stress rate 
of 1.6 dynes/cm2 was not significantly affected by activation of mGEnC-1 (Figure 4C). These 
results indicate that both rolling and firm adhesion of 32Dcl3 granulocyte cells as well as the 
average rolling velocity are affected by the activation status of mGEnC-1 and by different 
shear stress rates. Since the calculated shear stress rate in glomerular capillaries is 0.8 
dynes/cm2, this shear stress is the most suitable rate to test leukocyte trafficking in our in vitro 
flow system.
Removal of HS on TNF-α-activated mouse glomerular endothelial cells and the 
addition of heparin, tinzaparin or HS interfere with the rolling and adhesion of 
32Dcl3 granulocyte cells 
     Previously, we showed that heparin, the low molecular weight heparin tinzaparin, and HS 
reduced the firm adhesion of 32Dcl3 granulocyte cells to TNF-α-activated mGEnC-1 under 
static conditions in an in vitro adhesion assay (Table 1; chapter 4). 
Table 1. Percentage inhibition and the concentrations giving 25% inhibition of firm 
adhesion of granulocytes to activated mGEnC-1 by heparin, tinzaparin and heparan 
sulfate in a static adhesion systema
Heparinoid/GAG  % inhibition of adhesion at 250 μg/ml    IC25 in μg/ml
Heparin                      44.7 ± 1.7               18
Tinzaparin (Innohep®)                    54.1 ± 0.9               11
Heparan sulfate                     42.1 ± 0.5               36
aThe percentage inhibition of adhesion by 250 µg/ml heparin, tinzaparin or heparan sulfate is expressed as the mean ± 
SEM of 6 experiments. The concentrations giving 25% inhibition (IC25) in µg/ml are indicated. 
GAG, glycosaminoglycan.
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Here, we evaluated the effect of removal of HS on TNF-α-activated mGEnC-1 by heparinase 
III treatment, and the addition of heparin, tinzaparin and HS on the number of rolling and 
firmly adhering 32Dcl3 granulocyte cells, and on the rolling velocity of 32Dcl3 granulocyte 
cells on activated mGEnC-1 cells at the shear stress rate of 0.8 dynes/cm2. It appeared 
that removal of HS on mGEnC-1 and the addition of 250 μg/ml heparin, tinzaparin or HS 
significantly reduced about 2-4-fold the number of rolling and firmly adhering 32Dcl3 
granulocyte cells on TNF-α-activated mGEnC-1 (Figure 5A and B), while the rolling velocity 
of 32Dcl3 granulocyte cells increased more than 2-fold (Figure 5C). 
Figure 5. Removal of HS on TNF-α-activated mouse glomerular endothelial cells and the addition of heparin, 
tinzaparin or HS, interfere with the rolling and adhesion of 32Dcl3 granulocyte cells. A monolayer of mGEnC-1 
was stimulated with TNF-α for 18 hours. Activated mGEnC-1 was incubated with 32Dcl3 granulocyte cells without 
further addition, after removal of HS on mGEnC-1 with heparinase III, or co-incubated with 250 µg/ml heparin, 
tinzaparin or HS. The 32Dcl3 granulocyte cells were perfused at a shear stress rate of 0.8 dynes/cm2. The average 
number ± SEM of rolling cells (A), the average number ± SEM of firmly adhering cells (B) and the average ± SEM 
rolling velocity (C) is shown from three independent experiments. * p < 0.05 compared to untreated cells. 
HS, heparan sulfate.
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Figure 6. Dose-response effect of heparin and tinzaparin on the rolling and adhesion of 32Dcl3 granulocyte cells 
on TNF-α-activated mouse glomerular endothelial cells. A monolayer of mGEnC-1 was stimulated with TNF-α 
for 18 hours. Activated mGEnC-1 was incubated with 32Dcl3 granulocyte cells without further addition, or together 
with 10, 50 or 250 µg/ml heparin or tinzaparin, respectively. The 32Dcl3 granulocyte cells were perfused at a shear 
stress rate of 0.8 dynes/cm2. The average number ± SEM of rolling cells (A and B), the average number ± SEM of 
firmly adhering cells (C and D) and the average ± SEM rolling velocity (E and F) is shown from three independent 
experiments.
We also tested the effect of two lower concentrations of heparin and tinzaparin, i.e. 10 and 
50 μg/ml. Notably, the concentration of 10 μg/ml approximates the concentrations that can 
be found in the circulation of patients that have received heparin or tinzaparin intravenously. 
It appeared that even the addition of 10 μg/ml heparin (Figure 6A) or tinzaparin (Figure 6B) 
reduced the number of rolling 32Dcl3 granulocyte cells, while these effects were even more 
pronounced for the number of firmly adhering 32Dcl3 granulocyte cells (Figure 6C and D) 
and the average rolling velocity (Figure 6E and F). In summary, our data show that HS on 
activated glomerular endothelium is crucial for the interaction with leukocytes under dynamic 
flow conditions, while heparin(oids) interfere with the interaction of leukocytes with activated 
glomerular endothelium.
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Discussion
 
     In this study, we describe the rolling and adhesion of leukocytes to unstimulated or TNF-
α-activated mGEnC-1 at shear stress rates that approaches the shear stress rate in mouse 
glomerular capillaries. Furthermore, we evaluate the effects of clinically applied heparin, the 
low molecular weight heparin tinzaparin and HS, on leukocyte trafficking using an in vitro 
flow system.
     At the shear stress rates of 0.4 and 1.6 dynes/cm2 no or minor differences could be observed 
in the rolling, adhesion and velocity of 32Dcl3 granulocyte cells on unactivated mGEnC-1 
versus activated mGEnC-1, which may be explained by too low and too high volumetric flow 
rates, respectively. The lower rolling velocity of 32Dcl3 granulocyte cells at 1.6 
dynes/cm2 compared to 0.8 dynes/cm2 may be explained by the fact that fast rolling cells 
weakly interacted with activated mGEnC-1 and lost their interaction at 1.6 dynes/cm2, while 
the slowly rolling cells interacted more strongly with activated mGEnC-1 and resisted the 
shear stress rate of 1.6 dynes/cm2, which also has been found by others19. The calculated 
shear stress rate of about 0.8 dynes/cm2 in glomerular capillaries in vivo appeared to be the 
most suitable shear stress rate in our in vitro flow system. Activation of mGEnC-1 induced 
significantly more rolling and adhesion of 32Dcl3 granulocyte cells, which was accompanied 
with a reduced average rolling velocity of the 32Dcl3 granulocyte cells. To our knowledge, 
our data are the first to show leukocyte trafficking on a well-defined glomerular endothelial 
cell line using an in vitro flow system. Our data confirm the in vitro results of various other 
studies that show differences in the number of rolling and firmly adhering monocytes, 
eosinophils, leukocytes and granulocytes under different shear stress rates to activated human 
umbilical vein endothelial cells (HUVEC)20,21. Furthermore, an increased number of rolling 
and firmly adhering neutrophils accompanied with a reduced rolling velocity on TNF-α-
activated endothelium compared to unactivated endothelium in vitro has also been described 
for endothelium from other vascular beds22. 
      Recently, we have shown that HS on activated glomerular endothelial cells was crucial for 
the firm adhesion of leukocytes using a static adhesion assay. Furthermore, heparin, HS and 
low molecular weight heparin preparations such as tinzaparin reduced the firm adhesion of 
32Dcl3 granulocyte cells to activated mGEnC-1 about 2-fold under static conditions 
(chapter 4). In the current study, we demonstrated that removal of HS on activated mGEnC-1 
and addition of heparin, tinzaparin and HS reduced the number of rolling and firmly adhering 
32Dcl3 granulocyte cells several fold, which was accompanied with an increased rolling 
velocity. Rolling of leukocytes is mediated by L-selectin on the leukocyte and the L-selectin 
ligand, i.e. 6-O-sulfated HS, on activated (glomerular) endothelium4. Firm adhesion of 
leukocytes is mediated by integrins such as Mac-1 on the leukocyte and the Mac-1 ligand, i.e. 
N-and 6-O-sulfated HS, on activated (glomerular) endothelium4. The effects we observed
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after the removal of HS on glomerular endothelial cells directly prove that HS on activated 
glomerular endothelial cells is crucial for the rolling, firm adhesion and rolling velocity of 
leukocytes, most likely because of the loss of the L-selectin/Mac-1 HS ligands. Notably, the 
32Dcl3 granulocyte cells lack cell surface HS, so we exclusively could evaluate the role of HS 
on glomerular endothelial cells in the interaction with leukocytes. The effects of the addition 
of heparin, tinzaparin and HS can be explained by the competitive binding of these compounds 
to L-selectin and/or Mac-1. Therefore, both the loss of endothelial HS and the competitive 
binding of heparinoids to L-selectin/Mac-1 on leukocytes lead to interference with the 
leukocyte-endothelium interaction, i.e. a lower number of rolling leukocytes, a higher rolling 
velocity of leukocytes, and a lower number of firmly adhering leukocytes. Another possible 
explanation is that removal of endothelial HS or incubation with heparinoids leads to loss of 
bound chemokines that activate integrins on leukocytes required for the firm interaction with 
endothelial cells. However, this possibility is very unlikely, since our 32Dcl3 cells appear to be 
already fully activated and express high levels of L-selectin and Mac-1. Furthermore, we have 
preincubated activated mGEnC-1 with high concentrations of heparin in order to compete off 
HS-bound chemokines. However, this revealed that the adhesion of 32Dcl3 granulocyte cells 
was not affected (data not shown) as has been shown by others18. Other in vitro studies under 
flow conditions with different vascular beds also showed that the addition of heparinoids 
decreased the number of rolling and firmly adhering leukocytes to activated 
endothelium23-25. In a recent study, it was shown that in particular endothelial HS is important 
for the leukocyte trafficking over activated endothelium. Mice that were conditionally 
deficient in the HS biosynthetic enzyme N-deacetylase/N-sulfotransferase-1, i.e. in both 
endothelium and leukocytes, showed a a 2-3-fold reduction of N-, 2-O- and 6-O-sulfated 
groups on the endothelium and a higher velocity of rolling leukocytes by reduced binding to 
L-selectin26.
     Treatment of proliferative forms of glomerulonephritis with immunosuppressive drugs 
like corticosteroids and cyclophosphamide is basically the same as 30 years ago. Therefore, 
the determination of the exact structure of HS domains on activated glomerular endothelium 
that serve as ligands for L-selectin, Mac-1 or other leukocyte receptors could lead to the 
development of well-defined HS-based therapeutics without anticoagulant activity for 
supplementary treatment of these forms of glomerulonephritis. However, determination of the 
fine structure, i.e. sequence, of these specific HS domains remains a major future challenge, 
which will require additional research, in which our glomerular endothelial cell line 
mGEnC-1 and the used flow system could be of value. Until these defined HS-based 
compounds will become available, it is an interesting option to evaluate heparin and low 
molecular weight heparin preparations with a low antithrombotic activity as supplementary 
therapeutics in the treatment of proliferative glomerulonephritis27. 
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Abstract
     Heparan sulfate (HS) proteoglycans like syndecan-1 (sdc-1) play multiple roles during 
inflammation. During anti-glomerular basement membrane (GBM) nephritis induced by 
heterologous anti-GBM antibodies, glomerular PMN influx peaks 2 hours after injection of 
anti-GBM antibodies, while albuminuria develops within 1 day. During the autologous phase, 
mouse Ig anti-GBM IgG develops and albuminuria persists. Here, we evaluated the role of 
sdc-1 in experimental anti-GBM nephritis. 
     Wild type (WT) and sdc-1-deficient mice received rabbit anti-GBM IgG or control IgG, and 
were sacrificed after 1, 2, 4, 18 hours, 4 or 8 days. Glomerular PMN influx, expression of HS 
domains, deposits of rabbit/mouse Ig, complement 3c, fibrin, albuminuria, serum creatinine, 
histology and plasma levels of mouse Ig anti-rabbit IgG were determined. During the 
heterologous phase, the glomerular PMN influx was ~2-fold higher in sdc-1-deficient mice, 
which was associated with a higher glomerular endothelial expression of specific HS domains. 
During the autologous phase, sdc-1-deficient mice showed persistently higher albuminuria and 
serum creatinine levels than WT mice, which was accompanied with more severe glomerular 
injury. Sdc-1-deficient mice developed higher plasma levels and more glomerular deposits of 
mouse Ig and IgG1 anti-rabbit IgG, while the level of mouse IgG2a anti-rabbit IgG was lower. 
     In conclusion, sdc-1 deficiency aggravates experimental anti-GBM nephritis and shifts the 
Th1/Th2 balance.
116
                                               The role of syndecan-1 in anti-GBM nephritis
Introduction
     The syndecans belong to a family with four members of type I transmembrane heparan 
sulfate proteoglycans (HSPGs), which consist of an extracellular N-terminal domain with 
several heparan sulfate (HS) side chains, a single hydrophobic transmembrane domain, and a 
short C-terminal cytoplasmic domain1. Syndecans are expressed in a developmental and cell 
type-specific pattern and act as co-receptors for various ligands like growth factors and matrix 
molecules1-3. Syndecan-1 (sdc-1; CD138) is expressed on epithelial cells, endothelial cells and 
leukocytes4 and appears to play a role in tumorigenesis5. During inflammation the expression 
of sdc-1 on both endothelial cells and leukocytes can be upregulated, which suggests that 
sdc-1 also plays a role in the interaction of leukocytes with endothelium6,7. Sdc-1-deficient 
mice5,8 develop normally and are fertile, but show an enhanced adhesion of leukocytes in the 
ocular vasculature and in mesentery venules after tumor necrosis factor (TNF)-α treatment 
when compared to wild type (WT) mice9. 
     HS binds and modulates the activity of many inflammatory molecules such as chemokines, 
selectins, integrins and adhesion molecules10,11. The linear HS side chains are composed of 
about 150 units of glucosamine-uronic acid disaccharides that can be sulfated at the N-
position, 2-, 3- and/or 6-O-position, and epimerized at the C-5 position by a large family of 
HS-modifying enzymes12. The number of possible combinations of modifications within one 
HS chain can give rise to an enormous structural diversity, which is important for the specific 
binding of a myriad of factors. The importance of specific N- and 6-O-sulfated HS domains on 
activated endothelium for the adhesion of polymorphonuclear granulocytes (PMNs) has been 
documented11. Structural analysis of HS in kidney, lung and spleen from both WT and sdc-1-
deficient mice revealed no differences in HS disaccharide composition13. 
     The experimental model of passive anti-glomerular basement membrane (GBM) nephritis 
is induced by the intravenous injection of heterologous anti-GBM antibodies, which bind 
immediately together with complement to the GBM. In the early acute heterologous phase, 
i.e. within hours after anti-GBM IgG administration, glomerular PMN influx is peaking, while 
albuminuria is manifested within one day14-16. At high doses of heterologous anti-GBM serum, 
the albuminuria and glomerular lesions in the acute phase of anti-GBM nephritis are strictly 
PMN-dependent and complement-independent17, while at lower doses of anti-GBM antibodies 
also complement-dependent mechanisms may be operative18. In particular the cationic neutral 
proteinases elastase and cathepsin G, which are released by activated PMNs, contribute to 
glomerular damage and albuminuria in the acute heterologous phase of anti-GBM nephritis, 
since beige mice that are deficient in these proteinases failed to develop albuminuria after 
induction of anti-GBM nephritis19. The integrin Mac-1, expressed by PMNs, interacts with 
deposited complement 3c (C3c), which leads to the release of elastase and cathepsin G20. 
Subsequently, these cationic proteinases bind to the GBM, probably to anionic HS21-23, which 
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leads to increased GBM permeability and albuminuria20. The autologous phase of anti-
GBM nephritis is initiated by the immune response of the host to the injected heterologous 
anti-GBM antibodies, i.e. about one week after administration of anti-GBM antibodies24, 
and is characterized by persistent severe albuminuria. The development of antibodies to the 
heterologous anti-GBM antibodies has been identified as a Th1 response25. The deposition of 
mouse Ig anti-rabbit IgG along the GBM may be important for the persistence of albuminuria 
during the autologous phase of anti-GBM nephritis26.
     It is well-established that HSPGs like sdc-1 play a crucial role in the leukocyte-
endothelium interaction during inflammation in different vascular beds27,28. However, there 
is little knowledge about the role of HS(PGs) in glomerulonephritis, therefore, we evaluated 
experimental anti-GBM nephritis in both WT and sdc-1-deficient mice.
Methods
Animals
     C57BL/6 mice (Jackson Laboratories, Bar Habor, ME, USA), sdc-1-deficient mice in 
a C57BL/6 background5 and New Zealand white rabbits were bred, housed and handled 
according to the guidelines of the local animal ethics committee. Genotyping of mice with 
gene-specific primers was performed as previously described29.
Isolation of mouse GBM
     Glomeruli were isolated from C57/BL6 mice perfused with 0.01 M phosphate buffered 
saline (PBS) pH 7.2 with 1.25% Fe3O4. Glomeruli were sieved through a 75-μm sieve 
(Endecotts, London, UK), pelleted by a magnet, washed in PBS, resuspended in excess 
distilled water and shaken for 2 hours at 4ºC. Subsequently, the suspension was centrifuged 
for 15 minutes at 5910g at 4ºC and the pellet was sonicated three times for 15 seconds on ice 
with 45 seconds cooling intervals. Finally, the suspension was treated with 3% Triton X-100, 2 
mg/ml deoxyribonucleaseI (Roche Diagnostics GmbH, Mannheim, Germany) and 4% sodium 
deoxycholate for 18 hours, washed extensively in distilled water and lyophilized30,31. 
Immunization of rabbits with mouse GBM and purification of rabbit IgG
     Rabbits were subcutaneously injected with 1 mg GBM emulsified in complete Freund’s 
adjuvant (CFA; Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands), followed by 
subcutaneous booster injections of 1 mg GBM in incomplete Freund’s adjuvant (IFA) after 3, 
6 and 9 weeks. Control rabbit IgG was collected from rabbits that were immunized with PBS 
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in CFA/IFA. Pooled sera were centrifuged and passed through a 0.4-µm filter. Subsequently, 
IgG fractions were purified by protein-A affinity chromatography (Amersham Biosciences, 
Roosendaal, The Netherlands) and concentrated to 30 mg/ml by ultrafiltration with a XM-50 
Diaflow membrane (Amicon Corporation, Danvers, MA, USA). 
Characterization of rabbit anti-mouse GBM antibodies in ELISA
     Laminin (EHS; Campro Scientific, Berlin, Germany), agrin32, HS (Seikagaku, Tokyo, 
Japan), fibronectin (Bio-Connect BV, Huissen, The Netherlands) or collagen type IV (Sanbio 
BV, Uden, The Netherlands) was coated overnight at 4°C in PBS (10 μg/well). Wells were 
washed with PBS/0.05% Tween 20 (PBS/Tween) and blocked with 2% bovine serum albumin 
(BSA) (Sigma-Aldrich) in PBS for 2 hours and washed with PBS/Tween. Serial dilutions of 
rabbit anti-mouse GBM IgG in 2% BSA/PBS were added and incubated for 1 hour, wells were 
washed with PBS/Tween and incubated with goat anti-rabbit Ig (H+L) antibody conjugated 
with horseradish peroxidase (Jackson ImmunoResearch Laboratories, Inc., Pennsylvania, 
USA) in 2% BSA/PBS for 1 hour. Finally, wells were washed with PBS/Tween and incubated 
with tetramethylbenzidine (TMB) substrate solution (SFRI Laboratories, Berganton, France). 
After exactly 15 minutes, the reaction was stopped with 2 M H2SO4 and absorption was 
measured at 450 nm. 
Induction of anti-GBM glomerulonephritis in WT and sdc-1-deficient mice and 
determination of albuminuria and creatinine
     WT and sdc-1-deficient mice, 14 to 18 weeks-old, were injected in the tail vein with 8 
mg rabbit anti-mouse GBM IgG or 8 mg control rabbit IgG. Mice were sacrificed after 1, 2, 
4 and 18 hours, 4 and 8 days. Each group comprised of 8 mice. Urine was collected directly 
through bladder puncture or after 18 hours in metabolic cages. Collected kidneys were fixed in 
10% buffered formalin and paraffin embedded or snap frozen in liquid nitrogen. Albumin was 
measured by radial immunodiffusion (Mancini). Plasma and urinary creatinine concentrations 
were determined enzymatically (Roche Diagnostics).
Immunofluorescence staining
     Frozen sections (2 µm) were fixed in ice-cold acetone for 10 minutes and incubated with 
primary antibodies diluted in PBS containing 1% BSA and 0.05% sodium azide (IF-buffer) 
for 45 minutes. Directly labeled antibodies included goat anti-mouse C3c- and fibrinogen-
fluoresceine isothiocyanate (FITC) (Nordic, Tilburg, The Netherlands), goat anti-rabbit IgG 
Alexa 488 and goat anti-mouse IgG (H + L), IgG1 and IgG2a Alexa 488 (Invitrogen Life
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Technologies, Breda, The Netherlands). Unlabeled antibodies included anti-mouse CD31 (BD 
Biosciences, Alphen aan den Rijn, The Netherlands) and the VSV-tagged anti-HS antibodies 
AO4B08, EW3D10 and EW4G2 that recognize N- and 6-O-sulfated HS domains33-35. 
Sections were incubated with the appropriate IgG Alexa 488-detecting antibody or anti-VSV-
Cy3 (Sigma-Aldrich) in IF-buffer for 45 minutes. Finally, sections were postfixed with 1% 
paraformaldehyde-PBS and embedded in VectaShield mounting medium H-1000 (Brunschwig 
Chemie, Amsterdam, The Netherlands). The amount of rabbit IgG or mouse Ig, IgG1 and 
IgG2a deposited along the capillary wall was quantified by titrating the appropriate detecting 
antibodies. The titer was defined as the reciprocal of the dilution, which was still positive 
and expressed as arbitrary units (AU). The staining intensities of all antibodies were scored 
in 50 glomeruli on a scale between 0 and 10 (0 = no staining, 1 = 10% staining intensity 
along the capillary wall or on glomerular endothelial cells, with a maximum score of 10 for 
100% staining intensity). The scoring was performed by 2 independent observers on blinded 
sections.
Renal histology
     Renal sections (5 μm) were deparaffinized, dehydrated and stained with Periodic acid-
Schiff (PAS). Sections were counterstained with hematoxylin. At least 50 glomeruli per mouse 
were evaluated.
Immunohistochemical analysis of glomerular PMN influx
     Glomerular PMN influx was determined on deparaffinized and dehydrated sections 
by incubation with a rat antibody specific for granulocytes (NIMP-R14)36 for 1 hour. 
Subsequently, sections were incubated with a peroxidase-labeled anti-rat antibody (Dako, 
Glostrup, Denmark) in 5% normal mouse serum/PBS for 30 minutes followed by incubation 
with 1 mg/ml diaminobenzidine (Sigma-Aldrich) in 50 mM Tris-HCl pH 7.6 with 0.001% 
H2O2 for 10 minutes. Sections were counterstained with hematoxylin for 2 minutes. Two 
independent observers counted PMNs on blinded sections in at least 50 glomeruli per animal.
Determination of plasma levels of mouse Ig, IgG1 and IgG2a anti-rabbit IgG 
antibodies in ELISA
     Rabbit Ig was coated overnight at 4°C (10 µg/well). Wells were washed with PBS/Tween 
and blocked with 2% BSA/PBS for 2 hours. Serial dilutions of mouse plasmas were added 
and incubated for 1 hour. Subsequently, wells were washed with PBS/Tween, incubated 
with peroxidase-conjugated goat anti-mouse Ig (H+L; Tebu-Bio, Heerhugowaard, The 
Netherlands), goat anti-mouse IgG1 or IgG2a antibodies (Sanbio BV, Uden, The Netherlands) 
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in 2% BSA/PBS for 1 hour. The remainder of the ELISA was performed as described above. 
The titer was defined as the reciprocal of the dilution of the plasma giving an optical density of 
0.5 and expressed as U/ml.
Statistical Analysis
    Values are expressed as means ± SEM and significance was evaluated by Mann-Whitney 
U testing using GraphPad Prism, version 4.0 software (GraphPad Software, Inc., San Diego, 
CA).
Figure 1. Rabbit anti-mouse GBM antibodies react with purified collagen IV, laminin, heparan sulfate (HS), 
agrin and fibronectin. Results are expressed as means ± SEM optical density (OD) values at 450 nm from 3 
experiments.
Administration of rabbit anti-GBM antibodies to WT and sdc-1-deficient mice resulted in a 
binding of rabbit IgG along the GBM already after 1 hour (Figures 2A and 2B; Table 1), which 
remained unaffected until day 8. Rabbit IgG binding was accompanied with C3c deposition in 
Results
Induction of anti-GBM nephritis in WT and sdc-1-deficient mice and identification 
of the heterologous and autologous phase
     The generated rabbit anti-mouse serum stained exclusively the GBM of both sdc-1-
deficient and WT mice (data not shown). Furthermore, the rabbit anti-mouse GBM antibodies 
reacted in ELISA with purified agrin, HS, laminin, fibronectin and collagen type IV (Figure 1). 
        121
Chapter 6
both mice strains, which started with a fine granular staining along the GBM after 1 hour, 
which became linear after 2 hours (Figures 2C and 2D; Table 1). Some segmental staining of 
Bowman’s capsule and tubular basement membranes was observed, which was also noted in 
mice that received control rabbit IgG and has been described previously14. In both WT and 
sdc-1-deficient mice, focal and segmental deposits of fibrin could be observed after 4 hours, 
which increased until day 8 (Figures 2E and 2F; Table 1). The autologous phase started after 4 
days as revealed by the presence of mouse Ig anti-rabbit IgG along the capillary wall in both 
mice strains. However, in sdc-1-deficient mice about 2-fold more mouse Ig anti-rabbit IgG 
was present along the capillary wall after 4 and 8 days (Figure 2G-I; Table 1). Administration 
of control rabbit IgG to WT and sdc-1-deficient mice did not lead to glomerular binding and 
deposition of C3c, fibrin or mouse Ig at all evaluated time points (data not shown). These data 
indicate that sdc-1 deficiency does not affect the binding/deposition of rabbit anti-mouse GBM 
IgG, C3c and fibrin during the heterologous and autologous phase of anti-GBM nephritis. 
However, sdc-1 deficiency leads to an enhanced glomerular deposition of mouse Ig anti-rabbit 
IgG during the autologous phase.
Table 1. Presence of rabbit IgG, C3c, fibrin and mouse Ig anti-rabbit IgG during anti-
GBM nephritis in WT and sdc-1-deficient micea
Phase during  Time     Rabbit IgGb C3cb Fibrinb          Mouse Ig anti-rabbit IgG
anti-GBM     
nephritis                WT Sdc-1-/-
Heterologous 1 hour     ++++  ++ -           -  -
  2 hours     ++++  +++ ±           -  -
  4 hours     ++++  +++ +           -  -
  18 hours     ++++  + ++           -  -
Autologous 4 days     ++++  + +++           +  ++
  8 days     ++++  + ++++           ++ ++++
aC3c, complement 3c; WT, wild type; sdc-1, syndecan-1. 
bDeposition in WT and sdc-1-deficient mice is identical. 
Figure 2. Characteristics of the heterologous and autologous phase of anti-GBM nephritis in wild type (WT) 
and syndecan-1-deficient (Sdc-1-/-) mice. Immunofluorescence staining 2 hours after anti-GBM administration 
revealed binding of rabbit anti-GBM IgG (A and B) and mouse complement 3c (C3c) (C and D) along the capillary 
wall, which was similar between WT (A and C) and sdc-1-deficient mice (B and D). At day 8 (E and F) after induction 
of anti-GBM nephritis the glomerular deposition of fibrin was similar between WT (E) and sdc-1-deficient mice (F), 
while the deposition of mouse anti-rabbit Ig along the capillary wall was higher in sdc-1-deficient mice (H) compared 
to WT mice (G). Magnification x 400. (I) Glomerular deposition of mouse Ig anti-rabbit IgG was higher in sdc-1-
deficient mice compared to WT mice at 4 and 8 days after administration of rabbit anti-GBM IgG. The titers (means ± 
SEM) are shown from 8 WT and 8 sdc-1-deficient mice. * p < 0.05 versus anti-GBM injected WT mice.
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Sdc-1 deficiency leads to a higher glomerular PMN influx and a higher expression 
of inflammatory HS domains on glomerular endothelium in anti-GBM nephritis
     Next, we evaluated the glomerular PMN influx, being one of the key determinants of 
glomerular damage and albuminuria in the early phase of anti-GBM nephritis. Glomerular 
PMN influx could be observed one hour after administration of rabbit anti-GBM IgG (Figure 
3A). PMN influx was peaking after 2 hours and quickly decreased after 4-18 hours, while at 
day 4 and 8 only background levels of PMNs could be detected in both WT and 
sdc-1-deficient mice (Figure 3A-C). However, after 2 hours the glomerular PMN influx was 
significantly higher in sdc-1-deficient mice compared to WT mice (Figures 3A-C). Mice that 
received control rabbit IgG did not show glomerular PMN influx (Figure 3A-C). 
Figure 3. Glomerular PMN influx in wild type (WT) and syndecan-1-deficient (Sdc-1-/-) mice during the acute 
heterologous phase of anti-GBM nephritis. (A) Glomerular PMN influx, analyzed by immunohistochemical 
staining, peaked 2 hours after rabbit anti-GBM IgG administration in both WT and sdc-1-deficient mice and at this 
time point was significantly higher in sdc-1-deficient mice. After 18 hours, 4 and 8 days (B), the glomerular PMN 
influx was similar to untreated mice (A and B) (indicated by the dotted line) and control mice injected with rabbit IgG 
(C). The results are expressed as the means ± SEM from 8 WT and 8 sdc-1-deficient mice. ^ p < 0.01 versus untreated 
mice or mice injected with control rabbit IgG, * p < 0.01 versus anti-GBM injected WT mice. Magnification x 400. 
For full-colour representation see appendix.
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     Recently, we have identified an increased expression of inflammatory N- and 6-O-sulfated 
HS domains on cultured glomerular endothelial cells after activation with TNF-α, which 
were directly involved in the adhesion of granulocytes37. The anti-HS antibodies AO4B08, 
EW3D10 and EW4G2 identified these glomerular endothelial HS domains, respectively. Now, 
we evaluated the expression of these inflammatory HS domains on glomerular endothelium by 
double staining with these specific anti-HS antibodies and an anti-CD31 antibody. It appeared 
that the glomerular endothelial expression of the N- and 6-O-sulfated HS domains recognized 
by the anti-HS antibodies was significantly increased after 2 hours in both WT and sdc-1-
deficient mice compared to untreated mice or mice that received control rabbit IgG (Figures 
4A-D). Interestingly, the glomerular endothelial expression of the inflammatory HS domains 
was significantly higher in sdc-1-deficient mice compared to WT mice (Figure 4B-D). Taken 
together, sdc-1-deficient mice show a higher number of glomerular PMNs and a higher 
glomerular endothelial expression of inflammatory N- and 6-O-sulfated HS domains.
Sdc-1 deficiency leads to more albuminuria, a worse renal function and more 
glomerular injury in anti-GBM nephritis
     A significant albuminuria was already observed after 18 hours in the heterologous phase 
in both WT and sdc-1-deficient mice (Figure 5A), which was significantly higher in sdc-1-
deficient mice. Albuminuria increased further in the autologous phase after 4 and 8 days, 
whereas the significant difference between WT and sdc-1-deficient mice persisted (Figure 
5B). The renal function, i.e. the plasma creatinine concentration, was unaffected during 
the heterologous phase (Figure 5C), while plasma creatinine levels increased during the 
autologous phase (Figure 5D). After 8 days sdc-1-deficient mice had significantly higher 
plasma creatinine levels compared to WT mice. Mice that received control rabbit IgG did not 
develop albuminuria or renal function impairment (Figure 5A-D). 
     Renal histology after 18 hours was similar in WT and sdc-1-deficient mice, i.e. a minority 
of glomeruli showed segmental or global endothelial swelling with occlusion of the capillary 
lumens due to PAS-positive fibrinous material. At day 4 approximately 50% of the glomeruli 
of the sdc-1-deficient mice showed globally occluded and distended capillaries filled with 
PAS-positive fibrinous material, which was sporadically observed in WT mice. In addition, 
proteinacious tubular casts were more frequently observed in sdc-1-deficient mice compared 
to WT mice (Figure 6). At day 8 the differences between WT and sdc-1-deficient mice were 
even more pronounced, i.e. in sdc-1-deficient mice the majority of glomeruli showed globally 
distended capillaries with PAS positive material, occasionally cellular crescents, while tubular 
casts were frequent. In contrast, WT mice showed only thickening of the capillary wall, 
mostly open capillary lumens and no crescents, while tubular casts were sporadically observed 
(Figure 6). 
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Figure 4. Glomerular endothelial expression of inflammatory, N- and 6-O-sulfated, HS domains during the 
acute heterologous phase of anti-GBM nephritis. (A) Immunofluorescence double staining of N- and 6-O-sulfated 
HS domains recognized by the anti-HS antibodies AO4B08 (red), EW3D10 (red), EW4G2 (red) and the 
endothelium marker CD31 (green) showed an increased glomerular endothelial expression of inflammatory HS 
domains in sdc-1-deficient mice 2 hours after anti-GBM IgG administration. Magnification x 400. Semi-quantitative 
analysis of the glomerular endothelial expression of inflammatory HS domains recognized by AO4B08 (B), EW3D10 
(C) and EW4G2 (D) showed a higher expression of these HS domains in sdc-1-deficient mice compared to WT mice 2 
hours after anti-GBM IgG administration. The epitopes of the single chain anti-HS antibodies are given within 
parentheses. Staining intensities are expressed as means ± SEM from 8 WT and 8 sdc-1-deficient mice in arbitrary 
units (AU). Dotted lines indicate the base line score of untreated mice or mice injected with rabbit control IgG. 
* p < 0.05 versus anti-GBM injected WT mice. GlcNS6S, N- and 6-O-sulfated glucosamine; GlcA, glucuronic acid; 
IdoA2S, 2-O-sulfated iduronic acid. For full-colour representation see appendix.
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Figure 5. Syndecan-1-deficient (Sdc-1-/-) mice develop more albuminuria and a worse renal function. (A and B) 
The albumin/creatinine ratio (mg/mg) (ACR) was significantly higher in sdc-1-deficient mice at 18 hours, 4 days and 
8 days after anti-GBM IgG administration. The ACR of wild type (WT) and sdc-1-deficient mice at 1 hour (0.42 ± 
0.19 in WT mice, 0.30 ± 0.16 in Sdc-1-/- mice), 2 hours (0.54 ± 0.44 in WT mice, 0.93 ± 0.56 in Sdc-1-/- mice) and 4 
hours (1.26 ± 0.52 in WT mice, 2.01 ± 0.32 in Sdc-1-/- mice) was similar to untreated mice or mice injected with rabbit 
control IgG (indicated by the dotted line). (C and D) Plasma creatinine concentration (mg/dl) was significantly higher 
in sdc-1-deficient mice than in WT mice at 8 days after anti-GBM IgG administration. Plasma creatinine 
concentrations of WT and sdc-1-deficient mice after 1, 2, 4, 18 hours and 4 days were similar to untreated mice or 
mice injected with control rabbit IgG (indicated by the dotted line). The means ± SEM are shown (from 8 WT and 
8 sdc-1-deficient mice). ^ p < 0.05 versus untreated mice or control mice injected with rabbit IgG, * p < 0.05 versus 
anti-GBM injected WT mice.
Sdc-1 deficiency leads to a shift from a Th1 to a Th2 response in anti-GBM 
nephritis
     Sdc-1-deficient mice showed significantly more mouse Ig anti-rabbit IgG along the 
capillary wall compared to WT mice (Figure 1I). Evaluation of plasma levels of total mouse Ig 
anti-rabbit IgG revealed in sdc-1-deficient mice 2-fold higher levels than in WT mice at 
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day 4 (Figure 7A) and 8 (Figure 7B) after administration of rabbit anti-GBM IgG. However, 
there was no difference in total mouse Ig anti-rabbit IgG response when mice received control 
rabbit IgG. Irrespective of the presence of sdc-1, the response against rabbit anti-GBM IgG 
was significantly higher than the response against control rabbit IgG (data not shown). It has 
been described that the autologous phase in experimental anti-GBM is characterized by a Th1 
response25. We determined plasma levels and glomerular deposition of two Ig isotypes, IGg2a 
that is related to a Th1 response, and IgG1 that is related to a Th2 response. It appeared that 
in sdc-1-deficient mice plasma levels (Figure 7A and 7B) and glomerular deposits (Figure 7C 
and 7D) of mouse IgG1 anti-rabbit IgG were significantly higher, while plasma levels and 
glomerular deposits of mouse IgG2a anti-rabbit IgG were significantly lower compared to WT 
mice after 4 (Figure 7A and 7C) and 8 days (Figure 7B and 7D). 
     In summary, sdc-1 deficiency leads to an increased albuminuria and impaired renal function 
in anti-GBM nephritis, which may be explained by a higher glomerular PMN influx and 
by higher plasma levels and glomerular deposition of mouse Ig anti-rabbit anti-GBM IgG. 
Furthermore, sdc-1 deficiency leads to an increased antibody response against rabbit anti-
GBM IgG and to a shift from a Th1 to a Th2 response. 
Figure 6. Histology of glomerular injury in wild type (WT) and syndecan-1-deficient (Sdc-1-/-) mice during 
anti-GBM nephritis. Glomeruli in sdc-1-deficient mice showed more globally occluded and distended capillaries 
filled with Periodic acid-Schiff (PAS) positive fibrinous material (arrows) after 4 and 8 days. In addition, proteinacious 
tubular casts (asterisks) were more frequently observed in sdc-1-deficient mice compared to WT mice. At day 8 WT 
mice showed thickening of capillary walls (arrowhead) but mostly open capillary lumens. Magnification x 250. For 
full-colour representation see appendix.
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Figure 7. Syndecan-1-deficient (Sdc-1-/-) mice develop higher levels of mouse Ig/IgG1 anti-rabbit IgG and lower 
levels of mouse IgG2a anti-rabbit IgG than wild type (WT) mice during anti-GBM nephritis. The plasma levels 
of total mouse Ig and IgG1 anti-rabbit IgG in the sdc-1-deficient mice were higher, while plasma levels of mouse 
IgG2a anti-rabbit IgG were lower compared to WT mice 4 days (A) and 8 days (B) after administration of rabbit anti-
GBM IgG. Glomerular mouse IgG1 deposits were higher in sdc-1-deficient mice, while glomerular mouse IgG2a 
deposits were lower compared to WT mice 4 days (C) and 8 days (D) after administration of rabbit anti-GBM IgG. 
The results (means ± SEM) are expressed as titers of plasma levels in U/ml (A and B) or as titers of appropriate 
antibodies detecting glomerular deposits in arbitrary units (AU) (C and D) from 8 WT and 8 sdc-1-deficient mice. 
* p < 0.05 versus anti-GBM injected WT mice.
Discussion
 
     Previously, it has been shown that the HSPG sdc-1 is important for leukocyte trafficking on 
activated endothelium9,38. Therefore, we evaluated the role of sdc-1 in experimental anti-GBM 
nephritis. The rabbit anti-GBM serum we generated was effective in binding to the GBM and 
led to glomerular C3c and fibrin deposition in the heterologous and autologous phase of anti-
GBM nephritis, which is in accordance with previous studies14,17,19 and which was not affected 
by sdc-1 deficiency. 
     In both WT and sdc-1-deficient mice, glomerular PMN influx was peaking 2 hours after 
rabbit anti-mouse GBM IgG administration, which is consistent with previous studies14,17,19.
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However, the glomerular PMN influx in sdc-1-deficient mice was significantly higher 
compared to WT mice. Our findings are in accordance with previous data, since an increased 
adhesion of leukocytes has been shown in sdc-1-deficient mice in a retina perfusion model and 
in acute lung inflammation9,39. It appeared that the enhanced leukocyte adhesion mainly could 
be attributed to the sdc-1 deficiency of leukocytes which was underscored by an enhanced 
adhesion of sdc-1-deficient leukocytes to activated HUVEC in vitro9,38. Therefore, the higher 
glomerular PMN influx in sdc-1-deficient mice may be caused by an enhanced adhesion of 
PMNs to the activated glomerular endothelium. This may be explained by the impossibility 
of shedding, i.e. proteolytic cleavage, of the ectodomain of sdc-140-43. This soluble ectodomain 
that contains the HS side chains could compete for proinflammatory chemokines destined 
for the endothelium or could modify leukocyte adhesion by competitive binding to adhesion 
molecules such as selectins and integrins. An additional explanation for the higher PMN influx 
in sdc-1-deficient mice may be the significantly higher glomerular endothelial expression 
of specific inflammatory, N- and 6-O-sulfated, HS domains in these mice compared to WT 
mice at the moment of maximal PMN influx, i.e. 2 hours after anti-GBM administration. 
Recently, we found that these inflammatory HS domains are crucial for the firm adhesion 
of leukocytes to activated glomerular endothelial cells in vitro37. At this moment we have 
no mechanistic explanation for the higher expression of these inflammatory HS domains on 
activated glomerular endothelium in sdc-1-deficient mice. Apparently, sdc-1 on either the 
glomerular endothelium and/or on leukocytes has anti-inflammatory properties by controlling 
the expression of endothelial HS ligands for receptors on leukocytes, i.e. L-selectin and 
Mac-1, possibly by modulating intracellular cascades44,45. However, we can conclude that 
sdc-1 apparently is not the HSPG core protein that carries HS chains with the inflammatory, 
N- and 6-O-sulfated, HS domains, since these domains are also expressed on the glomerular 
endothelium of sdc-1-deficient mice.
     During the acute heterologous phase, i.e. after 18 hours, albuminuria was higher in sdc-1-
deficient mice compared to WT mice. This may be explained by the higher glomerular PMN 
influx, which could result in more release of proteinases by PMNs and thus more destruction 
of the capillary wall14. This increased influx led to a higher albuminuria at 4 hours, which 
became significant after 18 hours. This difference in albuminuria persisted in the autologous 
phase, while renal function of sdc-1-deficient mice was worse after 8 days. In line with this, 
glomerular injury in sdc-1-deficient mice was more severe compared to WT mice after 4 and 
8 days. As discussed for the heterologous phase, this may be explained by more glomerular 
damage mediated by PMNs, initially. However, it has been reported that the development of 
mouse Ig anti-rabbit IgG and subsequent deposition during the autologous phase may be a 
driving force in persistence of albuminuria26. Therefore, the observed 2-fold higher glomerular 
deposition of mouse Ig anti-rabbit IgG in sdc-1-deficient mice may serve as an explanation for 
the higher albuminuria in sdc-1-deficient mice during the autologous phase.
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Notably, both WT and sdc-1-deficient mice showed a higher response against rabbit anti-GBM 
IgG compared to control rabbit IgG. This can be explained by interference of the anti-GBM 
antibodies with the immune response against rabbit anti-GBM IgG. The anti-GBM anti- 
bodies contained reactivities against HS and agrin, which are both present on immunological 
cells11,46,47 and thus may be potential targets of the anti-GBM antibodies. Another explanation 
may be that the anti-GBM rabbit IgG serves as a planted antigen, while the control rabbit IgG 
remains in the circulation. The response against rabbit anti-GBM IgG is quantitatively and 
qualitatively different between WT and sdc-1-deficient mice. First, the response against rabbit 
anti-GBM IgG is higher in sdc-1-deficient mice than in WT mice. Furthermore, sdc-1-
deficient mice had higher plasma levels of mouse IgG1 anti-rabbit IgG and lower plasma 
levels of mouse IgG2a anti-rabbit IgG. This indicates a shift from a Th1 response, identified as 
the major T cell response in anti-GBM nephritis25, to a Th2 response in sdc-1-deficient mice. 
This has been described previously in sdc-1-deficient mice with allergic lung inflammation48. 
Furthermore, the higher response against rabbit anti-GBM IgG in sdc-1-deficient mice may 
be the result of a combination of the intrinsic sdc-1 deficiency of certain immunological cells 
such as B cells49,50 and immature dendritic cells51 and the potential effect of the anti-GBM 
antibodies on these immunological cells. However, at this moment it remains difficult to 
explain how a shift to a Th2 response leads to aggravation of the autologous phase in anti-
GBM nephritis, since Th2 induced antibodies in general are worse in complement fixation 
compared to Th1 induced antibodies. 
     In conclusion, sdc-1 regulates the PMN adhesion to activated glomerular endothelium 
during the heterologous phase of anti-GBM nephritis, either directly by shedding or indirectly 
via regulation of glomerular endothelial expression of inflammatory HS domains that promote 
the firm adhesion of leukocytes. Furthermore, sdc-1 influences the immune response against 
rabbit anti-GBM IgG during the autologous phase of anti-GBM nephritis. Overall, sdc-1 
seems to have anti-inflammatory properties in anti-GBM nephritis.
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Abstract
     Recently, we identified specific N- and 6-O-sulfated heparan sulfate (HS) domains on 
activated glomerular endothelial cells. In this study, we evaluated in lupus nephritis the 
expression of different HS domains on glomerular endothelium and in the glomerular 
basement membrane (GBM). 
     The expression of specific glomerular HS domains and the presence of immunoglobulins 
(Ig) were determined by immunofluorescence staining of kidney sections of patients 
with nephritis due to systemic lupus erythematosus (SLE) and MRL/lpr lupus mice. The 
expression/presence of glomerular HS domains and Ig was also evaluated after eluting Ig from 
renal sections of lupus mice using two elution methods, and in renal sections of lupus mice 
treated with heparinoids. 
     Both MRL/lpr mice and patients with lupus nephritis showed a decreased expression of HS 
in the GBM. The expression of N- and 6-O-sulfated HS domains on glomerular endothelium 
was decreased in MRL/lpr mice, but increased in SLE patients. MRL/lpr mice had more 
extensive glomerular Ig deposits than SLE patients. After elution of Ig, the glomerular 
endothelial expression of N- and 6-O-sulfated HS domains in MRL/lpr mice was recovered 
and even increased above normal levels, while the expression of HS in the GBM was restored 
to normal levels. Treatment with heparinoids prevented Ig deposition and preserved the 
expression of glomerular HS domains at normal levels in lupus mice.
     The expression of specific HS domains on glomerular endothelium and in the GBM is 
changed during lupus nephritis due to masking by Ig deposits and induction of inflammatory 
N- and 6-O-sulfated HS domains.
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Introduction
     A hallmark of systemic lupus erythematosus (SLE) is the development of anti-nuclear 
autoantibodies, in particular anti-chromatin autoantibodies, that include anti-dsDNA, anti-
histone and nucleosome-specific antibodies1,2. Furthermore, nucleosomes can be detected 
in the circulation of SLE patients and lupus mice, which may be the result of an aberrant 
apoptosis and/or an insufficient clearance of apoptotic cells/debris2. About 50% of patients 
with SLE will develop glomerulonephritis, which is characterized by granular deposits of 
immunoglobulins (Ig) in the mesangium and along the glomerular capillary wall, and the 
glomerular influx of leukocytes, leading to albuminuria, hematuria and impairment of renal 
function3.
     Heparan sulfate proteoglycans (HSPGs) are composed of a core protein with covalently 
linked linear heparan sulfate (HS) carbohydrate side chains. These HS side chains can consist 
of up to 150 disaccharide units of glucosamine-uronic acid residues that can be sulfated at 
the N-position, 2-, 3- and/or 6-O-position, and epimerized at the C-5-position4. The possible 
combinations of modifications within one HS chain gives rise to an enormous structural 
diversity, which is important for the specific binding of a myriad of factors. HSPGs are 
intrinsic constituents of the extracellular matrix, like the glomerular basement membrane 
(GBM), and responsible for the majority of anionic sites in the GBM5. It is assumed that the 
negatively charged HS in the GBM is important for the charge-selective filtration5,6, although 
recently its contribution has been questioned (Harvey S. et al. Podocyte-derived agrin is 
responsible for glomerular basement membrane anionic charge (abstract). J Am Soc Nephrol 
16 Abstracts Issue: TH-FC003, 2005). Furthermore, HSPGs are expressed at the cell surface 
of virtual all cells and are involved in many biologic processes, which often is mediated by 
the binding of relevant factors via their HS side chain. HS expressed at cell surfaces plays an 
important role during inflammatory processes by binding to chemokines, cytokines, selectins 
and integrins7,8. Several studies demonstrated that in particular N- and 6-O-sulfated HS 
domains on activated endothelial cells may serve as ligands for L-selectin and Mac-1, which 
are expressed on leukocytes4,7-9. 
     Based on previous work, we hypothesized that in SLE binding of anti-dsDNA and 
nucleosome-specific antibodies to nucleosomes in the circulation leads to neutralization of 
negative charges on the nucleosome thus making it overall more positive10. This masking 
of negative charge in the nucleosome leads to an enhanced binding/deposition of the anti-
nucleosome/nucleosome immune complexes to the negatively charged HS in the GBM 
mediated by the positively charged N-terminal histone tails within the nucleosome10-12. 
Recently, it was demonstrated with EM colocalization studies that deposited Ig is bound to 
extracellular chromatin bound to the GBM13. The amount of Ig deposits along the capillary 
loops and the degree of albuminuria correlated significantly with a decreased expression of HS 
in the GBM, while the expression of the HSPG core protein agrin remained unaltered14. 
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Previously, we showed that treatment of MRL/lpr lupus mice with heparin or low molecular 
weight (LMW) heparinoids prevented albuminuria, and specifically, the deposition of 
nephritogenic immune complexes in the GBM. Most likely, the administered heparinoids 
bound to the anti-nucleosome/nucleosome immune complexes, thus preventing the binding to 
HS, and thereby, the deposition of these immune complexes in the glomerular capillary wall15.
     In the current study, we evaluated the expression of different HS domains either in the 
GBM or on glomerular endothelial cells in murine and human lupus nephritis. The glomerular 
expression/presence of specific HS domains and Ig was also evaluated after elution of Ig from 
kidney sections of lupus mice following two methods, and in kidney sections of lupus mice 
treated with heparinoids. 
Methods
Animals
     Kidney sections of 18 weeks-old MRL/lpr mice, which were divided into three groups 
depending on their degree of albuminuria: “no albuminuria” (NA, albustix <300 µg/ml), 
“short albuminuria” (SA, albustix > 1000 µg/ml, albuminuria for a period shorter then 7 days) 
and “long albuminuria” (LA, albustix > 1000 µg/ml, albuminuria for a period of 14-21 days) 
were obtained as described previously14. Kidney sections of age-matched MRL +/+ mice were 
included as a control. At this stage these mice have no renal abnormalities and no albuminuria. 
Kidney sections of 21 weeks-old MRL/lpr mice, which were treated daily with LMW heparin 
or phosphate buffered saline (PBS) from week 8 until week 21, were obtained as described 
previously15. The local Animal Ethics Committee of the Radboud University Nijmegen 
Medical Centre approved all animal experiments. 
SLE patients
     Kidney biopsies from SLE patients with proliferative lupus nephritis (ISN/RPS class III 
or IV) (Table 1) were collected at the Division of Nephrology, Radboud University Nijmegen 
Medical Centre, which was approved by the local Human Ethics Committee of the Radboud 
University Nijmegen Medical Centre.
Immunofluorescence staining
     Indirect immunofluorescence stainings were performed on 2 µm cryostat renal sections. 
Sections were fixed in ice-cold acetone for 10 minutes and incubated with primary antibodies 
diluted in PBS containing 1% bovine serum albumin (BSA, Sigma-Aldrich Chemie BV, 
Zwijndrecht, The Netherlands) and 0.05% sodium azide (IF-buffer) for 45 minutes at room
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temperature. The expression of HS in the GBM was evaluated by staining with the anti-HS 
mouse monoclonal antibody JM403 (0.1 µg/ml), which recognizes HS in the GBM16. The 
glomerular endothelial expression of N- and 6-O-sulfated HS domains was evaluated by 
double staining with the VSV-tagged single chain anti-HS antibodies AO4B08, EW3D10 
and EW4G2, recognizing N- and 6-O-sulfated HS domains (10-50 µg/ml)17,18 and a rat 
anti-mouse CD31 (PECAM-1) monoclonal antibody (0.1 µg/ml, BD Biosciences, Alphen 
aan den Rijn, The Netherlands). To prevent nonspecific mouse Ig staining on mouse renal 
sections, the mouse-on-mouse kit (Brunschwig Chemie, Amsterdam, The Netherlands) 
was used according to the manufacturer’s protocol. Sections were washed in PBS and for 
detection incubated with the appropriate Alexa 488-conjugated secondary antibodies (5 µg/ml, 
Molecular Probes, Leiden, The Netherlands) or anti-VSV-Cy3 (2 µg/ml, Sigma-Aldrich 
Chemie) in IF-buffer for 45 minutes at room temperature. The presence of glomerular Ig 
was evaluated by incubation with the appropriate Alexa 488-conjugated anti-Ig antibodies (5 
µg/ml, Molecular Probes). Subsequently, sections were washed in PBS, postfixed with 1% 
paraformaldehyde in PBS, washed in PBS, and embedded in VectaShield mounting medium 
H-1000 (Brunschwig Chemie). The slides were evaluated by fluorescence microscopy (Leica 
DM4000B fluorescence microscope, Leica Microsystems B.V., Rijswijk, The Netherlands) and 
photographed with the Leica DFC300 FX digital camera (Leica Microsystems). The staining 
intensities of 25 glomeruli were scored on a scale between 0 and 10 on blinded sections by 
two independent observers. The r-values between the two observers ranged from 0.83-0.95. 
Six mice were analyzed in each group.
Elution of Ig deposits
     To study whether Ig could be eluted and HS staining could be subsequently restored, we 
tested two elution procedures on renal sections of MRL/lpr mice. Method I; Nonfixed 2 µm 
cryostat sections were submerged in 220 ml solution of 0.15 M glycine with 5 M urea, pH 2.8, 
of 4°C for exactly 2 hours and subsequently extensively washed in PBS at 20°C. Method II; 
Nonfixed 2 µm cryostat sections were submerged in 220 ml solution of 0.15 M glycine with 
5 M urea, pH 2.8, of 20°C with a subsequent cooling-down at 4°C for exactly 2 hours and 
followed by extensive washing in PBS at 20°C. Kidney sections of MRL +/+ mice were also 
subjected to the same elution procedures and used as controls to correct for Ig-independent 
effects of the elution procedures on the integrity of the HS domains as probed by the anti-HS 
antibodies. For each anti-HS antibody the ratio was calculated by dividing the expression of 
untreated sections of MRL +/+ mice by the expression of MRL +/+ sections that were eluted. 
To evaluate the effect of Ig on the elution procedure, renal sections of normal C57BL/6 mice 
loaded with excessive amounts of purified rabbit anti-mouse GBM IgG were subjected to 
elution procedure II as described above. Staining of anti-HS antibodies was compared to 
sections that were not subjected to elution procedure II.
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Statistical Analysis
    Values are expressed as means ± SEM and significance was determined by Mann-Whitney 
U testing using GraphPad Prism, version 4.0 software (GraphPad Software, Inc., San Diego, 
CA). P values < 0.05 were considered as significant.
Results
The expression of HS domains in the GBM and on glomerular endothelial cells is 
decreased in MRL/lpr mice with albuminuria
     We evaluated the expression of HS in the GBM and on glomerular endothelial cells of 18 
weeks-old MRL/lpr lupus mice with no albuminuria (NA), short albuminuria (SA) or long 
albuminuria (LA), and in age-matched MRL +/+ controls. Probing with the anti-HS antibody 
JM403, which recognizes N-unsubstituted HS domains especially in the GBM, revealed a 
significant decrease of HS in the GBM of the LA group compared to the MRL +/+ control 
group, while HS expression in the GBM of the NA and SA groups was similar to the MRL 
+/+ group, although there was a trend to a lower expression in the SA group (Figure 1A-E)14. 
Double staining with an anti-CD31 antibody and the anti-HS antibodies AO4B08, EW3D10 
and EW4G217,18, which recognize N- and 6-O-sulfated HS domains, revealed a decreased 
glomerular endothelial expression of the N- and 6-O-sulfated HS domains in the LA and SA 
groups compared to the MRL +/+ group, while the expression in the NA group was unaffected 
(Figure 2A-C). As will be discussed, we have evidence that these N- and 6-O-sulfated HS 
domains are associated with activated glomerular endothelial cells, and thus can be considered 
as inflammatory HS domains. We also evaluated glomerular Ig deposits, which revealed an 
increased presence of Ig along the capillary wall in both the SA and LA group compared to the 
MRL +/+ group, while the Ig deposition in the NA group was similar to the MRL +/+ group 
(Figure 2D). Our data suggest that Ig may mask specific HS domains in both the GBM and on 
glomerular endothelial cells.
Masking of HS domains in the GBM and on glomerular endothelial cells by Ig in 
MRL/lpr mice with albuminuria
     Previously, we obtained indirect evidence that in SLE HS in the GBM was masked by Ig 
deposits10-12,14. However, at that time we could not unmask the HS domain in the GBM that is 
recognized by the antibody JM403 by eluting Ig from renal sections. Most likely, the elution 
procedure led to destruction of the HS domain14. To remove Ig, we originally incubated 
renal sections of LA MRL/lpr mice in 0.15 M glycine with 5 M urea, pH 2.8, with a starting 
temperature of 4°C for exactly 2 hours at 4°C (”Ig elution method I”), which indeed resulted 
in removal of Ig as previously found14, but not in the full reappearance of HS along the
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Figue 1. Expression of heparan sulfate in the glomerular basement membrane of lupus and control mice. The 
expression of HS in the GBM of MRL +/+ control mice (A), MRL/lpr lupus mice with no albuminuria (B), short (C) 
and long albuminuria (D) was determined by probing with the monoclonal anti-HS antibody JM403. Staining intensity 
along the capillary wall was scored semi-quantitatively. Magnification 400x. The expression of HS in the GBM was 
significantly decreased in MRL/lpr mice with long albuminuria (E). * p < 0.05 compared to MRL +/+ control mice. 
GlcNH3+, N-unsubstituted glucosamine; NA, no albuminuria; SA, short albuminuria; LA, long albuminuria. 
capillary wall, i.e. in the GBM as measured by JM403 and on glomerular endothelial cells 
as measured by EW3D10 (Figure 3A and B). In the current study, we developed a slightly 
modified Ig elution procedure, in which we incubated renal sections of MRL +/+ mice and 
MRL/lpr mice in 0.15 M glycine with 5 M urea, pH 2.8, at a starting temperature of 20°C
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Figure 2. Expression of N- and 6-O-sulfated heparan sulfate domains on glomerular endothelial cells and Ig 
deposits along the capillary wall in lupus and control mice. The glomerular endothelial expression of N- and 6-
O-sulfated HS domains in MRL +/+ mice and MRL/lpr lupus mice with no albuminuria, short and long albuminuria 
was determined by double staining for CD31 and N- and 6-O-sulfated HS domains with the respective anti-HS single 
chain antibodies EW3D10 (A), AO4B08 (B) and EW4G2 (C). The epitopes of the single chain antibodies are given 
within parentheses. Costaining intensities were scored semi-quantitatively and revealed a significantly decreased 
expression of N- and 6-O sulfated HS domains in MRL/lpr lupus mice with short and long albuminuria (A-C). Ig 
deposition along the capillary wall was significantly increased in MRL/lpr mice with short and long albuminuria (D). 
* p < 0.05 compared to MRL +/+ control mice. GlcNS, N-sulfated-glucosamine; S, sulfate; IdoA, iduronate; GlcA, 
glucuronate; NA, no albuminuria; SA, short albuminuria; LA, long albuminuria.
followed by a cooling-down period of exactly 2 hours at 4°C (“Ig elution method II”). The use 
of Ig elution method II, revealed also the removal of Ig along the capillary wall from sections 
of SA and LA MRL/lpr mice down to the levels present in MRL +/+ and NA MRL/lpr mice. 
Moreover, by using elution method II we were now able to recover (partially) the staining for 
HS in the GBM as measured by JM403 and on glomerular endothelial cells as measured by 
EW3D10, while elution method I hardly recovered glomerular HS expression (Figure 3A and 
B). 
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Figure 3. Elution of Ig from renal sections of lupus mice unmasks the expression of glomerular heparan sulfate 
domains. Ig was eluted from renal sections of MRL/lpr mice with long albuminuria by two different methods as 
detailed in the Methods section and in the text (A). Both Ig elution method I and II lead to the removal of Ig (B), but 
only Ig elution method II leads to reappearance of HS in the GBM, as measured by staining with JM403, and on 
glomerular endothelial cells, as measured by staining with the anti-HS antibody EW3D10 (A). * p < 0.05 compared to 
MRL +/+ control mice. # p < 0.05 compared to untreated sections. Magnification 400x. 
GlcNH3+, N-unsubstituted glucosamine; GlcNS, N-sulfated-glucosamine; S, sulfate; NA, no albuminuria; SA, short 
albuminuria; LA, long albuminuria. 
Next, we estimated the direct effect of the Ig elution method I and II on the integrity of HS 
domains by subjecting sections of control MRL +/+ mice to elution method I and II followed 
by staining with the various anti-HS antibodies. This revealed that the staining by the anti-HS 
antibody JM403 was rather insensitive to the newly developed Ig elution method II, while the 
staining by the anti-HS antibodies EW3D10, AO4B08 and EW4G2 decreased about 1.5-fold 
after elution method II (Figure 4A and B).
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Knowing this, we subjected sections of LA MRL/lpr mice to the Ig elution method II, 
followed by staining with the anti-HS antibodies JM403 (Figure 5A), EW3D10, AO4B08 
and EW4G2 (Figure 5B-D), which revealed a nearly complete recovery of expression of HS 
domains in LA MRL/lpr mice compared to MRL +/+ mice. However, when we corrected the 
staining intensities of the anti-HS antibodies for the direct effect of the elution method on the 
binding of the anti-HS antibodies (see Figure 4B), we noticed a complete recovery of HS
Figure 4. Effect of the Ig elution procedure on the integrity of heparan sulfate domains in the GBM and on 
glomerular endothelial cells. This effect was determined by subjecting renal sections of MRL +/+ control mice to 
the Ig elution procedures (method I and II) followed by staining with the indicated anti-HS antibodies. Representative 
photographs of renal sections before and after Ig elution probed with the anti-HS antibodies JM403 and EW3D10, 
respectively, are shown. Magnification 400x (A). Semi-quantitative scoring of the staining intensities of the anti-HS 
antibodies JM403, EW3D10, AO4B08 and EW4G2 revealed that the epitope of JM403 is slightly affected, while 
the epitopes of EW3D10, AO4B08 and EW4G2 are significantly affected by the Ig elution method II (B). * p < 0.05 
compared to untreated sections. GlcNH3+, N-unsubstituted glucosamine; GlcNS, N-sulfated-glucosamine.
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in the GBM as measured by JM403, while the expression of inflammatory N- and 6-O-
sulfated HS domains on glomerular endothelial cells as measured by EWD3D10, AO4B08 and 
EW4G2, respectively, was about 1.5-fold higher than in MRL +/+ mice (Figure 5A-D). 
Figure 5. Elution of Ig from renal sections of MRL/lpr mice unmasks heparan sulfate domains in the GBM and 
on glomerular endothelial cells. Elution of Ig (method II) from renal sections of MRL/lpr mice with long 
albuminuria unmasked the expression of HS in the GBM, as measured by staining with the anti-HS antibody JM403 
(A), and the expression of N- and 6-O-sulfated HS domains on glomerular endothelial cells, as measured by staining 
with the respective anti-HS antibodies EW3D10 (B), AO4B08 (C) and EW4G2 (D). Correction of staining intensities 
for the effect of the Ig elution procedure on the epitopes of the anti-HS antibodies (see Figure 4), revealed that the 
expression of the N- and 6-O-sulfated HS domains on glomerular endothelial cells was higher than in MRL +/+ 
control mice, while the HS expression in the GBM was similar to MRL +/+ control mice. * p < 0.05 compared to 
untreated sections. # p < 0.05 compared to MRL +/+ control mice. GlcNH3+, N-unsubstituted glucosamine; GlcNS, 
N-sulfated-glucosamine; S, sulfate; IdoA, iduronate; GlcA, glucuronate; LA, long albuminuria.
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Decreased expression of HS in the GBM and increased expression of inflammatory 
N- and 6-O-sulfated HS domains on glomerular endothelial cells in SLE patients
     Analogous to the stainings performed in murine lupus nephritis, we stained renal sections 
of SLE patients with proliferative lupus nephritis (n=10; Table 1) and healthy controls (n=10) 
with JM403, EWD3D10, AO4B08 and EW4G2. As previously demonstrated10, the expression 
of HS in the GBM as measured with JM403 was decreased in SLE patients compared to 
healthy controls (Figure 6A and 7A). However, and in contrast to mice with lupus nephritis, 
the expression of inflammatory N- and 6-O-sulfated HS domains on glomerular endothelial 
cells as measured with EWD3D10, AO4B08 and EW4G2, and costained with anti-CD31, 
was significantly increased in SLE patients compared to healthy controls (Figure 6B and 
7B-D). Evaluation of Ig deposits along the capillary wall revealed less abundant Ig deposition 
in SLE patients compared to mice with lupus nephritis (compare Figure 7E and Figure 2D). 
Four human renal biopsies were subjected to Ig elution method II, followed by staining with 
the anti-HS antibody JM03, which revealed a nearly complete recovery of HS expression 
in the GBM (data not shown). This suggests that the masking of HS in the GBM by Ig in 
SLE patients is comparable to that in lupus nephritis mice, while the increased expression of 
inflammatory N- and 6-O-sulfated HS domains on glomerular endothelial cells is not masked 
by Ig in SLE patients to such a degree as in lupus mice. 
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     One could argue that Ig plays a possible protective role on the effects of elution procedure 
II on the integrity of the HS domains on renal sections with lupus nephritis. This could raise 
doubts whether the “correction factor” for the effect of the elution method on the integrity 
of HS domains as determined on MRL +/+ kidney sections is applicable for lupus sections. 
Therefore, we have performed immunofluorescence stainings with the anti-HS antibodies 
after Ig elution method II on mouse renal sections loaded with excessive amounts of rabbit 
anti-GBM IgG, which mimics the glomerular Ig deposition in lupus nephritis. It appeared 
that the effect of the elution procedure on the integrity of the HS domains on these sections 
loaded with excessive amounts of rabbit anti-GBM IgG was similar, i.e. the correction factor 
was ~1.5 fold, to the effect of the elution procedure on renal sections of MRL +/+ mice, in the 
presence of low amounts of Ig (data not shown). In summary, Ig masks specific HS domains in 
the GBM and on glomerular endothelial cells in MRL/lpr mice with albuminuria. Moreover, 
elution of Ig revealed an increased expression of the inflammatory N- and 6-O sulfated HS 
domains on glomerular endothelial cells.
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Treatment of MRL/lpr mice with LMW heparin prevents changes in the expression 
of HS domains in the GBM and on glomerular endothelial cells
     Previously, we showed that treatment of MRL/lpr mice with LMW heparin prevents the 
deposition of nucleosome/anti-nucleosome immune complexes along the capillary wall and 
the development of albuminuria15. Indeed, MRL/lpr mice treated with LMW heparin showed 
an almost normal expression of HS in the GBM (Figure 8A), whereas the expression of the 
inflammatory N- and 6-O-sulfated HS domains on glomerular endothelial cells was preserved 
(Figure 8B-D). This preserved HS expression in the GBM and on glomerular endothelial cells 
was associated with a significant decrease in Ig deposits along the capillary wall compared 
to PBS-treated MRL/lpr mice (Figure 8E). Notably, treatment with LMW heparin not only 
prevented Ig deposition and masking of HS domains, but also prevented the increased 
expression of the inflammatory N- and 6-O-sulfated HS domains on glomerular endothelial 
cells as observed in untreated MRL/lpr mice (Figure 5B-D) and SLE patients (Figure 7B-D). 
In summary, treatment of murine lupus nephritis with LMW heparin prevents Ig deposition 
along the capillary wall, is associated with a normal expression of HS in the GBM, and 
prevents inflammation-induced upregulation of the N- and 6-O-sulfated HS domains on 
glomerular endothelium. 
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Figure 6. Expression of heparan sulfate domains in the GBM and on glomerular endothelial cells in a patient 
with SLE nephritis and in a healthy control. Representative photographs showing the decreased expression of HS 
in the GBM (A) and the slightly increased expression of N- and 6-O-sulfated HS domains on glomerular endothelial 
cells (B) of a SLE patient and a healthy control, as measured by staining with the anti-HS antibody JM403 (A) or 
costaining with anti-CD31 (green) and the anti-HS antibody EW3D10 (red) (B). Magnification 400x. For full-colour 
representation see appendix.
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Figure 7. Analysis of the expression of heparan sulfate domains in the GBM and on glomerular endothelial cells 
in SLE patients and healthy controls. The expression of HS in the GBM, as measured by staining with the anti-HS 
antibody JM403, was significantly decreased in SLE patients (A). The expression of N- and 6-O-sulfated HS domains 
on glomerular endothelial cells, as measured by costaining with anti-CD31 and the respective anti-HS antibodies 
EW3D10 (B), AO4B08 (C) and EW4G2 (D), was significantly increased. Ig deposits along the capillary wall were 
also significantly increased in SLE patients (E). * p < 0.05 compared to healthy controls. GlcNH3+, N-unsubstituted 
glucosamine; GlcNS, N-sulfated-glucosamine; S, sulfate; IdoA, iduronate; GlcA, glucuronate.
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Discussion
 
     Previously, we found indirect evidence that in lupus nephritis HS in the GBM was masked 
by Ig, which leads to the reduction of functional anionic sites in the GBM and is associated 
with the development of albuminuria14. We also showed that the amount of Ig deposited along 
the capillary wall was significantly correlated with the degree of albuminuria. However, we 
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Figure 8. The expression of glomerular heparan sulfate domains is preserved in lupus mice treated with low 
molecular weight heparin. The expression of HS in the GBM, as measured by staining with JM403 (A), and the 
expression of N- and 6-O-sulfated HS domains on glomerular endothelial cells, as measured by costaining with anti-
CD31 and the respective anti-HS antibodies EW3D10 (B), AO4B08 (C) and EW4G2 (D), was preserved in MRL/lpr 
mice treated with low molecular weight (LMW) heparin and similar to that in MRL +/+ control mice (dotted line). 
The amount of Ig along the capillary wall in MRL/lpr mice treated with LMW heparin was the same as in MRL +/+ 
control mice (dotted line) (E). * p < 0.05 compared to MRL/lpr mice treated with PBS. GlcNH3+, N-unsubstituted 
glucosamine; GlcNS, N-sulfated-glucosamine; S, sulfate; IdoA, iduronate; GlcA, glucuronate. 
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never could prove unequivocally that Ig masked HS in the GBM, since elution of Ig from 
renal sections did remove Ig, but also affected the integrity of the HS domain in the GBM 
as evaluated by the monoclonal antibody JM40314. In the current study, we developed a 
modified Ig elution method that had a less detrimental effect on the integrity of HS domains 
as measured by anti-HS antibodies. Using this Ig elution method we now clearly could 
demonstrate that in murine lupus nephritis HS domains in the GBM and on glomerular 
endothelial cells are indeed masked by deposited Ig. This is also the case for expression of 
HS in the GBM in SLE patients (data not shown), which indicates that in lupus nephritis HS 
in the GBM is masked by Ig. Elution of Ig from renal sections of mice with lupus nephritis 
also revealed the unmasking of specific N- and 6-O-sulfated HS domains on glomerular 
endothelial cells as measured by specific anti-HS antibodies. Actually, when we corrected for 
the effect of the Ig elution procedure on the integrity of these HS domains, the glomerular 
endothelial expression of these N- and 6-O sulfated HS domains was even higher than in 
control mice. We have ample evidence that these N- and 6-O-sulfated HS domains can be 
considered as inflammatory HS domains on glomerular endothelial cells (chapter 4). First, 
the expression of these N- and 6-O-sulfated HS domains by glomerular endothelial cells in 
vitro is increased after activation with proinflammatory cytokines like tumor necrosis factor 
(TNF)-α and interleukin (IL)-1β. Second, these N- and 6-O-sulfated HS domains play a 
crucial role in the adhesion of granulocytes to glomerular endothelial cells as measured in a 
static in vitro adhesion system. Third, the glomerular endothelial expression of these N- and 
6-O-sulfated HS domains is also increased during the acute phase of experimental anti-
GBM glomerulonephritis (chapter 6). In the current study, we show activation of glomerular 
endothelial cells in lupus mice with albuminuria by measuring an increased glomerular 
endothelial expression of intercellular adhesion molecule (ICAM)-1 (data not shown), which 
has also been described by others19. Interestingly, without Ig elution we already could observe 
an increased glomerular endothelial expression of the inflammatory N- and 6-O-sulfated 
HS domains in SLE patients. Apparently, there was less deposited Ig in the renal sections of 
the SLE patients when compared to lupus mice, which could explain that there was a lower 
degree or even absence of masking of glomerular endothelial HS domains in SLE patients. 
On the other hand, although the amount of Ig deposited along the capillary wall in SLE 
patients was lower compared to lupus mice, the reduction in expression of HS in the GBM 
was similar to that in lupus mice. This may be explained by the preferential deposition in the 
GBM of the nucleosome/anti-nucleosome immune complexes13. In summary, in both murine 
lupus nephritis and in patients with proliferative SLE nephritis we could show an increased 
glomerular endothelial expression of inflammatory N- and 6-O-sulfated HS domains.
     Recently, we have shown that the HS-specific β(1-4)-endoglucuronidase enzym heparanase 
(HPSE) that cleaves HS at specific sites20,21 may be involved in the pathogenesis of proteinuria 
Acknowledgments
     This study was supported by program grant 902-27-292 from The Netherlands Organization 
for Scientific Research (NWO) and by grant C05.2152 from the Dutch Kidney Foundation. 
The skillful contributions of Drs. M. van Bruggen, C. Kramers and E. Steenbergen (Radboud 
University Nijmegen Medical Centre) are gratefully acknowledged. The LMW heparin was a 
generous gift from Dr. G. van Dedem (Diosynth, Oss, The Netherlands). 
Chapter 7
References
  1. Dieker JW, van der Vlag J, Berden JH. Triggers for anti-chromatin autoantibody production in SLE. Lupus. 
 2002; 11:856-864.
  2. Dieker JW, van der Vlag J, Berden JH. Deranged removal of apoptotic cells: its role in the genesis of 
 lupus. Nephrol Dial Transplant. 2004; 19:282-285.
  3. Berden JH. Lupus nephritis. Kidney Int. 1997; 52:538-558.
  4. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev 
 Biochem. 2002; 71:435-471.
  5. Raats CJ, van den Born J, Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance 
 for proteinuria. Kidney Int. 2000; 57:385-400.
152
in overt diabetic nephropathy by degradation of HS in the GBM22. In the current study, 
we also evaluated the glomerular HPSE expression, which appeared to be slightly, but not 
significantly, increased in SLE patients with proliferative lupus nephritis compared to the 
healthy controls (data not shown). Since we previously showed a normal content of glomerular 
HS in MRL/lpr mice, irrespective of the degree of proteinuria14, we suggest that the 
increased N- and 6-O-sulfated HS expression by glomerular endothelium is due to an altered 
modification process of HS during lupus nephritis. 
     Previously, we have shown that treatment of prediseased lupus mice with LMW heparin 
prevented the binding of immune complexes to the GBM and delayed the development of 
lupus nephritis15. In addition, we now could show that this treatment prevents the increase in 
expression of N- and 6-O-sulfated HS domains. The anti-inflammatory effect of treatment with 
LMW heparin, i.e. the prevention of the increased glomerular endothelial expression of the 
inflammatory N- and 6-O-sulfated HS domains, may be the result of both a reduced deposition 
of immune complexes and a reduced glomerular influx of leukocytes. 
     In conclusion, the expression of specific HS domains in the GBM and on glomerular 
endothelial cells is changed during lupus nephritis. These changes are due to both masking by 
Ig and by inflammatory stimuli, while treatment with heparinoids preserves the expression of 
HS domains in the glomerulus by preventing both processes. 
Glomerular heparan sulfate domains in lupus nephritis
        153
  6. Kanwar YS, Liu ZZ, Kashihara N, et al. Current status of the structural and functional basis of glomerular 
 filtration and proteinuria. Semin Nephrol. 1991; 11:390-413.
  7. Rops AL, van der Vlag J, Lensen JF, et al. Heparan sulfate proteoglycans in glomerular inflammation. 
 Kidney Int. 2004; 65:768-785.
  8. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol. 2006; 6:633-643.
  9. Wang L, Fuster M, Sriramarao P, et al. Endothelial heparan sulfate deficiency impairs L-selectin- and 
 chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol. 2005; 6:902-
 910.
10. van Bruggen MC, Walgreen B, Rijke TP, et al. Antigen specificity of anti-nuclear antibodies complexed to 
 nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol. 1997; 27:1564-
 1569.
11. van Bruggen MC, Kramers C, Walgreen B, et al. Nucleosomes and histones are present in glomerular 
 deposits in human lupus nephritis. Nephrol Dial Transplant. 1997; 12:57-66.
12. Kramers C, Hylkema MN, van Bruggen MC, et al. Anti-nucleosome antibodies complexed to nucleosomal 
 antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest. 
 1994; 94:568-577.
13. Kalaaji M, Mortensen E, Jorgensen L, et al. Nephritogenic lupus antibodies recognize glomerular basement 
 membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol. 
 2006; 168:1779-1792.
14. van Bruggen MC, Kramers K, Hylkema MN, et al. Decrease of heparan sulfate staining in the glomerular 
 basement membrane in murine lupus nephritis. Am J Pathol. 1995; 146:753-763.
15. van Bruggen MC, Walgreen B, Rijke TP, et al. Heparin and heparinoids prevent the binding of immune 
 complexes containing nucleosomal antigens to the GBM and delay nephritis in MRL/lpr mice. Kidney Int. 
 1996; 50:1555-1564.
16. van den Born J, Gunnarsson K, Bakker MA, et al. Presence of N-unsubstituted glucosamine units in native 
 heparan sulfate revealed by a monoclonal antibody. J Biol Chem. 1995; 270:31303-31309.
17. van de Westerlo EM, Smetsers TF, Dennissen MA, et al. Human single chain antibodies against heparin: 
 selection, characterization, and effect on coagulation. Blood. 2002; 99:2427-2433.
18. Lensen JF, Rops AL, Wijnhoven TJ, et al. Localization and functional characterization of 
 glycosaminoglycan domains in the normal human kidney as revealed by phage display-derived single 
 chain antibodies. J Am Soc Nephrol. 2005; 16:1279-1288.
19. McHale JF, Harari OA, Marshall D, et al. TNF-alpha and IL-1 sequentially induce endothelial ICAM-1 and 
 VCAM-1 expression in MRL/lpr lupus-prone mice. J Immunol. 1999; 163:3993-4000.
20. Okada Y, Yamada S, Toyoshima M, Dong J, Nakajima M, Sugahara K. Structural recognition by 
 recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups 
 with different effects and the essential target disulfated trisaccharide sequence. J Biol Chem 2002; 277: 
 42488-42495
21. Pikas DS, Li JP, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and 
 platelets. J Biol Chem 1998; 273: 18770-18777
22. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, Goldschmeding R, Zcharia E, 
 Vlodavsky I, van der Vlag J, Berden JH. Increased expression of heparanase in overt diabetic nephropathy. 
 Kidney Int 2006; 70: 2100-2108

Chapter 8
Summary and future directions of research
       
Chapter 8
     Proliferative glomerulonephritis is manifested in a range of diseases and is characterized 
by the glomerular influx of inflammatory cells (leukocytes). Heparan sulfate (HS) plays 
a prominent role during inflammation by binding to chemokines, cytokines, selectins 
and integrins. In particular, HS is important for the interaction between leukocytes and 
endothelium in the inflamed tissue as described in chapter 1 and 2. The expression and 
function of HS in different microvascular beds is not similar and it remains elusive which 
HS domains on activated glomerular endothelium are important for the interaction with 
leukocytes. The identification of functional inflammatory HS domains on glomerular 
endothelium could lead to the rational development of defined HS-based therapeutics 
for the supplementary treatment of glomerulonephritis. In this thesis, the expression of 
specific HS domains on glomerular endothelial cells and their function in the interaction 
with leukocytes are evaluated in vitro in leukocyte-endothelium adhesion assays, in vivo in 
experimental glomerulonephritis and in systemic lupus erythematosus (SLE) patients with 
glomerulonephritis.
     To assess the role of glomerular endothelial heparan sulfate (proteoglycans) (HSPGs) in the 
adhesion of leukocytes using in vitro adhesion systems, a glomerular endothelial cell line was 
required. In chapter 3, the isolation and characterization of cells from glomerular outgrowth 
of the immortomouse is described. The obtained mouse glomerular endothelial cell line clone 
#1 (mGEnC-1) cultured at 37°C was positive for endothelial markers like von Willebrand 
factor, podocalyxin, platelet endothelial cell adhesion molecule-1, endoglin, vascular 
endothelial-cadherin and the lectins Griffonia simplicifolia isolectin B4 and Ulex europaeus 
agglutinin I. Furthermore, mGEnC-1 was able to take up acetylated-low-density lipoprotein 
and formed tubes when cultured on Matrigel. Most importantly, by using transmission electron 
microscopy we could demonstrate that mGEnC-1 contained nondiaphragmed fenestrae, 
which is an important characteristic of glomerular endothelial cells. Finally, activation of 
mGEnC-1 with the proinflammatory cytokines tumor necrosis factor (TNF)-α or interleukin 
(IL)-1β induced an increased expression of the inflammatory endothelial adhesion molecules 
intercellular adhesion molecule-1 and vascular adhesion molecule-1. In conclusion, the 
mGEnC-1 cell line is the first glomerular endothelial cell line described in literature that 
retained the phenotypic characteristics of primary glomerular endothelial cells. 
     The expression of HS on glomerular endothelial cells and its role in the interaction with 
leukocytes was evaluated in vitro (chapter 4). The expression of several HSPGs and N- and 
6-O-sulfated HS domains on glomerular endothelial cells, i.e. primary human glomerular 
endothelial cells and mGEnC-1, was significantly increased after stimulation with TNF-α or 
IL-1β. The increased expression of N- and 6-O-sulfated HS domains on activated glomerular 
endothelial cells was associated with an increased mRNA expression of the HS-modifying 
enzymes N-deacetylase/N-sulfotransferase (NDST)-1 and -2, 6-O-sulfotransferase-1 and -2, 
and a decreased expression of 6-O-sulfatase-2. It appeared that the cytokine-induced 
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expression of inflammatory N- and 6-O-sulfated HS domains and the changes in the mRNA 
expression of the HS-modifying enzymes could be completely prevented by the addition of 
BAY-110782, which is an inhibitor of the canonical NF-κB signaling pathway. In the cell 
culture supernatant of activated mGEnC-1, HS enriched in N- and 6-O-sulfated domains could 
be detected. Of interest, the mRNA and protein expression of the HS hydrolyzing enzyme 
heparanase was increased more than 2-fold, which could serve as an explanation for the 
presence of HS in the cell culture supernatant. To study leukocyte adhesion to mGEnC-1, an 
in vitro static adhesion assay was developed with primary granulocytes and the granulocytic 
cell line 32Dcl3, which does not express HS. The firm adhesion of granulocytes to mGEnC-1 
increased 4-fold after activation with TNF-α or IL-1β, which could be completely prevented 
by inhibition of the canonical NF-κB pathway. Removal of HS from activated mGEnC-1            
resulted in a 2-fold decreased adhesion of granulocytes, while removal of chondroitin 
sulfate/dermatan sulfate had no effect. The addition of various glycosaminoglycans, 
chemically modified low molecular weight heparinoids and defined anti-HS antibodies in 
the static adhesion assay revealed that in particular N- and 6-O-sulfated residues in HS on 
mGEnC-1 were important for adhesion of granulocytes. The integrin Mac-1 and the selectin 
L-selectin, which are expressed by 32Dcl3 cells, may be considered as putative ligands 
for the inflammatory N- and 6-O-sulfated HS domains on mGEnC-1. Finally, we showed 
that heparin(oid) treatment of MRL/lpr mice with lupus nephritis prevented glomerular 
granulocyte influx, albuminuria and glomerulonephritis. In conclusion, the expression of 
N- and 6-O-sulfated HS domains on glomerular endothelium is upregulated after stimulation 
with TNF-α or IL-1β, which is mediated by the canonical NF-κB pathway. Furthermore, these 
inflammatory N- and 6-O-sulfated HS domains on glomerular endothelium are crucial for the 
firm adhesion of leukocytes.
     Adhesion under conditions of blood flow can be mimicked in vitro in a flow chamber, 
which enables to distinguish between the rolling and firm adhesion events under dynamic 
flow conditions (chapter 5). The physiological shear stress rate in glomerular capillaries was 
approximated to be 0.8 dynes/cm2 using Hagen-Poiseuille’s law. After activation of 
mGEnC-1 with TNF-α, the number of rolling and firmly adhering granulocytes increased, 
whereas the rolling velocity of granulocytes decreased when compared to unstimulated 
mGEnC-1. Removal of HS on TNF-α-activated mGEnC-1 and the addition of HS, heparin 
or tinzaparin reduced the number of rolling and firmly adhering granulocytes, whereas the 
average rolling velocity of granulocytes increased. In conclusion, HS on activated glomerular 
endothelial cells is crucial for the leukocyte trafficking on glomerular endothelium under 
dynamic flow conditions. Furthermore, heparinoids are able to interfere with the leukocyte-
glomerular endothelium interaction under dynamic flow conditions, which may have 
therapeutic potential.
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     It has been suggested that the cell surface HSPG syndecan-1 (sdc-1) plays a role 
in the leukocyte-endothelium interaction, while the expression of sdc-1 on mGEnC-1 
increased after activation with IL-1β or TNF-α (chapter 4). To evaluate the role of sdc-1 in 
glomerulonephritis, experimental anti-glomerular basement membrane (GBM) nephritis 
was induced in sdc-1-deficient and wild type (WT) mice by injection of rabbit anti-mouse 
GBM immunoglobulin (Ig) G (chapter 6). During the acute heterologous phase, maximal 
glomerular polymorphonuclear granulocyte (PMN) influx was observed 2 hours after 
administration of anti-GBM IgG in both sdc-1-deficient and WT mice, whereas PMN influx 
in sdc-1-deficient mice was significantly higher compared to WT mice. The expression of 
inflammatory N- and 6-O-sulfated HS domains on glomerular endothelium was higher in 
sdc-1-deficient mice than in WT mice, which may explain the higher glomerular PMN influx 
in sdc-1-deficient mice. Notably, these inflammatory HS domains are crucial for the firm 
adhesion of leukocytes as determined in vitro (chapter 4). An additional explanation for the 
higher PMN influx in sdc-1-deficient mice may be the lack of shedding of the ectodomain of 
endothelial sdc-1, which contains the HS side chains. Normally, the shedded ectodomain of 
sdc-1 can effectively compete for binding to ligands on leukocytes. During the autologous 
phase, albuminuria was significantly higher and renal function was worse in sdc-1-deficient 
mice compared to WT mice, which was accompanied with more severe glomerular injury in 
sdc-1-deficient mice. The plasma mouse Ig and IgG1 anti-rabbit IgG titers and glomerular 
mouse Ig and IgG1 anti-rabbit IgG deposits were significantly higher in sdc-1-deficient mice, 
which may be a driving force in persistence of albuminuria during the autologous phase. 
However, the plasma levels and glomerular deposition of mouse IgG2a anti-rabbit IgG were 
lower in Sdc-1-deficient mice, which indicates a shift from a Th1 (IgG2a) response, identified 
as the major T cell response in anti-GBM nephritis, to a Th2 (IgG1) response in Sdc-1-
deficient mice. In conclusion, Sdc-1 deficiency aggravates experimental anti-GBM nephritis 
and shifts the Th1/Th2 balance towards Th2 during anti-GBM nephritis. 
     SLE-associated glomerulonephritis is characterized by glomerular PMN influx and 
granular deposits of Ig along the glomerular capillary wall and in the mesangium. Albuminuria 
and renal insufficiency are the most serious manifestations of this disease. In chapter 7, 
the expression of specific glomerular HS domains and the presence of Ig in renal sections 
of SLE patients and MRL/lpr mice with lupus nephritis were evaluated. A decreased HS 
expression was observed in the GBM of both MRL/lpr mice and SLE patients. The expression 
of inflammatory N- and 6-O-sulfated HS domains on glomerular endothelium appeared to 
be decreased in MRL/lpr mice, but increased in SLE patients, which could be explained by 
the fact that MRL/lpr mice had more extensive glomerular Ig deposits than SLE patients. A 
method was developed to elute the Ig from the renal sections without destroying the integrity 
of HS domains recognized by anti-HS antibodies. After elution of Ig and correction for the 
effect of the elution procedure on the integrity of the HS domains, the glomerular endothelial
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expression of inflammatory N- and 6-O-sulfated HS domains in MRL/lpr mice was recovered 
and appeared also to be increased above normal levels. Furthermore, HS expression in the 
GBM was restored to normal levels. Treatment of MRL/lpr lupus mice with heparinoids 
prevented Ig deposition and preserved the expression of glomerular HS domains at normal 
levels. In conclusion, the expression of specific HS domains on glomerular endothelium and 
in the GBM is changed during lupus nephritis due to masking by Ig deposits and induction of 
inflammatory HS domains.
                                                                                                    Summary and future directions of research
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Chapter 8
Future directions of research
     Future research on the function of HS in glomerular inflammation should be focused 
on the further identification of the exact structures within HS on glomerular endothelium 
that are important for leukocyte adhesion. To this end, HS from both unstimulated and 
activated glomerular endothelial cells (in vitro from cultured cells and in vivo from mice with 
glomerulonephritis) should be isolated and the chemical make-up should be determined by 
HS disaccharide analysis and mass spectrometry. However, the inflammatory N- and 6-O-
sulfated HS domains may only comprise a very small portion of the total HS chain, which 
may not be revealed by these analyses. Therefore, as an alternative for the structural analysis 
of the total HS chain, partially digested HS derived from activated glomerular endothelium 
may be affinity purified by anti-HS antibodies or functional ligands like L-selectin or Mac-1, 
then followed by HS structural analysis. Finally, this could lead to the rational development 
of defined HS-based therapeutics that are able to interfere with the interaction, i.e. tethering, 
rolling and firm adhesion, of leukocytes on/to glomerular endothelium. The potential role of 
such developed HS-based glycomimetics in treating glomerulonephritis should be evaluated 
in vitro in static and dynamic adhesion assays, and in vivo in experimental models of 
glomerulonephritis like anti-GBM nephritis and lupus nephritis. Since the structure of HS is 
an overall result of the combined enzymatic activity of HS-modifying enzymes, the expression 
profile of HS-modifying enzymes in unactivated and activated glomerular endothelial cells 
(in vitro and in vivo) should be determined and compared to the HS structural analysis. In 
addition, silencing of specific HS-modifying enzymes by siRNA approaches followed by 
structural HS analysis and functional testing by evaluation of leukocyte adhesion (in vitro and 
in vivo) allows correlating HS structure and associated expression of HS-modifying enzymes 
to function. Finally, study of the regulation of the expression of the genes encoding the HS-
modifying enzymes that determine the structure of inflammatory HS domains could reveal 
mechanisms that may be potential targets for therapeutic intervention, as was shown for the 
canonical NF-κB signaling pathway in activated glomerular endothelial cells (chapter 4).
     Taken together, the exact structural identification of HS domains on glomerular 
endothelial cells that are functional in the interaction with leukocytes and the elucidation of 
the mechanisms that regulate the gene expression of HS-modifying enzymes determining 
these HS domains, could lead to the development of supplementary options for treatment of 
glomerulonephritis.
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     Proliferatieve glomerulonefritis manifesteert zich tijdens verschillende nierziekten en 
wordt gekarakteriseerd door de glomerulaire influx van ontstekingscellen (leukocyten). 
Heparansulfaat (HS) speelt een prominente rol tijdens ontsteking door de binding van 
chemokines, cytokines, selectines and integrines. HS is in het bijzonder van belang voor 
de interactie tussen leukocyten en endotheel in het ontstoken weefsel, zoals beschreven in 
de hoofdstukken 1 en 2. De expressie en functie van HS in verschillende microvasculaire 
vaatbedden is niet hetzelfde en het is niet bekend welke HS-domeinen op geactiveerd 
glomerulair endotheel van belang zijn voor de interactie met leukocyten. Het identificeren 
van functionele inflammatoire HS-domeinen op glomerulair endotheel zou kunnen leiden 
tot de ontwikkeling van gedefinieerde, op HS-gebaseerde, therapeutica voor het aanvullend 
behandelen van glomerulonefritis. In dit proefschrift wordt de expressie van specifieke HS-
domeinen op glomerulaire endotheelcellen en hun functie in de interactie met leukocyten 
bestudeerd. Hiervoor is in vitro gebruik gemaakt van een leukocyt-endotheel adhesiesysteem 
en in vivo van experimentele glomerulonefritis diermodellen en patiënten met systemische 
lupus erythematosus (SLE). 
     Een glomerulaire endotheelcellijn was noodzakelijk om de rol van heparansulfaat 
(proteoglycanen) (HSPGs) op glomerulair endotheel in de hechting van leukocyten te kunnen 
bestuderen in een in vitro adhesiesysteem. In hoofdstuk 3 wordt de isolatie en karakterisatie 
van cellen uit de glomerulaire uitgroei van de immortomuis (“onsterfelijke muis”) beschreven. 
De verkregen muis glomerulaire endotheelcellijn kloon #1 (mGEnC-1), gekweekt bij 37°C, 
was positief voor de endotheelmarkers “von Willebrand factor”, “podocalyxin”, “platelet 
endothelial cell adhesion molecule-1”, “endoglin”, “vascular endothelial-cadherin” en de 
lectines “Griffonia simplicifolia isolectin B4” en “Ulex europaeus agglutinin 1”. Daarnaast 
was mGEnC-1 in staat om “acetylated-low-density lipoprotein” op te nemen en buisjes te 
vormen wanneer werd gekweekt op “Matrigel”. Erg belangrijk was dat we met behulp van 
transmissie-electronenmicroscopie konden aantonen dat mGEnC-1 fenestrae bevatte zonder 
diafragma, wat een belangrijke karakteristieke eigenschap is van glomerulaire endotheelcellen. 
Tot slot, activatie van mGEnC-1 met de proinflammatoire cytokines “tumor necrosis factor 
(TNF)-α” of “interleukin (IL)-1β” induceerde een verhoogde expressie van de inflammatoire 
endotheliale adhesiemoleculen “intercellular adhesion molecule-1” en “vascular adhesion 
molecule-1”. Concluderend, de mGEnC-1 cellijn is de eerste glomerulaire endotheelcellijn 
die wordt beschreven in de literatuur met de fenotypische karakteristieken van primaire 
glomerulaire endotheelcellen. 
     De expressie van HS op glomerulaire endotheelcellen en de rol in de interactie met 
leukocyten werd bestudeerd in vitro (hoofdstuk 4). De expressie van verscheidene HSPGs 
en N- en 6-O-gesulfateerde HS-domeinen op glomerulaire endotheelcellen (primaire humane 
glomerulaire endotheelcellen en mGEnC-1) was significant verhoogd na stimulatie met TNF-α 
of IL-1β. De verhoogde expressie van N- en 6-O-gesulfateerde HS-domeinen op geactiveerde 
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glomerulaire endotheelcellen was geassocieerd met een verhoogde mRNA-expressie van 
de HS-modificerende enzymen N-deacetylase/N-sulfotransferase (NDST)-1 en -2, 6-O-
sulfotransferase-1 en -2, en een verlaagde expressie van 6-O-sulfatase-2. Het bleek dat de 
cytokine-geïnduceerde expressie van de inflammatoire N- en 6-O-gesulfateerde HS-domeinen 
en de veranderingen in de mRNA-expressie van de HS-modificerende enzymen volledig kon 
worden voorkomen door het toevoegen van BAY-110782, dat een remmer is van de klassieke 
NF-κB signaaltransductieroute. HS verrijkt in N- en 6-O-gesulfateerde HS-domeinen kon 
worden aangetoond in het celkweeksupernatant van geactiveerde mGEnC-1. Interessant 
was de tweevoudig verhoogde mRNA- en eiwitexpressie van het HS-hydrolyserend enzym 
heparanase, dat als verklaring zou kunnen dienen voor de aanwezigheid van HS in het 
celkweeksupernatant. Om de hechting van leukocyten aan mGEnC-1 te kunnen bestuderen, 
werd een in vitro statisch adhesiesysteem ontwikkeld met primaire granulocyten en de 
granulocytcellijn 32Dcl3, die geen HS tot expressie brengt. Het aantal vasthechtende 
granulocyten aan mGEnC-1 was viervoudig verhoogd na activatie met TNF-α of IL-1β 
en dit kon volledig voorkomen worden door remming van de klassieke NF-κB route. 
Het verwijderen van HS op geactiveerde mGEnC-1 cellen resulteerde in een tweevoudig 
verlaagd aantal vasthechtende granulocyten, terwijl het verwijderen van chondroïtine- of 
dermatansulfaat geen effect had. Het toevoegen van verschillende glycosaminoglycanen, 
chemisch gemodificeerde heparinoïden en gedefinieerde anti-HS antilichamen in het statische 
adhesiesysteem, liet zien dat vooral N- en 6-O-gesulfateerde HS-domeinen op mGEnC-1 
van belang zijn voor de hechting van granulocyten. De integrine “Mac-1” en de selectine 
“L-selectin”, die tot expressie worden gebracht door 32Dcl3 cellen, kunnen als mogelijke 
liganden dienen voor de inflammatoire N- en 6-O-gesulfateerde HS-domeinen op 
mGEnC-1. Tot slot konden we aantonen dat heparine/heparinoïd behandeling van MRL/lpr 
lupus nefritis muizen het ontstaan van de glomerulaire influx van granulocyten, albuminurie 
en glomerulonefritis kon voorkomen. Concluderend, de expressie van N- en 6-O-gesulfateerde 
HS-domeinen op glomerulair endotheel is verhoogd na stimulatie met TNF-α of IL-1β en 
wordt gemedieerd door de klassieke NF-κB route. Daarnaast zijn deze inflammatoire N- en 
6-O-gesulfateerde HS-domeinen cruciaal voor de vaste hechting van leukocyten. 
     Hechting van leukocyten onder bloedstromingscondities kan in vitro worden nagebootst 
in stromingskamers, waarin het rollen en de vaste hechting van leukocyten aan endotheel 
onder dynamische stromingscondities onderscheiden kunnen worden (hoofdstuk 5). De 
fysiologische “shear stress rate” in glomerulaire capillairen werd geschat op 0,8 dynes/cm2 met 
behulp van de wet van Hagen-Poiseuille. Het aantal rollende en vast hechtende granulocyten 
nam toe na activatie van mGEnC-1 met TNF-α, terwijl de gemiddelde rollingsnelheid van 
de granulocyten afnam, in vergelijking met ongestimuleerde mGEnC-1. Het verwijderen 
van HS op TNF-α-geactiveerde mGEnC-1 en de toevoeging van HS, heparine of tinzaparine 
verminderde het aantal rollende en vast hechtende granulocyten, terwijl de gemiddelde 
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rollingsnelheid van de granulocyten afnam, in vergelijking met ongestimuleerde 
mGEnC-1. Het verwijderen van HS op TNF-α-geactiveerde mGEnC-1 en de toevoeging van 
HS, heparine of tinzaparine verminderde het aantal rollende en vasthechtende granulocyten, 
terwijl de gemiddelde rollingsnelheid van de granulocyten toenam. Concluderend, HS op 
geactiveerde glomerulaire endotheelcellen is onder dynamische stromingscondities cruciaal 
voor de hechting van leukocyten aan het glomerulair endotheel. Daarnaast zijn heparinoïden 
onder dynamische stromingscondities in staat om te interfereren met de interactie tussen de 
leukocyten en glomerulair endotheel, dat op een potentiële therapeutische toepassing duidt.
     Er is gesuggereerd dat de celoppervlakte HSPG syndecan-1 (sdc-1) een belangrijke rol 
speelt in de leukocyt-endotheel interactie, terwijl de expressie van sdc-1 op mGEnC-1 toenam 
na activatie met IL-1β of TNF-α (hoofdstuk 4). Om de rol van sdc-1 te kunnen bestuderen 
in glomerulonefritis, werd experimentele anti-glomerulair basaalmembraan (GBM)-nefritis 
geïnduceerd in sdc-1-deficiënte en wildtype (WT) muizen door injectie van konijn anti-muis 
GBM immunoglobuline (Ig) G (hoofdstuk 6). Tijdens de acute heterologe fase werd 2 uur 
na toediening van anti-GBM IgG een maximale glomerulaire polymorfonucleaire granulocyt 
(PMN) influx waargenomen in zowel sdc-1-deficiënte als WT muizen. De expressie van 
N- en 6-O-gesulfateerde HS-domeinen op het glomerulaire endotheel was in sdc-1-deficiënte 
muizen hoger dan in WT muizen, wat een verklaring zou kunnen zijn voor de hogere 
glomerulaire PMN influx in sdc-1-deficiënte muizen. Het is van belang te benadrukken dat 
deze inflammatoire HS-domeinen cruciaal zijn voor de vaste hechting van leukocyten zoals 
in vitro is bepaald (hoofdstuk 4). Een aanvullende verklaring voor de hogere PMN influx 
in sdc-1-deficiënte muizen is het ontbreken van het afsplitsten van het ectodomein, die de 
HS-ketens bevat, van sdc-1 op het endotheel. In de normale situatie kan het afgesplitste 
ectodomein van sdc-1 effectief competeren voor binding aan liganden op leukocyten. Tijdens 
de autologe fase was de albuminurie significant hoger en de nierfunctie slechter in sdc-1-
deficiënte muizen in vergelijking met WT muizen, dat gepaard ging met meer glomerulaire 
schade in sdc-1-deficiënte muizen. De muis Ig en IgG1 anti-konijn IgG titers in het plasma 
en de glomerulaire muis Ig en IgG1 anti-konijn IgG deposities waren significant hoger 
in de sdc-1-deficiënte muizen, wat een drijvende kracht kan zijn in het voortduren van de 
albuminurie tijdens de autologe fase. Daarentegen waren de plasma titers en de glomerulaire 
deposities van muis IgG2a anti-konijn IgG significant lager in de sdc-1-deficiënte muizen. 
Dit wijst op een verschuiving van een Th1 (IgG2a) respons, de belangrijkste T cel respons in 
anti-GBM nefritis, naar een Th2 (IgG1) respons in sdc-1-deficiënte muizen. Concluderend, 
sdc-1-deficiëntie leidt tot een verslechtering van experimentele anti-GBM nefritis en een 
verschuiving van de Th1/Th2-balans tijdens anti-GBM nefritis. 
     SLE-geassocieerde glomerulonefritis wordt gekarakteriseerd door glomerulaire PMN 
influx en granulaire Ig deposities langs de glomerulaire capillaire wand en in het mesangium. 
Albuminurie en nierfalen zijn de meest ernstige manifestaties van deze ziekte. De expressie 
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van specifieke glomerulaire HS-domeinen en de aanwezigheid van Ig werd bestudeerd in 
niercoupes van SLE patiënten en MRL/lpr muizen met lupus nefritis (hoofdstuk 7). Een 
afgenomen HS-expressie werd waargenomen in de GBM van zowel MRL/lpr muizen als 
SLE patiënten. De expressie van inflammatoire N- en 6-O-gesulfateerde HS-domeinen op 
het glomerulair endotheel leek te zijn afgenomen in MRL/lpr muizen, maar toegenomen in 
SLE patiënten, wat verklaard zou kunnen worden door het feit dat MRL/lpr muizen meer 
glomerulaire Ig deposities hadden dan SLE patiënten. Er werd een methode ontwikkeld 
om het Ig vanaf de niercoupes te elueren zonder dat de integriteit van de HS-domeinen, 
die herkend worden door anti-HS antilichamen, volledig werd vernietigd. Na elutie van Ig 
en correctie voor het effect van de elutieprocedure op de integriteit van de HS-domeinen, 
werd de expressie van N- en 6-O-gesulfateerde HS-domeinen op het glomerulair endotheel 
hersteld en bleek zelfs hoger te zijn dan normaal. Daarnaast werd de expressie van HS in de 
GBM hersteld tot het normale niveau. Behandeling van MRL/lpr muizen met heparinoïden 
voorkwam Ig depositie en hield de glomerulaire expressie van HS-domeinen in stand op het 
normale niveau. Concluderend, de expressie van specifieke HS-domeinen op het glomerulair 
endotheel en in de GBM verandert tijdens lupus nefritis als gevolg van maskering door Ig 
deposities en de inductie van inflammatoire HS-domeinen.  
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     Toekomstig onderzoek naar de functie van HS in glomerulaire ontsteking zou zich 
moeten richten op het verder ophelderen van de exacte structuren in HS op het glomerulair 
endotheel die van belang zijn voor de hechting van leukocyten. Hiertoe zou HS geïsoleerd 
moeten worden uit zowel ongestimuleerde als geactiveerde glomerulaire endotheelcellen 
(in vitro van gekweekte cellen en in vivo van muizen met glomerulonefritis) en zou de 
chemische samenstelling bepaald moeten worden met behulp van HS-disaccharide analyse 
en massaspectrometrie. De inflammatoire N- en 6-O-gesulfateerde HS-domeinen kunnen 
slechts een klein deel van de totale HS-keten vertegenwoordigen die niet aan het licht 
komen met behulp van deze analyses. Daarom zou partieel geknipt HS van geactiveerd 
glomerulair endotheel als alternatief voor de structurele analyse van de totale HS-keten 
kunnen dienen. Dit partieel geknipt HS kan via affiniteitzuivering door anti-HS antilichamen 
of zijn functionele liganden zoals L-selectine of Mac-1 verkregen worden. Uiteindelijk 
zou dit kunnen leiden tot de rationele ontwikkeling van gedefinieerde, op HS-gebaseerde, 
therapeutica die in staat zijn om te interfereren met de interactie tussen leukocyten en het 
glomerulair endotheel, dat wil zeggen de initiële interactie, het rollen, en de vaste hechting 
van leukocyten. Het potentieel van zulke op HS-gebaseerde ontwikkelde glycomimetica in 
de behandeling van glomerulonefritis zou in vitro bestudeerd moeten worden in statische en 
dynamische adhesiesystemen en in vivo in experimentele diermodellen voor glomerulonefritis 
zoals anti-GBM nefritis en lupus nefritis. De structuur van HS is het cumulatieve resultaat 
van de gecombineerde enzymactiviteiten van HS-modificerende enzymen. Daarom dient 
het expressieprofiel van HS-modificerende enzymen in ongestimuleerde en geactiveerde 
glomerulaire endotheelcellen (in vitro en in vivo) te worden bepaald en te worden vergeleken 
met de HS-structuur analyse. Het stilleggen van specifieke HS-modificerende enzymen 
met behulp van siRNA gevolgd door HS-structuur analyse en functionele testen door het 
bestuderen van de hechting van leukocyten (in vitro en in vivo) stelt ons in staat de HS-
structuur en expressie van HS-modificerende enzymen te koppelen aan functie. Tot slot zou 
het bestuderen van de regulatie van de expressie van de genen die coderen voor de HS-
modificerende enzymen nieuwe mechanismen kunnen opleveren als potentiële doelen voor 
therapeutische interventie, zoals aangetoond voor de klassieke NF-κB signaaltransductieroute 
in geactiveerde glomerulaire endotheelcellen (hoofdstuk 4). 
     Samengevat, de opheldering van de exacte structuur van de HS-domeinen op glomerulaire 
endotheelcellen die functioneel zijn in de interactie met leukocyten, en het ophelderen van 
de mechanismen die de genexpressie reguleren van de HS-modificerende enzymen die 
verantwoordelijk zijn voor deze HS-domeinen, zou kunnen leiden tot de ontwikkeling van 
aanvullende behandelingsopties voor glomerulonefritis. 
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Figure 3. Glomerular PMN influx in wild type (WT) and syndecan-1-deficient (Sdc-1-/-) mice during the acute 
heterologous phase of anti-GBM nephritis. Glomerular PMN influx, analyzed by immunohistochemical staining, 
peaked 2 hours after rabbit anti-GBM IgG administration in both WT and sdc-1-deficient mice and at this time point 
was significantly higher in sdc-1-deficient mice. After 18 hours, 4 and 8 days, the glomerular PMN influx was similar 
to untreated mice and control mice injected with rabbit IgG. Magnification x 400.
Chapter 6, Figure 3C
Figure 4. Glomerular endothelial expression of inflammatory, N- and 6-O-sulfated, HS domains during the 
acute heterologous phase of anti-GBM nephritis. (A) Immunofluorescence double staining of N- and 6-O-sulfated 
HS domains recognized by the anti-HS antibodies AO4B08 (red), EW3D10 (red), EW4G2 (red) and the endothelium 
marker CD31 (green) showed an increased glomerular endothelial expression of inflammatory HS domains in sdc-1-
deficient mice 2 hours after anti-GBM IgG administration. Magnification x 400.
Chapter 6, Figure 4A
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Chapter 6, Figure 6
Figure 6. Histology of glomerular injury in wild type (WT) and syndecan-1-deficient (Sdc-1-/-) mice during 
anti-GBM nephritis. Glomeruli in sdc-1-deficient mice showed more globally occluded and distended capillaries 
filled with Periodic acid-Schiff (PAS) positive fibrinous material (arrows) after 4 and 8 days. In addition, proteinacious 
tubular casts (asterisks) were more frequently observed in sdc-1-deficient mice compared to WT mice. At day 8 WT 
mice showed thickening of capillary walls (arrowhead) but mostly open capillary lumens. Magnification x 250.
Figure 6. Expression of heparan sulfate domains in the GBM and on glomerular endothelial cells in a patient 
with SLE nephritis and in a healthy control. Representative photographs showing the decreased expression of HS 
in the GBM (A) and the slightly increased expression of N- and 6-O-sulfated HS domains on glomerular endothelial 
cells (B) of a SLE patient and a healthy control, as measured by staining with the anti-HS antibody JM403 (A) or co-
staining with anti-CD31 (green) and the anti-HS antibody EW3D10 (red) (B). Magnification 400x. 
Chapter 7, Figure 6
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